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Introduction
This thesis describes the results of the COPD study of the department of
Pulmonary Medicine, Enschede (COPE study), the Netherlands. In this chapter,
we will shortly reflect on the definition and epidemiology of COPD and the
rationale of the COPE study. Additionally, the outline of this thesis will be
explained.
Chronic Obstructive Pulmonary Disease 
Chronic Obstructive Pulmonary Disease (COPD) is a disease characterised by
progressive development of airflow limitation that is not fully reversible. COPD
is caused by an abnormal inflammatory response of the lungs to noxious parti-
cles or gases, in particular cigarette smoking (1). COPD constitutes a major pub-
lic health burden worldwide (1). The World Health Organisation (2) estimated
COPD to be the world’s fifth most common disease and fourth leading cause of
death. In 2000, the overall prevalence of COPD in general practice was estimat-
ed at 2.4% for men and 1.4% for women in the Netherlands. As COPD increas-
es with age, the highest prevalence rates are seen in people over the age of 75
years (16% in men and 4.4% in woman) (3). Both prevalence and mortality are
expected to increase in the coming decades (4;5). By 2015, the prevalence of
COPD in the Netherlands is predicted to increase to 3.3% in men and 2.3% in
women (a 59% increase in men and a 123% increase in women relative to the
1994 figures) (3). A recent cost-of-illness study (6) revealed the high costs of
COPD to the health care system and society. The total annual costs per patient
in the Netherlands are estimated at € 1024, with € 614 as direct costs and € 410
as indirect costs (7). Nowadays, the management of COPD includes smoking ces-
sation, optimisation of pulmonary status by pharmacotherapy, physical activity
and nutritional support (see Chapter 2).
Rationale of the COPE study 
At time the COPE study was designed, the value of self-management in COPD
was an unknown research area. In asthma (8-11) and other chronic diseases like
diabetes mellitus, rheumatic arthritis, self-management programmes had been
proven to be effective (12-14). But in COPD, the value of self-management pro-
grammes was not clear. In order to get more insight in the evidence available, we
CHAPTER 1
12
bw-monninkhof&valk  02-12-2003  08:59  Pagina 12
General Introduction
reviewed the literature of controlled trials about self- management in COPD
(Chapter 3).As pulmonary rehabilitation has been seen as an important treatment
modality in COPD and has been proven to increase exercise tolerance and qual-
ity of life (15), we incorporated important elements of pulmonary rehabilitation
in the design of our self-management programme. However, long-term effects of
revalidation are disappointing. A recently published article (16) showed that
patients returned to levels close to pre-rehabilitation at 24 months follow-up. So,
a self-management programme should be aimed at structural behavioural change
in order to maintain potential health effects.Therefore, we have chosen to imple-
ment important conditional elements in the programme based on the ASE-model
for behavioural change (Attitude, Social support and self-Efficacy) (17).The ASE
model is based on a social cognitive theory claiming that behaviour is influenced
by expectations, in particular the individual’s confidence in their ability to per-
form a given behaviour (self-efficacy).
This led to the development of the COPE self-management programme con-
sisting of three core elements: 1) a self-management education course, 2) guide-
lines for self-treatment of exacerbations in COPD and 3) a (near home) fitness
programme.The rationale for self-treatment of exacerbations was to give patients
a tool to treat their exacerbations at an early stage and preventing deterioration
of their condition. So, self-treatment might prevent loss of quality of life, and by
reduced doctor consultations, the costs of health care.
Therefore, the main objective of this thesis was to study the effect of a com-
prehensive self-management programme including self-treatment of exacerba-
tions and a fitness programme on clinical outcomes (health-related quality of life
(Chapter 4 and 6) and exacerbations (Chapter 5)) and costs (Chapter 7) in moder-
ate to severe COPD patients.
Whilst designing the COPE self-management study, we also took the oppor-
tunity to assess additional important research questions:
• Does optimisation of pulmonary status by appropriate up-to-date drug treat-
ment, inhalation instructions and smoking cessation result in beneficial
effects for COPD patients? (Chapter 8 and 9)
• What is the effect of discontinuation of inhaled corticosteroids on exacer-
bations, Health-Related Quality of Life (HRQoL) and costs in patients with
COPD? (Chapter 10 and 11)
• What is the role of bacterial colonisation in relation to inhaled corticos-
teroid treatment and subsequent risk of exacerbations? (Chapter 12)
• Which clinical factors can predict who needs treatment with antibiotics in
exacerbations of COPD? (Chapter 13)
13
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Study design
The COPE study was designed as a combination of two sub studies (see Figure
1). During the first substudy (discontinuation of ICS study), the lung function of
patients was optimised including a 4-month regimen of an inhaled corticosteroid
(fluticasone propionate 500 mg twice daily), bronchodilation, and a smoking ces-
sation programme for current smokers.All patients were instructed in the correct
use of their inhaled medication. After these four months, patients were random-
ly assigned to continue ICS or to receive placebo for 6 months.
For the second substudy, all patients were subsequently randomised again into
an intervention group receiving a comprehensive self-management programme
and a control group receiving regular care from the chest physician only (the
COPE self-management study). Patients attended the hospital every six months
during a two-year follow-up period.
Figure 1. Design COPE Study
Rationale for the additional research questions
Optimisation and smoking cessation
Unlike other studies reporting effects of self-management, we planned to measure
the net effect of a self-management programme without influence of for example
smoking cessation and optimisation of pulmonary status (i.e. optimal pharmaco-
logical treatment). Smoking cessation is the only strategy that has so far been
proven to reduce the rate of decline in lung function (18), to improve the progno-
sis for the COPD patient (19) and to improve HRQoL (20). The effects of the
smoking cessation programme including biochemically validated cessation rates,
and the results of the optimisation phase are described in Chapter 8 and 9, respec-
tively.
CHAPTER 1
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Discontinuation of inhaled corticosteroids
As inhaled corticosteroids (ICS) are remarkably effective in controlling inflam-
mation in asthma, and both asthma and COPD result from chronic inflammation,
clinicians regularly prescribe ICS in COPD without sufficient proof of its effec-
tiveness, safety and efficiency (21;22). Since the inflammatory pattern of COPD
is markedly different from that of asthma (23;24), the effects of ICS in COPD
were highly debated.
Although ICS seem to have no long-term benefit on the progressive decline
of the FEV1 (25), the FEV1 improves slightly in the first 3-6 months, an effect
that is maintained during follow-up treatment (26;27). Furthermore, two studies
reported beneficial clinical effects of ICS on frequency (27) and severity (28) of
exacerbations.This led to the idea that this initial improvement in lung function
due to ICS is worth pursuing, but the overall effect of prolonged ICS treatment
on exacerbations is not clear yet.We hypothesised that the COPD patients, who
were sensitive to ICS after optimisation, would develop exacerbations shortly
after discontinuation of ICS. Therefore, we performed a six-month randomised
controlled trial to study the effect of discontinuation with inhaled corticosteroids
after four months optimisation (Chapter 10). Furthermore, we assessed the eco-
nomic consequences of discontinuation of treatment with ICS in COPD (see
Chapter 11).
Exacerbations
Morbidity and mortality among patients with COPD are mainly related to acute
exacerbations of COPD (29;30) which occur on average one to three times a
year (31). The role of microorganisms in the development of exacerbations
remain unclear (32-34). It is hypothesised that simple bronchial colonisation or
overgrowth of potentially pathogenic microorganisms (PPM) may promote
bronchial inflammation (35;36) hence promoting bronchial injury and conse-
quently, by higher sputum levels of inflammatory mediators, exacerbations
(37;38). In order to provide more insight in the role of microorganisms in the
chronicity of COPD, we longitudinally collected sputum and serum samples in
stable state and during exacerbations.
Since ICS affect airway inflammation in COPD, we investigated whether dis-
continuation of ICS in colonised patients had effect on the acquisition of new
bacterial strains and so promoted exacerbations (see Chapter 12).The wide use of
antibiotic therapy in the treatment of exacerbations in COPD lacks evidence, effi-
cacy is debated and verification of a bacterial cause of an exacerbation in COPD
15
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is difficult.Therefore, we assessed which clinical factors can predict the need for
antibiotics in exacerbations of COPD by correlating clinical signs, symptoms and
laboratory data on first presentation of an acute exacerbation of COPD to micro-
biological data (see Chapter 13).
In Chapter 14, major results of these studies are discussed and put into per-
spective. Recommendations for clinical and public health practice as well as for
future research are given.A summary of the main findings (Chapter 15) concludes
this thesis.
Responsibility
This thesis is a compilation of work performed under joint responsibility of the
two authors. A division of the responsibility for each of the chapters had to be
made, and was established as follows: Chapters 1, 14 and 15 were written under
combined responsibility of both authors. Chapters 3, 4, 6, 7, 8 and 11 were writ-
ten under first responsibility of Evelyn Monninkhof and Chapters 2, 5, 9, 10, 12
and 13 under first responsibility of Paul van der Valk.
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Introduction
Chronic Obstructive Pulmonary Disease (COPD) is a disease characterised by the
progressive development of airflow limitation that is not fully reversible. COPD is
caused by an abnormal inflammatory response of the lungs to noxious particles or
gases (1) in particular cigarette smoking. COPD constitutes a major public health
burden world-wide (1). The World Health Organisation (2) estimates COPD to
be the world’s fifth most common disease and fourth leading cause of death. Both
prevalence and mortality are expected to increase in the coming decades (3).The
economic impact of COPD is huge, with an annual cost in the United States alone
of more than 23 billion dollars, due to medical expenditures and to indirect costs
of morbidity and premature mortality among COPD patients (4).
There is no doubt that the main risk factor for developing COPD is cigarette
smoking. Inhaled smoke acts in conjunction with underlying host susceptibility
and environmental factors and results in COPD in 10% to 20% of chronic smok-
ers (5;6).
Apart from the irreversible respiratory impairment, COPD has also systemic
consequences (7). In particular, there is accumulating evidence of skeletal muscle
impairment contributing to exercise intolerance, a frequent complaint in COPD
(8). Also, up to 35% of clinically stable patients with COPD experience involun-
tary weight loss as the severity of the disease progresses (9), which is not only
related to a disturbed energy balance but also to altered metabolism (7).
Therefore, a holistic approach should be taken in the treatment of COPD.
As patients become symptomatic from COPD, the most common complaints
are breathlessness with exercise intolerance, cough with or without sputum pro-
duction and fatigue. Dyspnea leads to inactivity, which leads to physical decon-
ditioning, and a vicious circle ensues with serious consequences such as depres-
sion (10).
The clinical course of COPD is one of gradual progressive pulmonary impair-
ment, which may eventually lead to respiratory failure. An acute exacerbation of
COPD is defined as a sustained worsening of a patient’s condition, from stable
state and beyond normal day-to-day variations, that is acute in onset and neces-
sitates a change in regular medication (11).
The frequency of these exacerbations increases with the severity of COPD
(5). Exacerbations have a major impact on health related quality of life (12). Early
identification of patients at particular risk for exacerbations may reduce morbid-
ity and mortality from complications associated with COPD exacerbations.
The goals of effective COPD management (1) are to prevent disease progres-
CHAPTER 2
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sion, relieve symptoms, improve exercise tolerance, improve health status, prevent
and treat complications, prevent and treat exacerbations and reduce mortality.The
management strategy is based on an individualised assessment of disease severity
and response to various therapies (1). In order to reach this goal an individual
treatment plan should be made with the following important elements : smoking
cessation, optimisation of pulmonary status by pharmacotherapy, physical activi-
ty, nutrition, and self-management.
Smoking cessation 
Smoking cessation (13;14) is the mainstay of the management of COPD because
it reduces the decline in pulmonary function, improves the prognosis (13;15) and
enhances quality of life (16). As COPD patients generally have a long smoking
history, they are considered strongly addicted to smoking, both physically and
psychologically. A strong nicotine addiction is likely to require structured coun-
selling to achieve cessation success (17).
Various smoking cessation programs including pharmacological and/or behav-
ioural elements have been applied, but most of them are unstructured and not
especially developed for COPD patients (13;18;19). There is an urgent need to
develop a smoking cessation programme targeted at COPD patients, because
there is evidence that this group is particularly heavily addicted.
Optimisation of pulmonary status by pharmacotherapy
None of the existing medications for COPD has been shown to modify the long-
term decline in lung function. Therefore, pharmacotherapy is only used to
decrease symptoms and complications (1). Standards for pharmacological treat-
ment of COPD recommend a stepwise approach guided by the severity of the
disease (20). Bronchodilator therapy (14) is the first step and remains (13) the
mainstay of the management of COPD.This may significantly reduce symptoms
of dyspnea by reducing hyperinflation, and may also improve exercise tolerance
(21). A second step is a trial with of inhaled corticosteroids (ICS) since it is not
clear whether or not ICS are beneficial in all COPD patients (22;23).
Several studies have indicated beneficial effects on respiratory symptoms (24),
decreased frequency (25) or severity (26) of exacerbations and health-related
quality of life (HRQoL) (25), but ICS have shown to be ineffective in arresting
long-term decline in lung function (21). Safety of long-term, high-dose ICS has
not been well established (27). An alternative step is a trial treatment wiht N-
21
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acetylcysteine (NAC) for patients with recurrent exacerbations. Treatment with
oral NAC may reduce the risk of exacerbations and improve symptoms in
patients with COPD (28;29).
Finally, patients with severe COPD and hypoxemia may need long term oxy-
gen therapy.
Long term administration of oxygen to patients with severe COPD and hypox-
emia, pulmonary hypertension, congestive heart failure or polycythemia has been
shown to increase survival (30).
Physical activity
Exercise intolerance is a characteristic and disturbing manifestation of COPD.The
pathophysiological basis of exercise intolerance is often multifactorial. Dyspnea
leads to inactivity, which leads to physical deconditioning, and a viscious circle
ensues with devastating responses (10). Exercise training, undertaken alone or in
the context of pulmonary rehabilitation, can improve the exercise intolerance of
patients with COPD. Exercise training is considered to be a mandatory part of
pulmonary rehabilitation. A pulmonary rehabilitation programme is a multidisci-
plinary programme of care for COPD patients that is individually tailored and
designed to optimise physical and social performance and autonomy (31). Several
simple designed, primarily home based or near home programmes of exercise
training also achieved improvement in exercise tolerance and HRQoL (32;35).
Pulmonary rehabilitation as well as more simple primarily home based or near
home programmes of exercise training have shown to produce short term bene-
ficial effects on exercise tolerance and HRQoL in COPD patients (36-41).
Maintenance of these initial improvements, however, is disappointing as many of
the initial improvements tend to disappear (32;33;37) in most studies .There is a
need for developing programs which focus on the implementation of exercise in
the normal daily pattern, in order to maintain long-term improvement in exer-
cise capacity.
Nutrition
Up to 35% of clinically stable (42;43) patients with moderate to severe COPD
experience involuntary weight loss as their condition progresses (9). Those who
do lose weight have more dyspnea and less exercise capacity than those who do
not, even when their underlying levels of pulmonary impairment are similar.
Moreover, body weight has an independent effect on survival in COPD (44).
CHAPTER 2
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The consequences of weight loss in COPD patients particularly relate to the
decrease in muscle mass and can be measured indirectly in clinically stable patients
by assessment of fat-free mass (FFM) (45). In COPD, tissue depletion is indicated
by a body mass index (BMI) below 22 kg/m2 or a fat free mass index below 16 in
males and 15 in females. Nutritional depletion contributes to respiratory and
peripheral skeletal muscle weakness and to decreased exercise performance, inde-
pendent of impaired lung function. Recent studies have shown that nutritional
abnormalities in COPD patients not only relate to a disturbed energy balance but
also to altered regulation of substrate metabolism caused by changes in anabolic
and catabolic stimuli (45). In a recent meta-analysis (9) nutritional supplementation
(two weeks or more) has not been demonstrated to be successful in improving
anthropometric measures, lung function or exercise capacity in stable COPD
patients. But many factors were not optimally fulfilled in those interventions such
as duration of the intervention, adequate composition of the suppletion, lack of an
anabolic stimulus such as exercise training to avoid an expansion of fat mass only
and compliance with the therapy. Not in all patients with COPD the negative effect
of low body weight can be reversed by appropriate therapy (44). More knowledge
of the pathogenesis of weight loss and muscle wasting is essential to develop new
nutritional and metabolic intervention strategies for COPD patients.
Self-management
Self-management of COPD is defined as effective behaviour based on sufficient
knowledge about COPD and its provoking factors, adequate coping behaviour,
compliance with inhaled medication, attention to changes in the severity of the
disease, and adequate inhalation technique. One of the components of self-man-
agement believed to be of importance is the self-adjustment of the medication
by the patient in case of an exacerbation.The term “self-treatment” is used when
COPD patients are provided with guidelines to self-adjust their dose of bron-
chodilators or to start a short course of oral steroids and/or antibiotics, based on
symptom perception, in case of an exacerbation.The idea of self-management is
as follows: a) To achieve effective self-management behaviour, COPD patients are
educated about the nature of their disease, the medication used and the influence
of extraneous factors such as smoking and regular exercise. b) In addition, they
are trained in the correct use of their inhaled medication and symptom percep-
tion. c) By using the attained knowledge and practising the skills they learned,
patients should then be able to cope with the disease in daily life, to control their
symptoms and to treat themselves in case of an exacerbation. d) In this way, exac-
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erbations could be curtailed at an early stage, HRQoL could be increased and
health care contacts could be reduced (46;47).
There is a global consensus, that an increase in disease-specific knowledge is
not sufficient to develop successful self-management behaviour (48;49).
Education should also focus on attitude, social support and self-efficacy accord-
ing to behavioural principles (49;50). In asthma, sustained patient education and
self-management programmes have proven to be successful in improving quality
of life and lung function and in reducing the economic burden of disease (51-
54).There is very little known so far, about the effectiveness of self-management
and self-treatment of COPD. A Cochrane review of published studies demon-
strates insufficient evidence to conclude about the effectiveness of self-manage-
ment programmes for COPD patients (55). Indeed, pulmonary rehabilitation has
been proven to increase exercise tolerance and HRQoL (40) in COPD patients,
but pulmonary rehabilitation is expensive and time consuming for both profes-
sionals and patients. Self-management programmes combined with a low-inten-
sity exercise programme may be more easily implemented and more cost-effec-
tive. New studies with sufficient size and follow-up are initiated to fill the knowl-
edge gap on the effect of these programmes.
Summary
COPD is a systemic disease with major impact worldwide. In the treatment of
COPD a holistic approach should be taken. In order to reach this, an individual
treatment plan should be made which includes at least elements of smoking ces-
sation, optimisation of pulmonary status by pharmacotherapy and exercise
embedded in a new lifestyle. Furthermore, more research on nutritional and
metabolic intervention strategies for COPD patients is needed. With the avail-
ability of all these treatment options, a nihilistic attitude toward the patient with
COPD is no longer justified 
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Abstract
Background: The idea of self-management is to teach patients how to optimal-
ly carry out the activities of daily living in the face of their physiological impair-
ment and to prevent or decrease the severity of exacerbations by means of life
style adaptation. In COPD, the value of self-management education is not clear.
This review was intended to clarify on the effectiveness of self-management pro-
grammes in Chronic Obstructive Pulmonary Disease (COPD).
Methods: We searched the Cochrane Airways Group trial registers, MED-
LINE, reference lists, and abstracts of medical conferences for controlled trials of
self-management education in patients with COPD.Two reviewers independent-
ly assessed each paper for methodological quality and extracted the data.
Results: The reviewers included 12 articles describing 8 randomised controlled
trials and 1 controlled clinical trial. Self-management education was compared
with usual care in 8 studies.The studies in this review assessed a broad-spectrum
of outcome measures with different follow-up times, and therefore meta-analysis
could not be undertaken.The studies showed no effect of self-management edu-
cation on hospital admissions, emergency room visits, days lost from work and
lung function. Inconclusive results were observed on health related quality of life,
COPD symptoms, use of health care facilities such as doctor and nurse visits. Self-
management education reduced the need for rescue medication, and led to an
increased use of courses of oral steroids and antibiotics for respiratory symptoms.
Conclusions: The data abstracted by this review are insufficient for forming
recommendations, because of the broad variation of outcome measures used and
other limitations to generalisations in the current published literature. Further
research in this area is clearly needed.
CHAPTER 3
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Introduction
Chronic Obstructive Pulmonary Disease (COPD) is a serious public health prob-
lem world-wide. The prevalence, morbidity and mortality are expected to rise,
especially in countries with a rapidly ageing population and even in populations
with reduced smoking rates (1). A study published by the World Bank /World
Health Organisation reported that COPD is likely to rise from being the 12th
most burdensome disease in 1990 to the 5th in 2020 (2).This will place an enor-
mous burden on the health-care system and will also cause a loss in health-relat-
ed quality of life (HRQoL) for many COPD patients. In COPD, therapy is often
primarily aimed at improving airflow obstruction by bronchodilator- and anti-
inflammatory therapy, despite indications that airflow obstruction is irreversible
and the apparent lack of effect of pharmacological interventions on the progres-
sive decline in health status. Despite optimal pharmacological treatment many
COPD patients experience substantial functional impairment (3). However, air-
flow obstruction correlates poorly with disease perception by the patient (4;5).
COPD is a systemic inflammatory disease, and besides airflow limitation and
hyperinflation, due to loss of elastic recoil, as well as intrinsic airway narrowing,
systemic deficits such as skeletal and respiratory muscle dysfunction are promi-
nent features. There is a growing need for other forms of therapy for COPD
patients, not only to control and alleviate symptoms and complications of respi-
ratory dysfunction, but also to teach them how to optimally carry out the activ-
ities of daily living (6) in the face of their physiological impairment.
In asthma, patient education and self-management programmes have proven to
be successful, at least when combined with regular review, in reducing the eco-
nomic burden of disease, as well as in improving quality of life and lung function
(7-10). In COPD, pulmonary rehabilitation has been proven to increase exercise
tolerance and quality of life (11).The drawback is that pulmonary rehabilitation
programmes will normally be more expensive and time consuming for both pro-
fessionals and patients, than self-management programmes and may be less wide-
ly available.
Worth and colleagues. (12) were the first to describe the effectiveness of a
self-management programme aimed at acquisition by the patient of self-manage-
ment skills and behavioural change. Unfortunately, this pilot study was uncon-
trolled and studied a small sample of COPD patients (N=21). Impressive reduc-
tions in the frequency of exacerbations and home visits by the family doctor were
observed, but no changes in lung function were found. Several controlled trials
have been conducted to evaluate the effectiveness of COPD education and self-
33
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management education programmes. This review is being conducted to address
the impact of those programmes on health outcomes and health-care utilisation.
Methods
Search of literature
Relevant studies were identified with assistance from the Cochrane Airways
Group from the following sources: Cochrane Airways Group register derived
from MEDLINE (January 1985 to October 2001), EMBASE (January 1985 to
October 2001), CINAHL (January 1985 to October 2001), hand searched respi-
ratory journals and meeting abstracts.The databases were searched using the fol-
lowing terms: ‘Self-Care’ (keyword) AND ‘Lung-Diseases-Obstructive’ (keyword)
AND (COPD OR chronic obstructive pulmonary disease OR emphysema OR
chronic bronchitis) AND (‘Patient-Education’ (keyword) OR self management
OR self-management OR self management). From these, the bibliographic lists
were hand-searched for additional papers. Also research groups in this field were
contacted for unpublished and non-registered ongoing trials.
Selection of literature
Two reviewers (E.M. and J.vd P.) independently selected studies for inclusion in
the review. Studies were included if they were randomised controlled trials
(RCT) or controlled clinical trials (CCT), which assessed the efficacy of self-
management education in COPD patients. We excluded studies with patients
having asthma as primary diagnosis, studies focusing mainly on pulmonary reha-
bilitation and studies before 1985. Before 1985, treatment of COPD was not
comparable with current practice.
The interventions were categorised according to whether or not they involved
COPD education and/or self-treatment guidelines i.e. issuing of a personal action
plan.We defined COPD education as a programme, which transfers information
about COPD and treatment of COPD in any of the following forms: written,
verbal, visual or audio. Minimal education included the provision of written
material alone or a short structured verbal interaction between a health-care
provider and a patient. However, it had to be embedded in a formal programme
where the primary goal was to improve the knowledge and understanding of
COPD. The educational programme might be directed towards smoking cessa-
tion, improving exercise, nutrition, self-treatment of exacerbations, inhalation
CHAPTER 3
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technique or coping with the activities of daily living, or a combination of these.
Self-treatment guidelines (action plan) were defined as a written plan produced
for the purpose of patient self-management of COPD exacerbations. It informs
patients about when and how to adjust and/or start medication in case of an
exacerbation.
We only selected COPD education studies which included any of the follow-
ing outcomes: health-related quality of life scores, symptom scores, number and
severity of exacerbations, courses of oral steroids or antibiotics, use of rescue
medication, hospital admissions, emergency room visits, use of other health care
facilities, days lost from work, lung function, and exercise capacity.
Data extraction and analysis
The data extraction and study quality assessment were independently performed
by two reviewers (E.M. and J.vd P.).Agreement was examined; disagreement was
resolved, if possible, by consensus and otherwise by consultation with a third
reviewer (P.vd V.). Data were extracted using a standardised data abstraction form
created for the study. The missing data from the primary study reports were
requested from the investigators. The methodological quality of the included
studies was assessed by using the criteria list of Jadad et al (13).The quality vari-
ables recorded in the criteria list of Jadad were the procedure of allocation, infor-
mation regarding withdrawals and dropouts and blinding of patients and outcome
assessment. In general maximal five points were to be obtained using this crite-
ria list. As blinding is impossible when assessing behavioural interventions the
maximum score is limited to three points.A higher score indicates better method-
ological quality. In addition, we extracted the general quality of the data in the
studies in terms of sample size, quality of the outcome assessment and length of
the follow-up period.
For every outcome, we assessed the effect of self-management versus usual
care. Outcomes were analysed as continuous and/or categorical variables using
standard statistical techniques. For continuous outcomes, the weighted mean dif-
ference or standardised mean difference with 95 % confidence intervals were cal-
culated as appropriate, and for rates the relative risks or odds ratios were pooled.
In case conventional meta-analytic techniques could not be applied, the effects in
both groups of the studies were described.
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Results
The search identified 395 (386 Cochrane database and 9 hand searched) titles and
abstracts that were screened to identify 33 potentially relevant articles about self-
management education in COPD. Full-text versions of these papers were obtained
and independently assessed by two reviewers. Twenty-one of the 33 articles were
excluded for the following reasons: the design of the study was not a CCT or RCT
(ten); most of the included patients had asthma as primary diagnosis (two); the
studies were published before 1985 (two); the studies were primarily focused on
pulmonary rehabilitation (six); or the outcome assessed was not appropriate (one).
The reviewers included 12 articles describing 8 randomised controlled trials and 1
controlled clinical trial. Eight of nine studies described COPD self-management
education compared with usual care. One study compared a rehabilitation pro-
gramme without exercise component with general health education (14).This study
was omitted from the review.The characteristics and type of interventions of the
included 8 studies are summarised in Table 1 and Table 2, respectively (8;15-24).
We contacted the authors of these studies for additional information required, how-
ever, not all authors could provide us with the additional requested information.
A total number of 1295 patients were randomised in the eight studies; 1106
patients completed these studies. The drop out rates ranged from 0% to 22.4%.
Five studies recruited their patients from outpatient clinics; one study recruited
from general practice, one from the community and one study recruited patients
from a mix of these settings.
Only two studies (8;15;16;24) reported the use of an action plan for self-treat-
ment of exacerbations in COPD embedded in a self-management programme.
Although, action plans and self-management education can be considered as sep-
arate interventions with different outcomes, we were not able to distinguish them
in this review since the number of studies in this research area were scarce.
Quality
The method to generate the sequence of randomisation was not clear in 1 of the
seven randomised controlled trials.The concealment of allocation was adequate in
the other 6 RCT’s. None of the interventions was double blind, because blinding
of the patients with respect to study status is almost impossible in behavioural clin-
ical trials.A description of withdrawals and dropouts was given in 7 of the 8 stud-
ies. Five studies  (8;15-17;19;23;24) scored the maximum number of three quality
points, two studies (18;20;21) two points and 1 study (22) scored one point.
CHAPTER 3
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First author and year
(reference number)
Design N Mean age
i/c*
Gender % male
i/c
FEV1%pred
i/c
Recruitment Follow-up
(months)
Outcomes
Gallefoss 1999a #
(8)
RCT 62 57/58 48/52 59/56 outpatients 12 health status
Gallefoss 1999b #
(15)
RCT 62 57/58 48/52 59/56 outpatients 12 compliance, courses of steroids, use of rescue
medication
Gallefoss 2000 #
(16)
RCT 62 57/58 48/52 59/56 outpatients 12 health status, hospital admissions, days lost
from work, GP-consultation, lung function
Blake 1990
(17)
RCT 94 63/64 80/82 ? outpatients 12 health status, hospital days, bed disability
days, restricted activity days, physician visits
Cockcroft 1987
(18)
RCT 75 69/71 69/67 ? outpatients 10 health status, hospital admissions, deaths
knowledge, symptoms
Emery 1998φ
(19)
RCT 50 67/67 67/67 43/39 outpatients + GP-patients
advertisements + word of
mouth
2 health status, knowledge, lung function
Gourley 1998 Ψ
(20)
RCT 98 69/69 100/100 ? outpatients 6 health status, patient satisfaction, knowledge
Solomon 1998Ψ
(21)
RCT 128 69/69 100/100 50/50 outpatients 6 symptoms, hospital admissions, ER-visits,
other health care facilities
Howland 1986
(22)
CCT 659 59/60 54/51 ? community patients 12 health status, lung function
Littlejohns 1991
(23)
RCT 152 63/63 67/63 45/50 outpatients 12 health status, no. exacerbations, courses of
steroids/ antibiotics, hospital admissions,
lung function, exercise capacity
Watson 1997
(24)
RCT 69 68/67 62/67 37/36 GP-patients 6 health status, symptoms, GP-visits, courses
of steroids/antibiotics, lung function
* i = intervention group  c = control group
# These papers were derived from the same study
Ψ These papers were derived from the same study
φ The third arm of this study was disregarded, because it was focussed on pulmonary rehabilitation
Table 1 Characteristics of Included Studies
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Outcomes
The results of the different outcome measures were summarised in Table 3.
HRQoL was measured in all 8 included studies, however, instruments for mea-
surement of HRQoL differed widely among the studies. COPD-specific HRQoL
by means of the St. George’s Respiratory Questionnaire (SGRQ) was measured in
2 studies (8;24). SGRQ total scores and domain scores were all lower (indicating
a better HRQoL) in the self-management education groups, but these differences
did not reach clinical significance. The SGRQ-domain physical activity showed a
significant and clinically relevant lower score (weighted mean difference (WMD)
-10, (95% CI: -18.5; -2.0); indicating a better HRQoL) in the self-management
education group, but there was significant heterogeneity between these two stud-
ies (Chi Sq 12.54 p< 0.05).
General HRQoL was measured with the Sickness Impact Profile (SIP) in three
studies (17;19;23). Data from these three studies were not suitable for meta-analy-
sis and showed incongruent results. One study (19) reported significant improve-
ment in total function measured by the SIP for the control group. However,
Tougaard and colleagues (17) showed better physical function and total function in
favour of the intervention group, and Littlejohns et al. (23) showed a significant
greater improvement in physical function in the intervention group. Other studies
used the Health Status Questionnaire 2.0 (20), the General Health Questionnaire
(18) and a self designed questionnaire (22) (consisting of elements of the health
locus of control scale, respiratory health questionnaire, Zung scales and SIP-scales)
to measure general health status. In the latest two studies, general HRQoL was not
significantly different between the self-management education and control group,
although Gourley et al. (20) showed significantly improved scores for the well-
being dimension of the Health Status Questionnaire 2.0 in the intervention group.
The effects of self-management education on COPD symptoms were exam-
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Study
(reference number)
Group
education
Individual
education
Patient
brochure
Audiotape Exercise Action
plan
Smoking
cessation
Nutrition
Gallefoss 1999a (8),
1999b (15), 2000 (16)
√ √ √ √
Blake 1990 (17) √ √ √
Cockcroft 1987 (18) √
Emery 1998 (19) √
Gourley 1998, (20)
Solomon 1998 (21)
√
Howland 1986 (22) √ √ √ √
Littlejohns 1991(23) √
Watson 1997 (24) √ √ √ √ √
Table 2 Characteristics of the Self-management Education Intervention per Study 
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ined in two studies (21;24). Solomon et al.(21) assessed symptoms with different
instruments: the BORG scale measuring breathlessness on a 12-point scale and
the Global Assessment Scale measuring symptom severity on a 6-point scale.
BORG scale scores indicated a positive direction of effect of self-management
education on breathlessness, although no statistical significant differences were
observed.The Global Assessment Scale showed a reduction (not statistically sig-
nificant) in symptom severity in the self-management education group while in
the control group no reduction was observed. In the study by Watson et al.(24)
patients scored their respiratory status in symptom diaries on a four-point scale
(usual; mild; moderate; severe).They found no significant between-group differ-
ences in the proportion of days rated as mild, moderate and severe.
Three studies assessed the use of oral corticosteroids for respiratory problems
(15;23;24). Gallefoss et al.(15) reported that 69% of patients in the intervention
group registered steroid courses compared to 44% in the control group, with a
median of three and four courses recorded during the study year, respectively.
Littlejohns et al. (23) reported that 49% of the patients in the intervention group
used oral steroids and 37% in the control group during the study year. Meta-
analysis of these studies showed an increased use of oral steroid courses in the
educated patients (Relative Risk 1.39, 95% CI 1.02 to 1.91). Watson et al.(24)
analysed from symptom diaries the days on prednisolone as percentage of the
days recorded.The intervention group spent 15% of the days recorded on pred-
nisolone compared to 9% in the control group.
Use of antibiotics for respiratory problems was assessed in two studies (23;24).
Littlejohns et al. (23) reported that 79% of the patients in the intervention group
were prescribed antibiotics during the study year compared to 52% in the con-
trol group.Watson et al. (24) analysed from symptom diaries the days on antibi-
otics as percentage of the days recorded. The intervention group spent 10% of
the days recorded on antibiotics compared with 4% in the control group.
Treatment differences in both studies were statistically significant.
One study (15) reported on the use of short-acting B2-agonist as rescue med-
ication. Use of rescue medication was coded as the Defined Daily Dosages
(DDD) for comparison of medications within the same chemical therapeutic
group. In this study the educated patients received less than half the amount of
rescue medication (median DDD =125) compared with the control group (medi-
an DDD=209).This reduction is statistically significant.
No significant differences between self-management and usual care were found
on hospitalisations, emergency room visits, doctor and nurse visits, days lost from
work and lung function (see Table 3).
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One study (23) reported the number of exacerbations. However, no compari-
son could be made because they only mentioned the number of acute exacerba-
tions in the intervention group.
Discussion
This review systematically evaluated eight studies of self-management education
for patients with COPD compared to usual care.The studies showed no effect of
self-management education on hospital admissions, ER-visits, days lost from work
and lung function. Inconclusive results were observed on HRQoL. A potential
reason for the absence of convincing effects on HRQoL is the limited use of
COPD-specific instruments. General HRQoL instruments may not be sensitive
enough to detect differences in COPD patients.The studies using the disease spe-
cific SGRQ showed a trend towards better quality of life in the educated patients.
Days lost from work might not be an adequate outcome in COPD patients
because many are in the older age groups and often retired. Since, in most COPD
studies a minority of the patients undertake paid work, we think restricted activ-
ity days, indicating days in which the normal activities are reduced by the dis-
ease, would be a better outcome measure.
We did not expect to find an effect of self-management education on lung
function. The accelerated decline in pulmonary function in COPD patients is
very difficult to affect. Smoking cessation is the only treatment that has so far
been able to reduce this accelerated decline (25).
Inconclusive results were observed on COPD symptoms and use of other
health care facilities.
Self-management education did reduce the need for rescue medication. This
may indicate that self-management education leads to a better disease control in
COPD patients. However, use of rescue medication was measured in only one
study, so the strength of evidence for this observation is poor.
Self-management education led to an increased use of courses of oral steroids
and/or antibiotics for respiratory symptoms. This apparent paradox does not
mean that self-management education leads to worsening of respiratory symp-
toms. Seemungal et al. (26) showed in a well-designed study that in COPD
patients 50% of the exacerbations were not reported to a doctor. Considering
this, it is most likely that the educated patients were more conscious of worsen-
ing of their symptoms, and that the threshold for seeking help was decreased. For
the future, it will be important to investigate potential beneficial effects (on
CHAPTER 3
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Outcome No. of studies
(refno✗)
Meta-analysis (refno) Results of the different outcome measures
general HRQoL 3  (17;19;23)
1 (20)
1 (18)
1 (22)
No - SIP: incongruent results
- Health Status Questionnaire  2.0: no difference in general; improved well-being scores
- General Health Questionnaire: no difference
- self-designed questionnaire
disease specific
HRQol
2 (8; 24) Yes (8;24) - meta-analysis SGRQ: indicating better HRQoL, but significant heterogeneity between
studies;
  WMD*=  –10 (-18.5; -2.0)
COPD symptoms 2 (21;24) No - Borg-scale: positive direction, not significant
- Global Assessment Scale: reduction in symptom severity; not significant
- symptom diaries: no difference
exacerbations 1 (23) No - no comparison between groups could be made
use of oral steroids 3 (15;23;24) Yes  (15; 23) - meta–analysis % patients which used oral steroids: increased use;
  RR= 1.39 (1.02; 1.91)
- Watson et al.: increased number of days on prednisolone
use of antibiotics 2 (23;24) No - increased use of the number of patients which used antibiotics
- increased number of days on antibiotics
rescue medication 1 (15) No - reduction of short-acting beta agonists use
hospitalisations 4 (16; 18; 21; 23) Yes (16;23) - meta-analysis: number of patients with one or more admissions: reduction, not
significant;
  RR= 0.80 (0.43;1.50)
- Solomon + Cockcroft: no difference
ER visits 1 (21) No - no difference
doctor / nurse visits 3 (16;21;24) Yes (16;21;24) - meta-analysis number of visits per year: non-significant reduction and significant
heterogeneity
  between studies; WMD= -0.36 (-0.75; 0.03)
days lost from work 2 (16;17) No - no difference
lung function 4 (19;16;23;24) Yes (19;16;23;24) - meta-analysis: FEV1%pred: no difference; SMD
#= -0.01 (-0.24;0.22)
exercise capacity 0 - -
✗Refno= reference number of the study
*WMD=weighted mean difference
 # SMD= standardised mean difference
Table 3 Results of the Different Outcome Measures: Self-management compared to Usual Care
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HRQoL and/or prevention of hospital admissions) but also side effects of
increased use of prednisolone over the long term.To answer these questions there
is a need for large studies with long follow-up.
The review also identified a number of limitations in the current published lit-
erature which need to be considered:
1 The studies in this review assessed a broad-spectrum of outcome parame-
ters with different time to follow-up. Meta-analytical comparisons could not
readily be made. For the main part, we have been limited to describing the
effects of self-management education on the different outcome parameters.
2 The COPD population was defined in varying detail and included different
diagnostic criteria. This could have led to heterogeneity in disease severity.
The mode of the self-management education programmes varied from
group education, individual education, to written education material only.
Use of an action plan for self-treatment of exacerbations was assessed in one
study only while we think it could be an important part of a self-manage-
ment education programme based on a review of asthma self-management
(7). This review showed positive effects on health outcomes of self-man-
agement interventions, including an action plan and regular health practi-
tioner follow-up, in adult asthma patients, whereas, interventions without
action plans were not always of obvious benefit.
3 The span of 14 years over which the trials were conducted will have intro-
duced changes to the educational contents and the mode of delivery and
background therapy. Most studies were not aimed at improving self-man-
agement skills or behavioural change while we think self-management
involves the transfer of knowledge as well as the acquisition by the patient
of certain important skills, finally leading to a change in their behaviour.
This is the only way education can have a long-term impact on the daily
life of the COPD patient because knowledge of facts about the disease does
not directly implicate behavioural change.A theoretical model of behaviour
and behavioural change, for example the ASE-model (27), can be very help-
ful in designing a self-management programme.The programme should be
focused on the core-elements of behaviour change in the theoretical model
(for example: enhancing self-efficacy expectations or social support).
Besides the above-mentioned limitations in the literature, absence of positive
results in most of the self-management education studies could also be caused by
non-reversibility of the disease. COPD is less variable disease than for example
asthma, and it is a disease where the scope for therapeutic interventions is much
CHAPTER 3
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more limited and therefore it is intrinsically harder to show positive results.
Furthermore, COPD patients are older and may have more difficulty in grasping
the issues of an educational programme. The effects of education can also be
influenced by the fact that COPD patients are more prone to anxiety and depres-
sion (28).
The data abstracted by this review form an insufficient basis for the formula-
tion of recommendations regarding the effectiveness of self-management educa-
tion for COPD patients, because of the broad spectrum of outcome parameters
and other important limitations in the current published literature. Further
research on the effectiveness of self-management education programmes should
be focussed on behavioural change evaluated in well designed randomised con-
trolled trials with long follow-up time so that definite conclusions can be made.
Standardised outcomes designed for use in COPD and outcomes as anxiety and
depression need to be addressed. In addition, there is a need for studies specifi-
cally directed at the use of guided self-treatment action plans.
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Abstract
Objective:The aim of this study was to assess the effects of a comprehensive self-
management intervention on Health Related Quality of Life (HRQoL), symp-
toms and walking distance in patients with stable moderate to severe COPD.
Methods: This study was part of the overall COPE study which consisted of
an Inhaled Corticosteroid (ICS) trial and a self-management trial. After the ICS
trial, all patients were randomised again to a self-management and a control
group. The self-management intervention consisted of a skill-oriented patient
education programme and a near-home fitness programme on top of usual care.
The control group received usual care by the treating chest physician. HRQoL
was measured by the St George’s Respiratory Questionnaire (SGRQ). Walking
distance by the six minute walking test. Patients recorded their symptoms in
diaries and graded their health status from 1-10 in a week report.
Results: We randomly allocated 248 COPD patients to either intervention
(127) or control (121) group. No differences in the SGRQ scores within and
between both groups were observed over one year. Similarly, we did not find dif-
ferences in symptom scores and six minute walking distance within and between
groups. The intervention group reported more exacerbations than the control
group. The majority (69%) of the exacerbations in the intervention group was
self-treated at home.
Conclusions: This study failed to show positive effects of a self-management
programme among moderate to severe COPD patients.
CHAPTER 4
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Introduction
Chronic Obstructive Pulmonary Disease (COPD) is a local and systemic inflam-
matory disease (1). Airflow limitation, hyperinflation due to loss of elastic recoil,
intrinsic airway narrowing, and systemic deficits such as skeletal and respiratory
muscle dysfunction are prominent features (2-5). In COPD, therapy is often pri-
marily aimed at improving airflow obstruction by bronchodilator- and anti-
inflammatory therapy, despite indications that airflow obstruction is not fully
reversible and apparent lack of effect of pharmacological interventions on the
progressive decline in lung function. In spite of optimal pharmacological treat-
ment, many COPD patients experience substantial functional impairment (6).
Consequently, there is a growing need for other forms of therapy for COPD
patients, not only to control and alleviate symptoms and complications of respi-
ratory dysfunction, but also to teach them skills for adaptational activities of daily
living to their physiological impairment (7). In other chronic diseases (i.e.
rheumatic arthritis, diabetes mellitus, and asthma) interventions based on self-
management principles have been shown to improve disease outcomes (8-11).
Self-management is a term applied to any formalised patient education pro-
gramme aimed at teaching skills to optimally control the disease, behaviour
change, and coping with the disease. The continuum of self-management pro-
grammes varies from the provision of written material only, to more intensive
patient management including exercise prescriptions.
In COPD, several studies on the efficacy of self-management education have
been published. A recent Cochrane Review (12) of our research group, includ-
ing 8 studies of self-management education for patients with COPD, concluded
that the available evidence is inconclusive due to different study designs, method-
ological limitations and a wide variation of reported outcome measures.
To evaluate the effectiveness of a comprehensive self-management programme
for patients with COPD, we conducted a large randomised controlled single cen-
tre trial (the COPE self-management study). This self-management programme
was offered after a period of lung function optimisation and a smoking cessation
programme, and included a near-home fitness programme and instructions for
self-treatment of exacerbations.
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Methods
From May 1999 through March 2000, all patients were recruited from the out-
patient pulmonary clinic of the Medisch Spectrum Twente: a 1150 bed teaching
hospital in Enschede, The Netherlands. To be eligible for the study, the patients
had to meet the following criteria: a clinical diagnosis of stable COPD, as defined
by American Thoracic Society criteria (13), no history of asthma, no exacerba-
tion in the month prior to enrolment, current or former smoker, age 40-75 years,
baseline pre-bronchodilator FEV1 25- 80% of predicted, pre-bronchodilator ratio
FEV1 / IVC ≤ 60%, reversibility of FEV1 post inhalation of 80 µg of ipratropi-
um bromide via metered dose inhalator with an aerochamber ≤ 12% of predict-
ed (14), TLC greater than the TLC predicted minus 1.64*SD, no maintenance
treatment of oral steroids or antibiotics, no medical condition with low survival
or serious psychiatric morbidity (e.g. cardiac insufficiency, alcoholism), absence of
any other active lung disease (e.g. sarcoidosis), use of medication such as nasal
corticosteroids, theophyllines, chronic use of acetylcysteine and all other bron-
chodilators was allowed.
The hospital’s medical ethical committee approved the study. All patients pro-
vided written informed consent.
Study design
The overall COPE study was divided into two substudies. During the first sub-
study (discontinuation of ICS study) (15), the lung function of patients was opti-
mised including a 4-month regimen of fluticasone propionate 500 µg twice daily,
bronchodilation and a smoking cessation programme for current smokers (16).
All patients were instructed in the correct use of their inhaled medication. After
these four months, patients were randomly assigned to continue fluticasone pro-
pionate 500 µg twice daily or to receive placebo for 6 months. Results of the first
sub study are published elsewhere (15;16).
Following the first sub study, all patients were randomised again into an inter-
vention group receiving a comprehensive self-management programme and a
control group receiving regular care from the chest physician only (the COPE
self-management study). Randomisation was performed in blocks of four, strati-
fied by sex and smoking status using sealed envelopes. Patients attended the hos-
pital every six months during the one-year follow-up.
CHAPTER 4
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Intervention
The intervention consisted of a self-management education course and a fitness
programme. In addition, the patients were supplied with a self-treatment action
plan and a specially made booklet with background information on the educa-
tion course and their disease. The education course took four months and the
physical training continued for the duration of the study (2 years).The self-man-
agement education course consisted of five 2-h group sessions of approximately
8 patients given by a respiratory nurse. Four sessions were given with a one-week
interval and the last (feedback) session was given 3 months after the fourth ses-
sion. The patient’s partner or a significant other was also invited to attend the
course. Patients who could not attend a planned group session could participate
in another course.
The first session addressed coping with breathlessness, i.e. reducing the nihilis-
tic idea about the treatment of COPD, obtaining better insight in the nature of
the disease, symptom perception and recognising triggers for breathlessness.
During this session, guidelines for self-treatment of exacerbations (action plans),
based on symptom perception, were introduced. In order to interpret and use
these guidelines properly, they were discussed each session.
During the second session the importance of exercise and relaxation were
emphasised. Patients were motivated to participate in the fitness programme.
Furthermore, attention was paid to ergonomic posture and energy conservation
during daily activities or work. The third session concentrated on nutrition and
its implications for COPD patients. The risk of involuntary weight loss was
emphasised. Patients were instructed to monitor their weight weekly, and they
were provided with advice how to gain weight in case of underweight or invol-
untary weight loss. The themes of the fourth session were communication and
social relationships. Changing role patterns and communication with the chest
physician and other health care professionals were stressed. Patients were trained
how to prepare their scheduled visits to their chest physician.The feedback ses-
sion was aimed at exchanging experiences and maintaining the acquired knowl-
edge and skills.
The self-treatment action plan was based on symptom perception. If patients
experienced an increase of respiratory symptoms and normally would have called
their physician, they could start with a short course of prednisolone and an addi-
tional course of antibiotics in case of increase of purulent sputum.
Besides physical goals, the fitness programme was aimed at coping with the
disease, recognising their individual capacity, social interactions and behavioural
change.
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The programme consisted of 1 or 2 one-hour small group training sessions per
week under guidance of a physiotherapist trained in COPD care.The frequency
of the training sessions depended on the initial physical state of the patient. In
the first few months, inactive patients were offered two sessions per week to get
started. Incorporation of exercise in daily life above the fitness training was
patients’ own responsibility. Preferably, patients were referred to a physiotherapist
stationed in the neighbourhood of the patient. The programme included strength
training, breathing and cardiovascular exercises (stationary bicycling, walking
etc). An important factor of the programme was the individual tuning of the
training intensity within group training. The physiotherapist together with the
patient regularly determined the individual goals of the training. Furthermore,
each patient had a training log in which their training performances and goals of
training were registered.
Patients in the control group received usual care from their chest physician.
Pharmacological treatment of exacerbations was standardised as much as possible.
In order to obtain valid data about exacerbations, this group of patients was
instructed to call the COPE study office if they felt in need of assistance for a wors-
ening of their respiratory symptoms, and they would normally have called their
chest physician or GP in stead. At the COPE office, the data managers dealt with
all telephone calls first.A physician, subsequently, offered treatment advice by tele-
phone or invited the patient to come to the hospital for consultation. Patients in
the intervention group were instructed to contact the COPE office in case of
doubt, a fast deterioration of their pulmonary condition, or absence of improve-
ment by self-treatment of an exacerbation. Subsequently, the same procedure as in
the control group was followed.
Treatment of exacerbations was standardised to a short course of oral corti-
costeroids of 30 mg prednisolone for a period of 10 days and when necessary
antibiotics. First choice of antibiotics was amoxicillin/clavulanic acid 625 mg four
times daily for a period of 10 days. Second choice was doxycycline 100 mg daily
for a period of 10 days. Patients in the self-management group had  prescriptions
or medication at home.
Outcome measurements
At baseline, 6 months and one year follow-up health related quality of life
(HRQoL) was measured by means of the Dutch version of the St George’s
Respiratory Questionnaire (SGRQ) (17).The SGRQ is a disease specific instru-
ment composed of 76 items that are weighted to produce scores in the domains:
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“symptoms”, “activity” and “impact”. A total score is calculated from all items
and provides a global view of the patient’s respiratory health. The scores range
from 0 to 100, a score of 100 indicating maximum disability.A difference of four
units or more indicates a clinically relevant effect (18;19). Exacerbations were
defined as worsening of respiratory symptoms that required treatment with a
short course of oral corticosteroids or antibiotics as judged by the patient in de
self-treatment group or by the study physician in the intervention and control
groups.Walking distance was measured at randomisation and after one year fol-
low-up by the standardised six minute walking test (6MW) (20). The perfor-
mance of the test was standardised (21): patients performed a practice walk, were
instructed pre test, and no encouragement was used during the test. A change of
54 meter or more in walking distance is considered clinically important (22).
Patients were asked to complete a two-week diary for symptoms of COPD
prior to each follow-up visit (23). These COPD symptoms were measured by a
breathlessness score, cough, sputum volume and sputum colour. Every week
patients graded their general well-being score (range 1-10) in a week report.
Mean scores for each of four periods of three months were used for analysis.
After one year follow-up, self-confidence regarding COPD was measured by
one item, to which patients could respond on a five-point Likert scale (1=large
reduction in self confidence ; 5= large improvement in self confidence).
Also demographic data were collected. This included the level of education
achieved. Low education was defined as 10 years or less, moderate was up to and
including 12 years and high was more than 12 years of formal education.
Statistical analysis
We calculated that a total of 125 patients (per treatment group) were required
to detect a clinically relevant difference of 4 units on the SGRQ Total score
between both groups with 80% power and a two-sided 0.05 α-level test.
All analyses were performed according to the intent-to-treat principle.
Within and between group differences in continuous variables over time
(HRQoL scores; distance walked in 6 minutes; symptom scores; well-being week
report scores) were assessed by analysis of repeated measurements using Proc
Mixed (mixed models approach) from SAS (24) and 95% confidence intervals
were calculated. Difference between groups in self-confidence at the end of the
study period was analysed with a Chi-square test.
Except for the repeated measurements analyses, all statistical analyses were per-
formed using SPSS version 10 (25).
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Figure 1 Flow Diagram of Subject Progress through the COPE Study
Results
Of the 509 eligible patients, a total of 269 were enrolled in the overall COPE
study (Figure 1). All patients who finished the first substudy (n=242) plus 6
patients who where excluded for this substudy because of intolerance of the
CHAPTER 4
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Base population
n = 615
Excluded
n= 106; 17.5%
Transport/mobility problems: 19
Refused to participate: 54
Other reasons: 33
Written informed consent
n= 386
Excluded
n= 123; 24.2 %
Problems with change in medication: 20
Transport/ mobility problems: 10
Refused to participate: 93
Patients included
n= 269
Patients not meeting entry criteria at visit 1
(lung function + general criteria)
n= 117; 30.3 %
Reversibility : 49
TLC: 8
FEV1 : 25 FEV /VC: 19
Other reasons: 16
Withdrawn during run-in period of 10 months
n=21; 7.8%
Dead: 7
Failure to return: 11
Lobectomy: 1
Other: 2
Eligible patients
n=509
One-year follow-up
SM group n=122
Randomised n=248
Self-management (SM) group n=127
Control group n=121
One-year follow-up
Control group n=114
Withdrawn during 1 year follow-up
SM group n =5; 3.9%
Dead: 3  Other: 2
Control group n=7; 5.8%
Dead : 3  Carcinoma: 2  Other: 2
1
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inhaled steroid fluticasone propionate, entered the self-management study. So, 248
COPD patients were randomly allocated to either the self-management (n=127)
or control (n=121) group.Table 1 shows the baseline characteristics of both treat-
ment groups.These were similar with respect to all known prognostic variables.
The mean age of the participants was 65 ± 7 years, and the mean FEV1 percent
predicted was 57 ± 15 %. Three patients in the self-management group and 1 in
the control group have received pulmonary rehabilitation in the past. Only 65% of
the patients used inhaled corticosteroids (ICS) at randomisation due to the proce-
dure of the former ICS trial; placebo patients who did not experience rapid recur-
rent exacerbations and did not have a 20% or 300 ml decrease in FEV1 after 6
months follow-up, did not receive ICS again at the start of the self-management
trial (15).
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Self-management
group
Control
group
Number of patients 127 121
Age (mean ± sd; years) 65 ± 7 65 ± 7
Male (%) 85 84
Body Mass Index (mean ± sd; kg/m2) 27 ± 4 27 ± 4
Number of exacerbations in year preceding study (mean ± sd) 1.4 ±1.5 1.3 ±1.6
Smoking status (%)
Ex-smokers 72 74
Current smokers 28 26
Lung function post bronchodilation (mean ± sd)
FEV1 (L) 1.71 ± 0.56 1.76 ± 0.54
FEV1 % predicted of normal 56.1 ± 15.4 58.4 ± 14.5
VC (L) 3.89 ± 0.85 3.77 ± 0.84
Inhaled corticosteroid use (%) 65 64
Long-acting ß-agonists use (%) 46 45
Total score SGRQ (mean ± sd) 37 ± 18 38 ± 17
Six Minute Walk (mean ± sd; meters)* 428 ± 91 442 ± 83
Education level (%)
low 68 59
moderate 21 23
high 11 18
# All variables were measured at baseline unless otherwise stated
* Mean values were based on 122 and 118 patients in the intervention and control group respectively
Table 1 Baseline Characteristics of the Two Treatment Groups#
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In the intervention group 5 patients (3 deaths, 2 other) dropped out, as did 7
patients (3 deaths, 2 carcinoma, 2 other) in the control group.Thus, 122 patients
in the intervention and 114 in the control group completed the 1-year follow-
up (see Figure 1).
Five of the patients randomised to the intervention group refused to attend the
self-management education course. These patients were younger and had a bet-
ter health status compared to the other patients in the intervention group.
Ninety-eight (77 %) patients participated in the fitness programme, and the mean
attendance frequency per week was 0.77 ± 0.22 (n=68).
During one year follow-up, the median number of exacerbations was 2 (range
0-12) and 1 (range 0-9) per patient in the intervention and control group, respec-
tively. The majority (69%) of the exacerbations in the intervention group was
self-treated at home.
Health related quality of life
Results of the repeated measurements analysis of the SGRQ scores are present-
ed in Table 2. No significant differences were detected between the groups over
one year. The proportion of patients for whom HRQoL has improved, been
maintained or deteriorated based on the minimal important difference of 4 points
on the SGRQ Total score was not significantly different between both groups. In
the intervention group, 37% (45/122) of the patients had an improvement of
HRQoL compared to 33% (37/113) in the control group. HRQoL deteriorated
in 36% (44/122) of the patients in the intervention group compared to 32%
(36/113) in the control group.
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Self-management Control Treatment Effect
(Self-management – Control)
SGRQ baseline
n=127
6 month
n=124
12 month
n=122
baseline
n=121
6 month
n=117
12 month
n=113
∆ 95% CI
Total 37.2 (1.6) 37.3 (1.6) 37.4 (1.7) 38.1 (1.5) 38.6 (1.5) 37.7 (1.6) -0.6 -2.8; 1.7
Symptoms 47.8 (2.0) 48.6 (1.9) 46.1 (2.1) 48.5 (2.0) 47.3 (2.1) 47.3 (2.0) 1.1 -2.5; 4.8
Activity 50.7 (2.3) 50.8 (2.2) 51.4 (2.3) 52.9 (1.9) 52.1 (2.0) 52.3 (2.0) -0.2 -3.2; 2.8
Impact 26.2 (1.6) 25.7 (1.6) 26.4 (1.7) 26.5 (1.6) 28.1 (1.5) 25.8 (1.6) -1.4 -3.9; 1.1
# Results were obtained with repeated measurements analyses with Proc Mixed (SAS)
Table 2 Mean (SE) SGRQ Scores at Each Study Time Point and Mean Difference Between 
Both Treatment Groups#
bw-monninkhof&valk  02-12-2003  08:59  Pagina 56
Effects of self-management in COPD
Six minute walk
During the one year follow-up, the mean distance walked (SD) in six minutes
was reduced by 13 (7) meters in the intervention group and 2 (5) meters in the
control group.These differences are not statistically nor clinically relevant.
Symptoms & well-being score
No between-group differences were seen in breathlessness (-0.04 95% CI –0.2;
0.12) and sputum production (-0.03 95% CI –0.2; 0.1) score, abstracted from
diaries. Small differences in cough (-0.1 95% CI -0.3;0.01) and sputum colour 
(-0.1 95% CI –0.3; 0.02) scores were seen in favour of the intervention group.
Although these differences reached borderline significance, these are probably not
clinically relevant.
The mean (± SD) well-being week report scores were not different between
groups. The proportion of patients for whom the well-being score improved or
deteriorated did not significantly differ between groups: 41.7% (30/72) improved
in the intervention group and 36.4% (28/77) in the control group.
Self-confidence
No statistically significant difference in the proportion of patients reporting
improved, maintained or deteriorated self-confidence was observed between
groups (p=0.289), however, a positive trend in favour of the self-management
group was observed. The proportion of patients reporting improved self-confi-
dence was greater in the intervention group (21.2% versus 13.6%). Additionally,
a smaller proportion of patients reported deteriorated self-confidence in the
intervention group (15% versus 19%).
Discussion
This randomised controlled trial did not find a positive effect of a comprehen-
sive self-management programme on HRQoL, walking distance, symptoms and
exacerbation frequency in COPD patients. Subgroup analysis did not reveal spe-
cific categories for which this negative result did not hold.
Before drawing conclusions, several aspects of the intervention, the study
design and study population should be reviewed in the context of literature.
Two comparable self-management studies also failed to show positive effects
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on HRQoL measured by SGRQ (26;27). A third study found a clinically signif-
icant improvement on HRQoL measured by the SGRQ in the self-management
group after one year follow-up (28).This study, however, differed on two impor-
tant aspects from our study. First, the population recruited from general practice
was more severely impaired. Second, the intervention in this study was far less
intensive than in our study. It consisted of a patient brochure and action plan
only, and no exercise component was included.
The patients in this study were fairly well stabilised and had moderate to severe
COPD (mean FEV1 57% predicted). During an optimisation phase before the self-
management trial, all patients received inhalation instruction in small group ses-
sions, COPD medication was optimised, and current smokers were offered a smok-
ing cessation programme.As a result, unlike other studies reporting effects of self-
management, we were able to measure the net effect of a self-management pro-
gramme without influence of for example smoking cessation and optimisation of
medication (i.e. optimisation bias). At the same time, the study population was
probably pre-selected on motivation, as is the case in all randomised trials. Patients
gave consent to participate in an investigation that was going to last for three years,
and at time of randomisation for the self-management trial, they were already par-
ticipants for 10 months. It should be noted that the participation rate (63%) is high.
Although this type of pre-selection might raise concerns about generalisability, the
validity of the study is not compromised (no selection bias) because randomisation
ensured comparability of intervention and control group.
Although our inclusion criteria selected almost exclusively moderate to severe
patients in stage II of the GOLD classification (3), the mean HRQoL of these
patients was relatively high. Consequently, the room for improvement in this
group of patients was limited.We observed the same phenomenon in a previous
asthma study (29), and have no explanation for this except that in this area of
the Netherlands people are not used to complain about their health.
We expected a deterioration in HRQoL over time in the control group con-
sidering the results of the ISOLDE study (30).This study showed that health sta-
tus as measured by the SGRQ declines about 3.2 units/year in patients with
moderate to severe COPD. We did not find this expected deterioration in
HRQoL in the control group.This lack of decline may be due to the facts that
our patients were less severe than the ISOLDE patients, and that participating in
a trial may improve performance not because of any specific condition being test-
ed, but simply because of the increased attention they receive (the so-called
Hawthorne effect). It should be noted that this trial could not be blinded.
Although some patients in the control group might have changed their behav-
CHAPTER 4
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iour after notification of allocation, it is unlikely that this phenomenon have
masked a real effect in the intervention group.
In general, exacerbations deteriorate HRQoL in patients with COPD (31).
However, in our study HRQoL did not differ between the intervention and con-
trol group despite an almost two times higher exacerbation frequency. Probably,
self-treated exacerbations have another impact on HRQoL than physician treat-
ed exacerbations.This might be due to the fact that early self-treatment of exac-
erbations by the patient might prevent further deterioration of the condition and
self-treatment might increase disease-specific self-confidence and self-determina-
tion of the patient. Furthermore, the apparent paradox of increased use of cours-
es of oral steroids or antibiotics for respiratory symptoms in self-management tri-
als (28;32;33), does not mean that self-management education leads to worsen-
ing of respiratory symptoms but more likely to an enhanced ability to recognise
symptoms earlier.
In general, insufficient compliance with a self-management programme dimin-
ishes possible effects. In our study, however, the high attendance rates during the
course, the follow-up visits and the fitness programme indicate a rather high
compliance.
The intensity of our programme can be discussed.Ten hours self-management
education and weekly visits to a physiotherapists is rather intensive. However, to
reach improvement in exercise performance, higher exercise intensity is probably
needed (34).To induce physiological changes Casaburi et al. recommended exer-
cise above anaerobic threshold 30-45 minutes more than 3 times a week.
Conversely, this is not a realistic option for outpatients with moderate COPD, and
increasing exercise capacity needs not to be the only goal of training pro-
grammes. Important patient specific goals like increased functionality, increased
walking capacity, dyspnoea sensation and socialisation might be gained by less
intensive programmes.
Although the SGRQ and the six minute walk test are frequently used as out-
come measures in COPD research, these might be insensitive to pick up (small)
relevant self-management specific changes. For example the SGRQ does not
reflect the management and control aspect of quality of life. In future studies cog-
nitive and psychological outcomes such as coping strategies, anxiety and depres-
sion should be included besides HRQoL measures.
With these reservations in mind, we might conclude that for this category of
stable moderate to severe COPD patients, who are receiving close to optimal
treatment, this type of intervention does not lead to measurable effects on
HRQoL, symptoms and walking distance. Future research should focus on other
59
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types of interventions, other (more severe) COPD patients, and other types of
outcomes such as anxiety, depression or coping strategies, and more sensitive
scales to measure these outcomes.
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Abstract
Objective: The aim of this trial was to evaluate the impact of self-management
on exacerbations and health care contacts in stable COPD patients.
Methods: We randomly allocated 248 COPD patients to either intervention
(n=127) or control (n=121) group. The intervention group received a self-man-
agement programme consisting of patient education including guidelines for self-
treatment and a fitness programme above usual care. Exacerbations were defined
as increased COPD related symptoms requiring oral prednisolone and/or antibi-
otics. Exacerbations and health care contacts were prospectively recorded.
Results: During one-year follow-up, 537 exacerbations were reported: 360 in
the intervention group and 177 in the control group. In the intervention group,
98 (77%) patients had at least one exacerbation compared to 70 (58%) in the con-
trol group.The majority (69%) of all exacerbations in the intervention group were
self-treated at home, resulting in a 42% reduction in doctor consultations per
patient per year. Symptoms were less severe in the intervention group. No
between-group difference in the type of exacerbations according to the classifica-
tion of Anthonisen was observed.
Conclusions: This study indicated that a self-management programme includ-
ing self-treatment of exacerbations for COPD patients resulted in a two-fold
increase on reported exacerbations. Because most were self-treated by the
patients, this reduced the number of doctor consultations.
CHAPTER 5
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Self-management and self-treatment in COPD 
Introduction
The clinical course of chronic obstructive pulmonary disease (COPD) is one of
gradual progressive impairment, which may eventually lead to respiratory failure.
In COPD, therapy is often primarily aimed at improving airflow obstruction by
bronchodilator- and anti-inflammatory therapy (1). Despite optimal pharmaco-
logical treatment many COPD patients experience substantial functional impair-
ment (2). Moreover, patients with COPD are prone to frequent acute exacerba-
tions in COPD, which have a major impact on quality of life (3). Morbidity and
mortality among patients with COPD are for the most part related to acute exac-
erbations (4;5), which occur one to three times a year (6;7). One study (6) and
unpublished data of our own group show that patients are well able to notice an
early deterioration of their respiratory condition. The study of Seemungal et al.
(3) found that only half of the patients reported their exacerbations although
there was no difference between reported and unreported exacerbations in terms
of symptoms, exacerbation frequency, duration or peak flow. Early self-treatment
of exacerbations in COPD by the patient might prevent further deterioration of
the condition, reduce health care contacts and possibly prevent hospitalisations.
But in order to acquire these skills, self-treatment guidelines (also referred to as
action plans in asthma programmes) should be embedded in a patient self-man-
agement education programme (8). A recent Cochrane Review (9) of 8 studies
of self-management education for patients with COPD described that only one
study (10) evaluated the effects of self-treatment of exacerbations in COPD.They
found an improved quality of life and an increase in the amount of treatments
with prednisolone and antibiotics. Recently Bourbeau et al. (11), found fewer
exacerbations, a clinically significant reduction in utilization of health care con-
tacts without long-term improvement in Health Related Quality of Life
(HRQoL) in a large COPD self-management trial, evaluating the effect of self-
treatment guidelines.
We conducted a large randomised controlled trial (the COPE self-manage-
ment study), that following optimisation of treatment evaluated the effects of a
self-management programme including self-treatment of exacerbations and a
near-home low-intensity fitness programme on frequency of exacerbations and
health care utilisation for patients with COPD.
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Methods
Patients
From May 1999 through March 2000, patients were recruited from the outpa-
tient pulmonary clinic of the Medisch Spectrum Twente, an 1150 bed teaching
hospital in Enschede, The Netherlands. To be eligible for the study the patients
had to meet the following criteria: 1) a clinical diagnosis of stable COPD, as
defined by American Thoracic Society criteria (12); 2) no history of asthma; 3)
no exacerbation in the month prior to enrolment; 4) current or former smoker;
5) age between 40-75 years; 6) baseline pre-bronchodilator FEV1 25- 80% of 
predicted; 7) pre-bronchodilator ratio FEV1 inspiratory vital capacity ( IVC)
value of  60% or less; 8) reversibility of FEV1 post inhalation of 80 µg of iprat-
ropium bromide via metered dose inhalator with an aerochamber 12% of pre-
dicted value or less (13); 9) Total Lung Capacity (TLC) greater than the TLC pre-
dicted minus 1.64*SD; 10) no maintenance treatment of oral steroids or antibi-
otics; 11) no medical condition with low survival or serious psychiatric morbid-
ity (e.g. cardiac insufficiency, alcoholism); 12) absence of any other active lung
disease (e.g. sarcoidosis); and 13) use of medication such as nasal corticosteroids,
theophyllines, chronic use of acetylcysteine and all other bronchodilators was
allowed.
The hospital’s medical ethical committee approved this study. All patients pro-
vided written informed consent.
Trial design
The overall COPE study was divided into two substudies. During the first sub-
study (discontinuation of ICS study), the lung function of patients was optimised
including a 4-month regimen of fluticasone propionate 500 µg twice daily, bron-
chodilation and a smoking cessation programme for current smokers (14). All
patients were instructed in the correct use of their inhaled medication.After these
four months, patients were randomly assigned to continue fluticasone propionate
500 µg twice daily or to receive placebo for 6 months. Results of the first sub-
study are published elsewhere (15).
Following the first substudy, all patients were randomised again into an inter-
vention group receiving a comprehensive self-management programme, includ-
ing guidelines for self-treatment of exacerbations, and a control group receiving
usual care from their own chest physician only (the COPE self-management
study). Randomisation was performed in blocks of four, stratified by sex and
CHAPTER 5
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smoking status using sealed envelopes. Patients attended the hospital every six
months during a one-year follow-up period.
Intervention
The intervention consisted of the introduction of a self-treatment action plan
embedded in a self-management programme. The self-management programme
consisted of a self-management education course and a near-home low-intensity
fitness programme. In addition, the patients were supplied with a specially made
booklet with background information on the course and their disease. The self-
management education course consisted of five 2-h group sessions of approxi-
mately 8 patients given by a respiratory nurse. Four sessions were given weekly
during one month and the last (feedback) session was given 3 months after the
fourth session. The partner or a significant other was also invited to attend the
course. Patients who could not attend a planned group session could participate
at the next course. Besides physical goals, the fitness programme was aimed at
coping with the disease, recognizing their individual capacity, social interactions
and behavioral change. The programme consisted of 1 or 2 one-hour weekly
small group training sessions including strength training, breathing and cardio-
vascular exercises (stationary bicycling, walking etc) under guidance of a physio-
therapist trained in COPD care. Overall, the course emphasised behaviour mod-
ification by acquisition of COPD self-management skills.The four education ses-
sions dealt with the following themes: coping with breathlessness, exercise and
relaxation, nutrition, communication and social relationships.A fifth feedback ses-
sion aimed at exchanging experiences and maintaining the acquired knowledge
and skills. In the first session, guidelines for self-treatment of exacerbations, based
on symptom perception, were introduced. In order to be able to interpret and use
these guidelines properly, these were discussed each session. Patients were
instructed to start with a short course of prednisolone, when they experienced
an increase of respiratory symptoms and normally would have called their physi-
cian.A course of antibiotics had to be added in case of increase of purulent spu-
tum.When patients initiated self-treatment, they had to start a symptom diary for
2 weeks (16). Also, they were instructed to complete a standardised exacerbation
report to note any appearance or increase in intensity of “major” symptoms (dys-
pnoea, cough, sputum amount, sputum purulence) or ”minor” symptoms (nasal
discharge/congestion, wheeze, sore throat, cough, fever, need of extra bron-
chodilator), a modified version of the Anthonisen score (17). In doubt, a fast dete-
rioration of their pulmonary condition, or absence of improvement, they were
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instructed to contact the COPE study personnel by phone. Medical advice was
given by telephone or they were invited to come to the hospital for check-up.
Patients in the control group received usual care from their own chest physician.
Apart from standardising pharmacological treatment of exacerbations, no attempt
was made to change usual care. In order to obtain valid data about exacerbations,
this group of patients was instructed to call the COPE study office if they felt in
need of assistance for a worsening of their respiratory symptoms, and they would
normally have called their chest physician or GP instead. At the COPE office, the
data managers dealt with all telephone calls first.A physician, subsequently, offered
treatment advice by telephone or invited the patient to come to the hospital for
consultation.At start of the treatment, they also had to complete a symptom diary
for 2 weeks. A standardised report of all physician contacts in both groups was
made, which registered patient’s complaints as mentioned above in major and
minor symptoms in a Anthonisen score (17) and the treatment prescribed.When
an exacerbation was diagnosed, patients were treated with a short course of pred-
nisolone 30 mg a day for ten days and antibiotics as judged by the staff physician.
First choice of antibiotics was amoxicillin/clavulanic acid (Augmentin®) 625 mg
four times daily for a period of 10 days. Second choice was doxycycline 100 mg
daily for a period of 10 days.
Outcome measurements
Exacerbations were defined as worsening of respiratory symptoms that required
treatment with a short course of oral corticosteroids or antibiotics as judged by the
patient in the self-treatment group or by the study physician in the intervention-
and control groups. Healthcare contacts were registered as contacts by telephone
with the chest physician, outpatients visits and emergency room visits, hospital
admissions, and other medical contacts like e.g. a visit to the general practitioner.
All instances of self-treatment of exacerbations were registered separately.
The type of an exacerbation was measured by the Anthonisen score (17).The
occurrence of increased dyspnoea, sputum volume and sputum purulence was
defined as a Type-1 exacerbation.When two of these three symptoms were pre-
sent this was classified a Type-2 exacerbation.Type-3 exacerbations were defined
as at least one of the three symptoms in addition to at least one of the follow-
ing findings: upper respiratory infection (sore throat, nasal discharge within the
past 5 days, fever without other cause; increased wheezing; increased cough).
Prior to each follow-up visit and during exacerbations patients completed a
two-week symptom diary (16). COPD symptoms were characterised by a breath-
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lessness score, cough, sputum volume and sputum colour. The start of an exac-
erbation was defined by the initiation of self-treatment or by contacting a physi-
cian for the exacerbation. In order to complete the exacerbation data, we asked
the patients’ general practitioners to report all patient contacts and drugs pre-
scribed for exacerbations of COPD. Pharmacists reported all drugs used during
the study period.
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Base population
n = 615
Excluded
n= 106; 17.5%
Transport/mobility problems: 19
Refused to participate: 54
Other reasons: 33
Written informed consent
n= 386
Excluded
n= 123; 24.2 %
Problems with change in medication: 20
Transport/ mobility problems: 10
Refused to participate: 93
Patients included
n= 269
Patients not meeting entry criteria at visit 1
(lung function + general criteria)
n= 117; 30.3 %
Reversibility : 49
TLC: 8
FEV1 : 25 FEV /VC: 19
Other reasons: 16
Withdrawn during run-in period of 10 months
n=21; 7.8%
Dead: 7
Failure to return: 11
Lobectomy: 1
Other: 2
Eligible patients
n=509
One-year follow-up
SM group n=122
Randomised n=248
Self-management (SM) group n=127
Control group n=121
One-year follow-up
Control group n=114
Withdrawn during 1 year follow-up
SM group n =5; 3.9%
Dead: 3  Other: 2
Control group n=7; 5.8%
Dead : 3  Carcinoma: 2  Other: 2
1
Figure 1 Flow Diagram of Subject Progress through the COPE Study
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Additionally, every week patients recorded the use of prednisolone or antibiotics
in a week report. Well-trained lung function technicians performed spirometry
on water sealed spirometers according to standardised guidelines (18). FEV1 and
IVC were measured until three reproducible recordings (less than 5% difference)
were obtained. Highest values were used for analyses.
At baseline, after 6 months and one year follow-up, HRQoL was measured by
means of the Dutch version of the St George’s Respiratory Questionnaire
(SGRQ) (19). The scores range from 0 to 100, a score of 100 indicating maxi-
mum disability. A difference of four units or more indicates a clinically relevant
effect (20;21).
Statistical analysis 
Baseline characteristics are reported as means ± SD or as percentages within
groups. Analyses were performed according to the intention-to-treat principle.
Differences between the groups in various health care contacts were assessed
by Chi-square statistics.
Between-group differences in lung function were assessed by analyses of
repeated measurements using Proc Mixed (mixed models approach) from SAS
(22) and 95% confidence intervals were calculated. Except for the repeated mea-
surements analyses, all statistical analyses were performed using SPPS for win-
dows (23).
Results
Of the 509 eligible patients, a total of 269 were enrolled in the overall COPE
study (Figure 1). All patients who finished the first substudy (n=242) plus 6
patients who where excluded for this substudy because of intolerance of the
inhaled steroid fluticasone propionate, entered the self-management study. So, 248
COPD patients were randomly allocated to either the self-management (127) or
control (121) group.Table 1 shows the baseline characteristics of both treatment
groups.These were similar with respect to all known prognostic variables.
The mean age (±SD) of the participants was 65 ± 7 years, and the mean FEV1
percent predicted was 57 ± 15 %. Three patients in the self-management group
and one in the control group had received pulmonary rehabilitation in the past.
Only 65% of the patients used inhaled corticosteroids (ICS) at randomisation due
to the procedure of the former ICS trial; placebo patients who did not experi-
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ence rapid recurrent exacerbations and did not have a 20% or 300 ml decrease
in FEV1 after 6 months follow-up, did not receive ICS again at the start of the
self-management trial (15).
In the intervention group 5 patients (3 deaths, 2 other) dropped out, as did 7
patients (3 deaths, 2 carcinoma, 2 other) in the control group.Thus, 122 patients
in the intervention and 114 in the control group completed the 1-year follow-
up (see Figure 1).
Five of the patients randomised to the intervention group refused to attend the
self-management education course. These patients were younger and had a bet-
ter health status compared to the other patients in the intervention group.
Ninety-eight (77 %) patients participated in the fitness programme, and the mean
attendance frequency per week was 0.77 ± 0.22 (n=68).
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Self-management group Control group
Number of patients 127 121
Age (mean ± sd; years) 65 ± 7 65 ± 7
Male (%) 85 84
Body Mass Index (mean ± sd; kg/m2) 27 ± 4 27 ± 4
Number of exacerbations in year preceding study (mean ± sd) 1.3 1.3
Smoking status (%)
Ex-smokers 72 74
Current smokers 28 26
Lung function post bronchodilation (mean ± sd)
FEV1 (L) 1.71 ± 0.56 1.76 ± 0.54
FEV1 % predicted of normal 56.1 ± 15.4 58.4 ± 14.5
VC (L) 3.89 ± 0.85 3.77 ± 0.84
Inhaled corticosteroid use (%) 65 64
Long-acting ß-agonists use (%) 46 45
Total score SGRQ (mean ± sd) 37 ±  18 38 ±  17
Six Minute Walk (mean ± sd; meters)* 428 ±  91 442 ±  83
Education level (%)
low 68 59
moderate 21 23
high 11 18
# All variables were measured at baseline unless otherwise stated
* Mean values were based on 122 and 118 patients in the intervention and control group respectively
Table 1 Baseline Characteristics of the Two Treatment Groups#
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Exacerbations
We registered 537 exacerbations in 168 patients, 360 (2.8 per patient per year)
in the intervention group and 177 (1.5 per patient per year) in the control group.
(Table 2) In the control group 70 of 121 patients (58%) had at least one exacer-
bation compared to 98 of 127 patients (77%) in the intervention group. No dif-
ference in type of exacerbations according to Anthonisen was observed between
the two treatment groups (see Table 3). Exacerbations were treated with antibi-
otics in 60% (SD 41%) and 57% (SD 46%) of all exacerbations in the self-man-
agement and control group, respectively.
Symptom scores and Health Related Quality of Life
We collected information on symptoms in 81% of the exacerbations in both
treatment groups. Symptom scores abstracted from patient diaries during exacer-
bations indicated less severe exacerbations in de self-management group com-
pared to the control group (see Table 4).
No significant differences in HRQoL were detected within and between the
treatment groups over one year (24).
CHAPTER 5
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Self-management group (127) Control group (121)
Total number of exacerbations 360 (98 patients) 177 (70 patients)
Self-treated exacerbations 247 12
Outpatient and emergency room visits 36 64
Advice by phone 32 49
Hospital admissions 15 16
Other# 30 36
  #For example treatment elsewhere on holidays, by a general practitioner etc
Table 2 Exacerbations and Healthcare Contacts in the Two Treatment Groups
Self-management group$ Control group*
Anthonisen 1 122 (48%) 61 (56%)
Anthonisen 2 83 (33%) 28 (26%)
Anthonisen 3 49 (19%) 19 (18%)
Total 254 108
# Only the data of 71% of the exacerbations in the Self-management group and 61% of the control group
were available for analysis.
$ Scored by the patients and physicians,
*Scored by the physicians
Table 3 Anthonisen scores Between Both Treatment Groups#
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Health care contacts
In the intervention group 247 (69%) exacerbations were self-treated at home,
resulting in a reduction of unscheduled doctors consultations of 42% per patient
per year compared to the control group: 0.54 per patient per year in the inter-
vention group and 0.93 in the control group, respectively.
In the intervention group, 15 of the 360 exacerbations (4%) resulted in a hos-
pital admission compared with 9% (16/177) in the control group (p=0.02) (Table
2).The mean amount of hospital admissions per person in the control group was
1.14 compared to 1.15 in the intervention group. The mean time of admission
was 12.1 days in the self-management group and 10.8 days in the control group.
Only one patient (out of the control group) died during admission because of an
exacerbation in COPD.
Lung function
Adjusted for baseline differences and time effects no significant difference
between the two groups was observed in lung function post bronchodilation over
the one-year follow-up period. The difference between the FEV1% predicted in
the self-management and control group over time was 0.3 95% CI (-1.7; 1.1) in
favour of the control group.
Safety
One patient in the self-management group developed icterus as an adverse reac-
tion to amoxycilline clavulanic acid but recovered without any lingering symptoms.
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Symptom Self-management
n=79
Control
n=57
Treatment Effect
(Self-management – Control)
mean (SD) mean (SD) ∆ 95% CI
Breathlessness
(Range 0-4)
1.9 (0.8) 2.2 (0.8) -0.3 -0.6; -0.06
Cough
(Range 0-3)
1.4 (0.5) -0.2 -0.4; -0.008
Sputum production
(Range 0-3)
1.3 (0.5) 1.5 (0.6) -0.2 -0.4; 0.005
Sputum colour
(Range 0-3)
1.1 (0.6) 1.2 (0.7) * -0.1 -0.3; 0.1
* Mean number was based on information of 55 patients
Table 4 Mean (se) Symptom Scores at Exacerbation and Mean Difference 
Between Both Treatment Groups
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Discussion 
This study indicates that a self-management programme including self-treatment
of exacerbations for COPD patients results in a two-fold increase in reported
exacerbations, of which 70% were self-treated with prednisolone or antibiotics.
We did not observe a positive effect on HRQoL. Fewer patients had to consult
their (chest) physician by phone or by an outpatient visit. These findings are in
accordance with the results of a recent Cochrane Review on self-management
education for patients in COPD (9).Three studies included in this review assess-
ing the use of oral corticosteroids in relation to exacerbations in COPD
(10;25;26) reported 6-25 % more steroid courses or steroid use in the interven-
tion group compared to the control group, indicating more exacerbations in the
intervention group.Two of these studies (10;26) reported use of antibiotics: 27%
more prescriptions and 6% more days on antibiotics in the intervention group
compared with the control group, respectively. In contrast to these studies, a
recent self-management study by Bourbeau et al. (11) reported 18% less exacer-
bations in the intervention group of more severe COPD patients.The self-man-
agement programme was quite similar to our study with exception of individual
education instead of group education and follow-up by phone.The absence of an
increase in the number of exacerbations in the intervention group in Bourbeau’s
study might in part be explained by the observation that the intervention group
was less severe than the control group since 6% fewer patients were on mainte-
nance treatment with oral steroids.
The two-fold higher exacerbation rate in the self-management group in our
study might be explained by underreporting of exacerbations in the control
group. Seemungal et al. (3) found that only 50% of the exacerbations in COPD
are reported, independent of the severity. Also, Bourbeau et al. (11) mentioned
50% underreporting by patients of changes in respiratory conditions. Another
plausible reason for the increased reporting of exacerbations may be the
improved and/or early recognition of exacerbations due to the self-management
education course. Self-treatment guidelines give patients a tool to treat their
exacerbations at an early stage without the possible delay induced by procrasti-
nating in contacting their physician or the delay caused by postponement of look-
ing for medical advice over the weekend. Another reason may be frequent
encouragement of the patients throughout the education course to start self-
treatment as soon as their respiratory condition deteriorated. Since we were wor-
ried whether patients would be prepared to treat themselves with prednisolone
or antibiotics and hence reduced potential effects, we emphasised the use of self-
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management at all four education sessions. In our study, however, the high atten-
dance rates during the education course, the follow-up visits and the fitness pro-
gramme indicate a rather high compliance to the self-treatment guidelines or
even overtreatment. Maybe in the future overtreatment will diminish when
patients gain more experience in self-treatment.
Although in our study self-management education led to an increased use of
courses of oral steroids and/or antibiotics for respiratory symptoms, this apparent
paradox does not mean that self-management education leads to worsening of
respiratory symptoms and long-term health status. For the future, it will be
important to investigate potential beneficial effects but also side effects of
increased use of  courses of prednisolone over the long-term like hyperglycemia,
myopathy, mood changes, osteoporosis secondary infections and adrenal suppres-
sion (27-29).
Although we did not expect a reduction in the amount of the exacerbations,
we expected the self-treated exacerbations to be less severe than exacerbations
in the control group and so recover more rapidly than the control group, since
patients could start self-treatment immediately after onset of symptoms and so
hospitalisation could be prevented. No difference in type of exacerbations accord-
ing to Anthonisen was observed between the two treatment groups. However, the
Anthonisen classification indicates the type but not the severity of exacerbations
(30). The two-week symptom diaries recorded by the patients during exacerba-
tions might better reflect the severity of exacerbation. In our study, the patient
diaries indicated less severe exacerbations in the self-management group com-
pared to the control group.
Since only moderate to severe COPD patients were included in this study with
a low probability for admission to the hospital at exacerbation, hospital admis-
sion, a generally accepted severity criterion in COPD exacerbations (30), could
not be used to score severity in this study. Also, length of hospital stay is not a
good marker for severity of exacerbations (30).
We found a 42% reduction in the total amount of doctor consultations in the
self-management group. Three studies (11;31;32) reported a reduction of these
visits, one study (32) reported no differences in emergency room visits between
the self-management education and the control group. Since in our study patients
were often referred to the emergency room for other reasons than the severity
of exacerbation, the number of emergency room visits and number of visits to
the outpatients clinic were merged.
The fact that we did not find a reduction in COPD related hospitalisations is
similar to four more studies reporting COPD related hospitalisations in self-man-
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agement programmes (26;31-33). However, Bourbeau et al. (11) found a 40%
reduction in hospital admissions for exacerbations in a group of more severe
COPD patients, already admitted once before entering his study. Since only
patients who were hospitalised for an exacerbation of COPD at least once in the
preceding year could enter the study, part of this effect might be explained by
including more severe, less stable, and non-optimised patients in the Bourbeau
study. Because patients in our study were fairly well stabilised and had moderate
to severe COPD (mean FEV1 57% predicted), they were less prone to severe
exacerbations, necessitating admission in the hospital. During an optimisation
phase before the self-management trial, all patients in our study received inhala-
tion instruction in small group sessions, COPD medication was optimised, and
current smokers were offered a smoking cessation programme.As a result, unlike
other studies reporting effects of self-management, we were able to measure the
net effect of a self-management programme including self-treatment without
influence of for example smoking cessation and optimisation of medication (i.e.
optimisation bias).
In conclusion, this study has demonstrated that a self-management programme
including a skill-oriented patient education programme, a near-home low-inten-
sity fitness programme and guidelines for self-treatment of exacerbations, for hos-
pital outpatients with moderate to severe COPD leads to a two-fold increase in
the number of exacerbations and a 42% reduction in the number of consultations
with the pulmonary physician without a clinical relevant improve in HRQoL. In
order to distinguish between overtreatment and underreporting of exacerbations
further investigations are needed.
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Abstract
Background: The COPE self-management programme, including a self-manage-
ment education course, self-treatment of exacerbations and a fitness programme,
appeared to have no significant effect on Health Related Quality of Life
(HRQoL) as measured by the St George’s Respiratory Questionnaire (SGRQ).
This is in contrast to our hypothesis and despite expressions of satisfaction of
patients to healthcare workers.To understand this discrepancy a qualitative study
was performed.
Methods: A purposive sample of 20 participants of the COPE self-manage-
ment programme were interviewed at home using in-depth, semi-structured,
interviews. Interviews were audio taped and transcribed verbatim and analysed
according grounded theory.
Results: The fitness programme was most positively evaluated by patients due
to the perceived increase of exercise capacity and the social aspect of the group
training. Major effects gained by the self-management education course reported
by patients were the skills to evenly distribute their energy and to listen to their
body signals. Most patients thought favourable about self-treatment of exacerba-
tions.The possibility to start early, not having to call a doctor and autonomy were
raised as important advantages. Furthermore, several patients reported increased
self-confidence and coping behaviour as important effects of the COPE pro-
gramme. Finally, many patients reported feeling safe due to the frequent follow-
up visits and 24 hour access to the hospital, and this aspect elicited to be very
important.
Conclusions: In this study, the qualitative interviews suggest that the SGRQ
and possibly other existing HRQoL instruments might fail to capture the full
experience of patients in self-management studies. The need for more elaborate
qualitative research on this subject is indicated.
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Qualitative evaluation of the self-management programme
Introduction
Chronic Obstructive Pulmonary Disease (COPD) is characterized by an impaired
respiratory function (1;2), and systemic deficits such as skeletal and respiratory
muscle dysfunction are prominent features (3;4). COPD has a detrimental effect
on the performance of daily activities (5;6) and consequently on health related
quality of life (HRQoL) (7). Since treatment modalities for COPD, other than
smoking cessation, are largely aimed at alleviating symptoms, improving HRQoL
in patients with COPD has nowadays become a major goal of treatment and a
central feature of clinical studies. Different HRQoL instruments have been devel-
oped to quantify the impact of COPD on a patients’ daily life, health and well-
being (5,8-10). In clinical trials, these instruments are used because of their eval-
uative properties - measuring changes in HRQoL - and their discriminative prop-
erties, measuring differences in health status between patients.
The COPE self-management study is a large randomised controlled trial
designed to evaluate the effectiveness of a self-management education course and
a fitness programme for patients with COPD.The primary outcome was HRQoL
measured by the St. George’s Respiratory Questionnaire (SGRQ) (5).This instru-
ment was chosen because of its wide use in COPD studies and well-described
measurement properties (5,11-15). In this trial, the COPE self-management pro-
gramme appeared to have no significant effect on HRQoL as measured by the
SGRQ, both in time within the intervention group, as in comparison to the usual
care control group (16).
This result, however, was strongly disputed by several other signals. In gener-
al, participating patients used to express full satisfaction with the programme dur-
ing personal contacts with their lung physician or with the research team.
Moreover, other healthcare workers associated with the participating patients,
predominantly indicated to observe improvements in their patients’ health. To
understand the striking discrepancy between these subjective signals and the
objective SGRQ data in the COPE study, we performed a qualitative study. In
COPD, we are aware of one study combining quantitative and qualitative research
methods to evaluate a behavioural intervention (17).This study assessed HRQoL
changes in patients with COPD after pulmonary rehabilitation. They concluded
that qualitative methods complemented and enhanced data gained from HRQoL
questionnaires due to identification of unique issues not captured by the ques-
tionnaires. The interview participants noted increased energy level, confidence
and control over COPD, improved emotional well-being and ability to perform
certain physical activities.These effects were partly reflected by the CRQ and the
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SF-36, however, neither questionnaire was capable of solely identifying all of
these positive results.
The primary aim of this study was to assess how patients perceive the effects
of the self-management intervention on their HRQoL. Furthermore, we com-
pared the patients’ experiences with the SGRQ domains to assess which topics
appear to be represented by the SGRQ and which topics may be missing.
Methods
All COPD patients were recruited from one outpatient pulmonary clinic and
were aged between 40 and 75 years. The diagnosis of COPD was confirmed by
spirometry (ratio of FEV1 to FVC ≤ 60 %, FEV1 percent predicted ≤ 80%) and
absence of a bronchodilator response (∆FEV1% predicted following inhalation of
80 µg of ipratropium bromide ≤ 12%) (18). Patients were excluded if they had
asthma as primary diagnosis, medical conditions with a low survival rate, or other
diseases that might influence compliance, bronchial symptoms or lung function
(e.g. alcoholism, cardiac insufficiency, and sarcoidosis). Detailed in- and exclusion
criteria of the COPE study are previously described (19).
From 127 patients in the intervention group of the COPE self-management
study, a purposive sample of 20 patients (10 males and 10 females) were randomly
selected from a list with patient numbers stratified by sex. An independent
researcher (MvdA) who was unaware of the patients and their numbers did the
selection. These patients were interviewed at home using in-depth, semi-struc-
tured, interviews.The study physician asked the patients to participate by phone.
We sampled patients until we had a sufficient number to provide topic saturation
(no additional topics emerged during the final phase of analysis (20).
The COPE self-management intervention consisted of a three elements:
1 A self-management education course, supplemented by a specially made
booklet with background information on the education course and their
disease. The self-management education course consisted of five 2-h group
sessions. Four sessions were given with a one-week interval and the last
(feedback) session was given 3 months after the fourth session.The first ses-
sion addressed coping with breathlessness, obtaining better insight in the
nature of the disease, symptom perception, and coping with triggers for
breathlessness. During the second session the importance of exercise and
CHAPTER 6
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relaxation were emphasised. Patients were motivated to participate in the fit-
ness programme. Furthermore, attention was paid to ergonomic posture and
energy conservation during daily activities or work. The third session con-
centrated on nutrition and its implications for COPD patients. The risk of
involuntary weight loss was emphasised. The themes of the fourth session
were communication and social relationships. Changing role patterns and
communication with the chest physician and other health care professionals
were stressed. The feedback session was aimed at exchanging experiences
and maintaining the acquired knowledge and skills.
2 A fitness programme, which consisted of 1 or 2 one-hour small group train-
ing sessions per week for the duration of the study (2 years) under guidance
of a physiotherapist trained in COPD care. The programme included
strength training, breathing and cardiovascular exercises and, besides physi-
cal goals, the fitness programme was aimed at coping with the disease,
recognising their individual capacity, social interactions and behavioural
change.
If possible, patients were referred to a physiotherapist stationed in their
neighbourhood in order to facilitate participation and to increase social
interaction with other patients in the same geographical area.
3 Guidelines for self-treatment of exacerbations with a short course of oral
steroids and if necessary complemented with antibiotics. These guidelines
were based on symptom perception and were introduced during the first
education session. In order to be able to interpret and use these guidelines
properly, they were discussed again each session. In case of doubt, a fast
deterioration of their pulmonary condition, or absence of improvement,
patients were encouraged to contact the COPE study personnel by phone.
Medical advice was given by telephone or they were invited to come to the
hospital for check-up.
Qualitative study design
The interviews were conducted by a trained independent researcher (MvdA) at
the patients’ home. The main topics of the interviews are presented in Table 1.
The interviews were semi-structured in order to address all relevant aspects of
the intervention, but to maintain the exploratory design of the study the inter-
views were structured according to a three-step approach:
The first question on a topic was generic and exploratory (e.g. Part of the
intervention was the fitness programme: has anything changed in your life due to
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this programme?)
After a topic was touched upon, the researcher asked if other aspects in rela-
tion to this topic had been changed due to the COPE study (Has something else
changed due to the fitness programme?)
In order to obtain saturation on a topic, the interviewer asked for amplifica-
tion using counselling techniques (i.e. offering paraphrase and seeking confirma-
tion that she had understood correctly, for example: so what you are saying is
that the fitness programme has improved your exercise tolerance?).
The interview-format was pre-tested in two pilot interviews, which were
excluded from further analyses. In order to establish reproducibility, the inter-
viewer used an interview guide containing a standard introduction, purpose and
conclusion of the interview. Furthermore, interviews were audio taped and tran-
scribed verbatim. During the whole study, all changes and decisions on the study
procedure and analysis were registered in a log.
Data analysis
Transcripts were analysed using principles of grounded theory (21). Two
researchers (MvdA and EM) independently analysed portions of five interview
transcripts to identify relevant text segments. In this open coding process relevant
concepts were identified from the interview transcripts in a line-by-line analysis
(20). A code addresses the interpretation of a text segment. Subsequently, both
researchers met to discuss discrepancies between codes and to develop consensus
on these codes.A third independent researcher (KK) familiar with the study pur-
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Topics
♦ the COPE programme in general
♦ the fitness programme
♦ the self-management education course
- coping with breathlessness
- the importance of exercise and relaxation
- healthy nutrition and weight control
- communication and social relationships
♦ self-treatment of exacerbations
Table 1 Main Topics of the Interviews
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Code Definition
Fitness programme
fitness programme Everything pertaining to participation in the COPE fitness programme,
except exercise capacity, ergonomic posture, breathing techniques and
relaxation.
exercise capacity Physical ability of the patient.
exercise All physical activities of the patient, except attending the fitness programme,
home and garden activities and activities of daily living. (sports; cycling;
walking)
home and garden activities All activities in and around the house i.e. housekeeping; gardening
activities of daily living The basic activities of daily life i.e. washing ,dressing, eating, cooking.
mobility Everything relating to the ability to move around and to go places.
breathing technique Everything related to breathing technique (e.g. pursed lip breathing) to
control dyspnea
ergonomic posture Knowledge about the best body positions in COPD.
relaxation Recognizing the value of relaxation and relaxation techniques
social activities Social activities in general.
peer group support Social support from other patients.
Self-management education course
energy conservation How does the patient deal with his/her reduced energy?
trigger avoidance Being aware that certain agents can cause coughing or dyspnea, and avoiding
these triggers (e.g. inhaled irritants).
healthy nutrition Everything dealing with healthy nutrition and eating habits.
weight Everything related to weight and weight loss, including knowledge about the
risk of loosing weight.
disease knowledge-other Knowledge of other aspects of COPD, except symptom control
communication chest physician Can patients adequately express themselves and do they perceive
understanding by the chest physician?
symptoms To what level are patients bothered by dyspnea, cough, phlegm, and other
COPD-related symptoms.
symptom control What actions does the patient take to control his/ her symptoms?
Self-treatment of exacerbations
self-treatment Knowledge and attitude regarding self-treatment of exacerbations with
prednisolone or antibiotics.
attitude towards use of
prednisolone and antibiotics
Attitude of the patient towards using prednisolone and antibiotics in general.
General
self-confidence Confidence of the patient in his/her capabilities.
anxiety Anxiety in relation to COPD (course of the disease; dyspnea)
coping How do patients cope with their COPD?
assertiveness Assertiveness of the patient
safety Everything with regard to feeling safe by participating in the study. For
example: 24 hours access to the hospital; frequent check-ups
effects of regular inhaled
medication
Effects and side effects of regular inhaled medication
organisation Everything concerning the way the COPE study was run (e.g. meetings,
attitude of the nurses, et cetera)
age Do patients claim their age to be a cause of their current health status?
recommendation self-
management programme
Would the patient recommend the COPE self-management programme to
other COPD patients?
Table 2 The Definite Code List and the Definitions of the Codes 
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pose was consulted if no code consensus was reached.The resulting code list was
then validated using the transcripts of 5 consecutive interviews. The three
researchers independently coded these transcripts. New codes evolving from
these transcripts were added to the code list. Inter-rater agreement was calculat-
ed by comparing the coding of the researchers pairwise. Inter-rater agreement on
codes varied from 0.79 to 0.88.This resulted in a final code list depicted in Table
2. Subsequently, all interview transcripts were reviewed using the final code list.
After the first 15 completed interviews, five new interviews were performed to
assess topic saturation. Finally, we indexed the transcripts cross-sectionally
according to the codes.Thus all text segments relevant for each code were assem-
bled, facilitating an overall interpretation of the indexed data.This interpretation
process consisted of three steps: first, an initial interpretation was formulated, car-
ried out by a pair of researchers (EM and MvdA) to avoid personal biases.
Second, two other authors (MP and KK) each reviewed these initial interpreta-
tions. Third, a consensus-based final interpretation was formulated. These inter-
pretations reflect the general notion emerging from the indexed patient respons-
es as well as any conspicuous responses. In the result section these interpretations
are reported, each illustrated with the most characteristic quotes.
Results
Twenty patients were interviewed.The mean age of the participants at the time
of the interview was 66 ± 8 years. Table 3 shows the baseline characteristics of
the study population. The interview results are presented in accordance to the
main elements of the COPE self-management programme. Additionally, general
important findings are addressed.
Fitness Programme
The fitness programme appeared to be the most important aspect of the COPE
programme since it elicited the largest number of comments of the respondents.
In general, the participants were very positive about the fitness programme and
this was mainly due to their increased exercise capacity. A patient recounts: ‘In
those two years, I have built up more endurance and breath. I have really benefited from it’.
Another patient noted: ‘At the start of the COPE study, I was very short of breath.
When I was walking with my wife, I frequently had to stop. Now, she has to stop’. Some
patients reported to be more mobile as a result of the endurance capacity gained
CHAPTER 6
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by the fitness programme: ‘But now, if the car is not available, I go by bike to shop.
Before, I couldn’t do this anymore’. The interviews also identified that the social
aspect of the group fitness training is very important to many patients. One
patient stated: ‘I am living alone, so I find the training enjoyable. Most times, we talk 10
minutes before the training starts. For me, it is important that I meet people again.’
Additionally, some patients stressed the importance of peer group support. One
patient said, ‘And then you think to yourself: I am not the only one who has COPD’.
Patients were also positive about the acquired breathing technique to control
their dyspnea and the relaxation exercises. ‘I have learned that you can exercise best
while breathing out instead of while breathing in. In the beginning, I found this very strange,
but it is very important’ stated one patient. Overall, the patients enjoy going to the
fitness programme, and they want to continue after the COPE study. However,
most patients did not become more active outside the fitness programme because
they were already moderately active (i.e. cycling, walking, swimming).
Self-management education course
Energy conservation appeared to be a major aspect for patients to deal with in
daily life. Some patients reported having learned to evenly distribute their ener-
gy and to listen to their body signals due to the self-management education
course. One patient said: ‘If I don’t feel very well in the morning, then I have breakfast
in my pyjamas and rest for a while and do everything in stages’. Other effects gained
by the self-management education course were enhanced disease knowledge and
accompanying skills in general and concerning symptom control. One patient
stated: ‘You learn to pay more attention to your body signals.You master everything better
87
N=20
Age (mean ± sd; years) 66 ± 8
Male (%) 50
Body Mass Index (mean ± sd; kg/m2) 28.7 ± 4.8
Total score SGRQ (mean ± sd) 32 ± 12
FEV1% predicted of normal (mean± sd) 55 ± 18
Six Minute Walk (mean ± sd; meters) 420 ± 117
Current smokers (%) 15
Table 3 Characteristics of the Interviewed Patients 
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and I am very happy with that’. Other patients comment on their increased symp-
tom control: ‘If I feel that my dyspnea is progressing, then I pay attention to my breath-
ing. I just sit down and relax’ Another patient remarked: ‘If I get an attack (of breath-
lessness), then I sit down and try to breath as quietly as possible until everything goes back
to normal. This is a result of the education course’.
Although patients were positive about their increased energy conservation and
symptom control, most patients had no benefit of the session concerning healthy
nutrition and weight control. One patient commented on healthy nutrition: ‘I can’t
say that I eat healthier now.We have always eaten healthy’. Few patients reported to have
learned that loosing weight is not always beneficial in COPD patients. The other
patients discussed the theme weight control in the sense of loosing weight, which
is opposite to the theme of the education course. During the course, the risk of
involuntary weight loss and being underweight for COPD was stressed.
Finally, the communication with the chest physician had not changed due to
the self-management education course. Most patients reported to have a good
relationship with their physician already before the COPE study, and reported no
changes in this relationship.
Self-treatment of exacerbations
Most patients favourably evaluated self-treatment of exacerbation with pred-
nisolone and antibiotics.The possibility to start early, not having to call the doc-
tor and self-determination were raised as important advantages. One patient said:
‘When I was not feeling very well, my phlegm was too yellow and I had got a touch of
flu, that strange feeling, than I knew that I could treat myself.Then, I started a course of
prednisolone and antibiotics.’
Another patient stated: ‘I appreciate that those medicines are at my own disposal, and
that I don’t have to call a doctor first. I find this very easy’. Beside these affirmative
approaches, some patients commented that they do not like prednisolone for it’s
side-effects i.e. ‘feeling stuffed’ and weight gain. A patient commented: ‘I am not
an advocate of prednisolone because it makes me feel stuffed, and my eyelids and legs get
swollen’.
General
Most patients reported that their COPD related symptoms like cough and spu-
tum production have not changed during the COPE study. Likewise, the perfor-
mance of ADL and home and garden activities have not been influenced by the
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COPE study. Some patients in fact experienced a decline in their current health
status, which they (partly) ascribed to their increasing age.
Some patients, though, did report experiencing reduced dyspnea, which was
generally attributed to increased exercise capacity. Some patients reported spon-
taneously that increased self-confidence was an important effect of the COPE
study. One patient stated: ‘Maybe this has nothing to do with my lungs, however, I am
more self-confident. When I started, I was very anxious and restless’. Another patient
commented: ‘Being able to treat my own symptoms gave me a feeling of pride: the fact
that I survived without a doctor for another day or ten’. Furthermore, a few patients
reported that their coping behaviour had improved as a result of the study.
An interesting finding was that many patients expressed to feel more safe by
participating in the COPE study and this appeared to be very important to
patients. Several responses of our subjects are related to this theme. First, patients
mentioned the frequent follow-up visits as a reassuring element. One patient stat-
ed: ‘The thorough check-up of my lung function and other signs, is the most important
aspect of the course. You feel you are in capable hands.Then they check you again, whether
something else is wrong. I really appreciated that’. Second, the 24-hour access to the
hospital and a low barrier to seek help were highly valued. As two patients said,
respectively: 1) ‘If there is something wrong, you can alert the hospital immediately’ 2)
‘As soon as anything serious occurs, I will be in the hospital right away. So, what can hap-
pen to me?’ Third, for some patients the integrated self-management programme
provides them with guidelines that reduce uncertainty: ‘I am not a person that seeks
out all kind of medical things by myself.They showed me the way and I followed it’.
Discussion
This qualitative study suggests that the COPE self-management study in general
has resulted in positive effects on the patients’ daily life and well-being.
In order to fit our results in the field of current HRQoL research, we will sum-
marise the most important effects in four HRQoL domains (22): physical, psy-
chological, social and practical functioning. The COPE fitness programme has
affected the physical domain by increased exercise capacity, improved breathing
technique and more attention for relaxation. Increased coping behaviour, disease-
specific self-confidence and self-determination are psychological effects due to
participating in the COPE study.The latter two might be attributed to the self-
treatment component of the COPE study. Furthermore, feeling safe appeared to
be an important attribute from the patients’ perspective. This aspect, however, is
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not exclusively limited to participants of the COPE self-management pro-
gramme; i.e. the control group might also have experienced these safety feelings
as a result of participating in the study. Nevertheless, the self-management pro-
gramme could have increased safety feelings in at least three ways: first, the
option to self-treat an exacerbation early may have given patients a stronger sense
of control; second, within the programme patients are encouraged repeatedly to
contact the hospital when feeling insecure or loosing control of their health; and
third, the comprehensive, integrated, character of the intervention may be per-
ceived by patients as a reliable supporting system.
Effects on social function can be attributed to the group aspects of the COPE
fitness programme. Patients perceive the fitness programme as a social activity and
benefit from the peer group support. Furthermore, increased mobility as a result
of increased exercise capacity and reduced dependency of physicians due to self-
treatment might also have influenced social functioning.
Practical functioning could be influenced by the increased symptom control
and acceptation of energy conservation. Due to better energy conservation, daily
activities can be performed with reduced dyspnea. Dyspnea is reduced by pre-
venting increase of hyperinflation of the lungs as a result of a more balanced use
of their breathing capacity. Hyperinflation is one of the major causes for dyspnea
(23). Patients might also perceive less psychological distress in performing daily
activities due to acceptation of their reduced energy and the knowledge that they
are able to complete the activity.
The identified positive psychological effects like increased disease specific self-
confidence are not unexpected, because self-efficacy was used as a theoretical
concept (24) in the design of the COPE self-management programme in order
to achieve behavioural change. Self-efficacy refers to the person’s confidence in
his or her capability to execute particular behaviours. In fact, self-efficacy has
been shown to directly predict health status in chronic patients (25). In the study
of Elving et al. generalized self-efficacy appeared to be an independent predictor
of health status, as measured with the SF-36. Specifically, self-efficacy predicted
the social and mental dimension of health status. The study of Camp et al. (17)
indicates that pulmonary rehabilitation implies a process of change in which sev-
eral psychosocial factors, like self-confidence, serve as important mediating vari-
ables. First, acquiring certain skills and knowledge helps patients to manage their
COPD more effectively and leads to a greater confidence and sense of control
over the disease. Subsequently, the patients outlook on the future and their over-
all physical and emotional well-being will improve.This causal model might also
explain the findings of our qualitative study.
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The extent to which the results categorised in the four HRQoL domains are
in agreement with the SGRQ outcomes, will be discussed below. The SGRQ
Total score can be divided into three domain scores: Symptoms (distress caused
by respiratory symptoms i.e. wheeze, cough and sputum), Activities (physical
activities that cause or are limited by breathlessness) and Impacts (social and psy-
chological effects of the disease).
The absence of improvement in the symptom domain of the SGRQ seems in
general to be in agreement with the results of this qualitative study. Patients in
this study did report virtually no changes in distress from cough and sputum due
to the COPE self-management programme.As COPD is a not fully reversible dis-
ease, patients will always suffer from respiratory symptoms. As patients improve
and are able to perform more activities, they will always meet new barriers.
This qualitative study indicated multiple positive effects of the COPE study on
physical function, whereas the SGRQ Activity score did not change.Two reasons
might explain this discrepancy. First, the SGRQ addresses moderately strenuous
activities, like walking up stairs, which are simply no longer performed by the
majority of these patients because they have already adapted their environment
and activities to the restrictions caused by COPD. Consequently, some activities
addressed by the SGRQ will not easily change even when exercise capacity
increases. Second, cycling, an activity which is typical for the Dutch culture, is
absent in the SGRQ. Improved cycling activity can be an early sign of increased
exercise capacity. Indeed, patients in this qualitative study did report improved
cycling activity as an effect of the fitness programme.
As with de SGRQ Activity domain, the lack of social and psychological effects
as measured by the Impacts domain is incongruent with the effects revealed by
the interviews. The interviews identified that social contacts with other COPD
patients was a very important aspect of the COPE self-management programme.
This finding might partly be explained by the fact that a substantial part of the
COPD patients live socially isolated because COPD has restricted their social
activities.This hypothesis is supported by the finding that patients strongly appre-
ciated the peer group support as an important source of recognition, social sup-
port, and sociability.The SGRQ Impact domain does not address disease specif-
ic social isolation nor the importance of social support. Apparent psychological
effects of the COPE self-management programme elicited by the interviews were
increased self-confidence and safety feelings. Both the safety and self-confidence
concept may be reflected by four SGRQ items: 1) ‘I get afraid or panic when I
cannot get my breath’ 2) ‘I feel that I am not in control of my chest problem’ 3)
‘I have become frail or an invalid because of my chest’ 4) ‘Exercise is not safe for
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me’. However, the weight of these items within the SGRQ Impacts score is low.
Furthermore, it is unlikely that these items provide a valid representation of the
self-confidence and safety constructs.
The value of feeling safe seems contradictory to the idea of self-management,
i.e. enhancing self-care and taking responsibility for the disease. On the other
hand, self-management and especially self-treatment of exacerbations will only
work if an adequate safeguard is available. If the patients are not able to fall back
on a medical expert, the threshold for effective self-treatment will be too high.
Similarly, disabled elderly are enabled to stay living on their own by using an
alarm button for emergency situations (26;27).
The fact that the fitness programme appears to be the most important aspect
of the COPE self-management programme might explain the discrepancy
between studies showing beneficial outcomes after pulmonary rehabilitation (28)
and a recent Cochrane Review showing no real benefit for self-management edu-
cation (29). As this qualitative study showed that a fitness programme does not
only influence physiological aspects (i.e. exercise capacity) but also social func-
tioning of the patients, a group exercise component might be an essential com-
ponent for future self-management studies.
In this study, the qualitative interviews showed that the SGRQ and possibly
other existing HRQoL instruments might fail to capture the full experience of
patients in self-management interventions.This study suggests at least three ele-
ments of HRQoL, reported by patients as very important aspects of well-being,
namely self-confidence, feeling safe, and social isolation, that are not adequately
represented by the SGRQ.A recent study also stressed that to maximise HRQoL
in patients with COPD, psychological factors need to be carefully assessed and
addressed (30). Consequently, it seems recommendable to adjust the HRQoL
measure accordingly, i.e. to develop a measure that more closely and explicitly
reflects these psychological and social dimensions.
In general, operationalisation of SGRQ items may be improved by including
more or other stimuli that are relevant to COPD patients, e.g.: including cycling
to the item physical activities. Additionally, the weights assigned to the different
domains may need to be revised to represent more adequately patient’s value.
Another reason for the weak correlation between the SGRQ and the interview
results might be an insufficient validation of the Dutch translation of the ques-
tionnaire.
In summary, the available validated HRQoL instruments might fail to detect
important aspects of patients’ health status. In our view, this calls for additional
qualitative and quantitative research to further explore these neglected areas in
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quality of life of COPD patients and perhaps of other chronic diseases as well.
Potentially, this research will not only contribute to improved measures of
HRQoL but will also add to the development of more effective self-management
programmes.
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Abstract
Objective: Main objective of this study was to investigate whether a compre-
hensive self-management programme, including self-treatment guidelines for
exacerbations and a fitness programme, for COPD patients is an efficient treat-
ment option for COPD patients.
Methods: We randomly allocated 248 COPD patients to either self-manage-
ment (127) or usual care (121). Data on preference based utilities (EuroQol-5D),
health-related quality of life (HRQoL), health-care resource use and productivi-
ty losses associated with exacerbations were prospectively collected. Quality-
adjusted life years (QALYs) were calculated.The economic analysis took the soci-
etal perspective and the observation period was one year.
Results: As we observed that the groups were equally effective in terms of
QALYs and HRQoL (SGRQ), we described a cost minimisation analysis only.
The self-management programme specific costs amounted to € 642 per patient.
In the base-case cost analysis, the incremental cost difference amounted to € 838
per patient per year in favour of usual care.When only direct medical costs were
included the incremental annual costs of self-management relative to usual care
was € 179 per person per year. If time costs for the fitness programme were set
to zero, the costs for self-management diminished to € 542. Sensitivity analysis
showed that these results were robust to changes in the underlying assumptions.
Conclusions: We conclude that the COPE self-management programme is not
an efficient treatment option for COPD patients. The programme was twice as
expensive as usual care and had no measurable beneficial effects on QALYs or
HRQoL
CHAPTER 7
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Introduction
Chronic Obstructive Pulmonary Disease (COPD) causes considerable morbidity
and mortality worldwide.The Global Burden of Disease Study ranked COPD as
the 12th leading cause of morbidity and the sixth leading cause of death (1). By
the year 2020, COPD is predicted to become the fifth leading cause of disabili-
ty and the fourth leading cause of death (1). Besides a substantial loss in health-
related quality of life (HRQoL) for many patients, the disease places a large
financial burden on health-care systems and society. Recently, a large scale inter-
national survey revealed that the annual costs of caring for one COPD patient
varied from $1023 in the Netherlands to $5646 in the USA (2).
Pharmacological treatment of COPD aims to control and alleviate symptoms
and complications of respiratory dysfunction. Non-pharmacological treatment
might be directed to teach patients how to optimally carry out the activities of
daily living in the face of their physiological impairment and has nowadays been
recognised as an opportunity for the reduction of disability and handicap from
the disease (3). Self-management education is a form of non-pharmacological
treatment aimed at teaching skills to optimally control disease, to obtain behav-
iour change and to reach better coping with the disease.
Given the reality of limited health care budgets, it is important to analyse
whether the costs of introducing a comprehensive self-management programme
for patients with COPD outweigh the potential subsequent savings in health care
utilisation and productivity (indirect costs). Additionally, the cost consequences
should be balanced against outcomes based on preference based utilities like
quality-adjusted life years (QALYs). Since QALYs allow decision-makers to com-
pare health-care interventions both within and across diseases, this measure is
currently recommended for all economic evaluations (4;5).
The COPE self-management study was a large randomised controlled trial
designed to evaluate the effectiveness of a self-management education course and
a near-home fitness programme for patients with COPD above usual care (6).
This programme included guidelines for self-treatment of exacerbations with oral
prednisolone and/or antibiotics.The primary outcome was HRQoL measured by
the St. George’s Respiratory Questionnaire (SGRQ) (7). The COPE self-man-
agement programme appeared to have no significant effect on HRQoL, both over
time within the intervention group, as in comparison to usual care (6).
Furthermore, the mean number of exacerbations was 2.8 (SD 2.7; median 2) and
1.5 (SD 1,9; median 1) per patient during one year follow-up in the intervention
and control group, respectively. The majority (69%) of all exacerbations in the
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intervention group was self-treated at home, resulting in a 42% reduction in doc-
tor consultations per patient per year compared to the control group.
This paper reports the economic evaluation of the COPE self-management
programme. As the clinical evaluation did not show significant effects on
HRQoL, we did not expect substantial differences in QALYs, the focus of this
analysis was to investigate whether a comprehensive self-management pro-
gramme for COPD patients is an efficient treatment option for COPD patients
compared to usual care as provided by secondary care chest physicians.
Methods
The design, inclusion criteria and interventions of the COPE self-management
study have been described in detail previously (6;8) and are summarised as fol-
lows.
All COPD patients were recruited from one outpatient pulmonary clinic and
were aged between 40 and 75 years. The diagnosis of COPD was confirmed by
spirometry (ratio of FEV1 to FVC ≤ 60 %, FEV1 percent predicted ≤ 80%) and
absence of a bronchodilator response (∆FEV1% predicted following inhalation of
80 µg of ipratropium bromide ≤ 12%) (9). Patients were excluded if they had
asthma as primary diagnosis.
The COPE self-management study is a randomised controlled trial comparing
the effects of a comprehensive self-management programme with a control group
receiving usual care from the chest physician only. The self-management educa-
tion course consisted of five 2-h group sessions with approximately 8 patients
given by a respiratory nurse. The accompanying fitness programme consisted of
1 or 2 one-hour small group training sessions per week under supervision of a
physiotherapist trained in COPD care and continued for the duration of the study
(1-year). An important factor of the programme was the individual tuning of the
training intensity within group training.
The self-treatment action plan was based on symptom perception. If patients
experienced an increase of respiratory symptoms and normally would have called
their physician, they could initiate a 10-day course of prednisolone 30 mg and
simultaneously an additional 10-day course of antibiotics in case of increase of
purulent sputum.
First choice of antibiotics was amoxicillin/clavulanic acid 625 mg. Second
choice was doxycycline 100 mg.
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Outcomes
Primary outcome for the base-case analysis (main analysis) was defined in terms
of Quality Adjusted Life Years (QALYs).The number of QALYs is derived by the
adjustment of survival data for community-based utilities.Weights for these util-
ities were obtained from the Euroqol-5D questionnaire (10), which provides a
descriptive profile and an utility.This questionnaire includes 5 dimensions (mobil-
ity, self-care, daily activities, pain and mood). A higher utility means a better
health status and the maximum score is 1 (best imaginable health state).
Furthermore, we measured disease specific HRQoL by means of the Dutch
version of the St George’s Respiratory Questionnaire (SGRQ) (7).The SGRQ is
composed of 76 items that are weighted to produce scores in three domains and
a total score. Scores range from 0-100 with lower scores indicating better health
status. A change of score of four points is considered to be clinically significant
(11;12).
Economic evaluation 
A decision analytic model was developed to evaluate the (incremental) costs of
the self-management and control strategy. Figure 1 depicts the decision analytic
model and the base-case probabilities for each step in the model.
A base-case cost-utility analysis was performed according to the U.S. panel on
CEA guidelines (13-15) .This analysis took the societal perspective and the time
perspective was one year.The base-case analysis incorporated assumptions based
on the clinical evaluation of the COPE self-management trial (see Figure 1).
One-way sensitivity analyses were performed to evaluate the relative impact of
the various parameters in the analysis. Cost components were varied over a range
of 50 – 200% of the actual cost. The probabilities of experiencing at least one
exacerbation in both groups were varied between the lower and upper 95% con-
fidence limits. Probabilities of a limited activity day, a hospital admission, and the
mean number of exacerbations per patient were varied over clinically meaning-
ful ranges. Furthermore, we performed an analysis excluding indirect costs and
an analysis setting the time costs for the fitness programme to zero. The latter
was induced by the notion that patients could value time spent exercising equiv-
alent to time spent in other leisure activities (5).
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Figure 1 Decision tree depicting the self-management and control strategy and the base-case 
probabilities for each transition. Furthermore, the base-case analysis incorporated the following
assumptions derived from the clinical evaluation of the COPE study: (1) the probability to participate
in the fitness programme is 0.77; (2) the probabilities of an outpatient visit, telephone consultation
and general practitioner (GP) visit for an exacerbation (excluding self-treated exacerbations and hos-
pitalisations) in the self-management group were 0.37, 0.33 and 0.30, respectively. In the usual care
group, these probabilities were 0.43, 0.33 and 0.24; (3) the mean number of exacerbations was 2.8 in
the self-management group and 1.5 in the usual care group.
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Measurement of resource utilisation
Resource use was measured in natural units and was valued in monetary terms by
multiplying these units by the costs per unit. Costs were distinguished into pro-
gramme costs, direct medical costs, direct non-medical (travel) costs and indirect
costs.The number of programme related physiotherapy visits of each patient in the
intervention group was prospectively recorded by the physiotherapists. Data on
health care resource utilisation associated with COPD exacerbations were prospec-
tively recorded during the study by active follow-up of the patients’ records, both
inpatient and outpatient, with regard to hospitalisations, scheduled and emergency
outpatient visits.We also contacted all the patients’ general practitioners (GPs) to
enquire about treated exacerbations. The treating physician recorded treatment of
exacerbations with prednisolone and antibiotics in a standardised report form. In
case of self-treated exacerbations, patients also recorded the use prednisolone and
antibiotics in a two-week diary and in a standardised report form. Additionally,
pharmacists reported all drugs delivered during the study period. Standard values
for travel distances to the hospital, GP and physiotherapist as specified by current
Dutch guidelines on good pharmaco-economic practice were used (16). Indirect
costs were defined as lost productivity during usual daily activities caused by exac-
erbations and time costs borne by the individual. Patient recorded time lost from
usual daily activities (i.e. housekeeping) and paid employment because of exacer-
bations in a standardised report form. Mean patient time required for the self-man-
agement education course, a physiotherapy visit and an unscheduled emergency
outpatient visit were estimated at 15, 1.5 and 2.5 hours (including waiting and trav-
el time), respectively.
Resource valuation
Standard cost prices as specified by current Dutch guidelines on good pharma-
co-economic practice were the first-choice source for resource unit valuation
(16).Also, lost productivity during usual daily activities due to exacerbations and
time spending in the self-management education course and fitness programme
was valued according to these guidelines (€ 8 per hour).As only 18% of our pop-
ulation were in paid employment, we used this price to convert all limited activ-
ity days (8-hour workday) into monetary terms regardless of employment status
or income of individual participants. Medication costs for exacerbations were
based on market prices for dispensed medication and included pharmacy cost.
The costs of self-management education included salary costs of the respiratory
nurses, travel and parking costs, time costs, costs of the self-management booklet
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and rent for office space.The cost of the different unscheduled health care con-
tacts (outpatient, telephone consultation, GP visits) included salary, travel, park-
ing and time costs, if applicable. Costs of daily medication use and scheduled out-
patient visits were excluded from the base-case analysis because these were
equally divided in both groups.
Costs were based on 2002 unit prices in the Netherlands. For conversion to
U.S. dollars, costs in euros should be multiplied by a factor of 0.934, based on
the 2002 Purchasing Power Parities as issued by the organisation for Economic
Co-operation and Development (www.oecd.org).
Due to the short-time perspective, costs and effects were not discounted for
time preferences.
Statistical analysis
An intent-to-treat analysis was performed, including all randomised subjects
regardless of their compliance.Within and between group differences in EuroQol
utility score and SGRQ Total score were assessed by analysis of repeated mea-
surements using Proc Mixed (mixed models approach) from SAS and 95% con-
fidence intervals were calculated.
QALYs were determined by calculating the area under the curve (time x util-
ity score) for each participant. Mean differences in QALYs were tested using t
test statistics.
Results
Patients and QALYs
Two-hundred-forty-eight (248) moderate to severe COPD patients were ran-
domly allocated to either the self-management (n=127) or control (n=121)
group.Treatment groups were similar with respect to the known prognostic vari-
ables. In the intervention group 5 patients (3 deaths, 2 other) dropped out, as did
7 patients (3 deaths, 2 carcinoma, 2 other) in the usual care group. Thus, 122
patients in the intervention and 114 in the usual care group completed the 1-year
follow-up.Table 1 shows the baseline characteristics of both treatment groups.
Repeated measurement analysis did not reveal differences within and between
treatment groups in mean utility score measured by the Euroqol-5D and HRQoL
measured by the SGRQ (see Table 2). The mean number of QALYs standardised
to one year follow-up were equal in both treatment groups: 0.81 (SD 0.17) and
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Self-management
group
Usual care group
Number of patients 127 121
Age (mean ± sd; years) 65 ± 7 65 ± 7
Male (%) 85 84
Body Mass Index (mean ± sd; kg/m2) 27 ± 4 27 ± 4
Number of exacerbations in year preceding study (mean ± sd) 1.4 ±1.5 1.3 ±1.6
Smoking status (%)
Ex-smokers 72 74
Current smokers 28 26
Lung function post bronchodilation (mean ± sd)
FEV1 (L) 1.71 ± 0.56 1.76 ± 0.54
FEV1 % predicted of normal 56.1 ± 15.4 58.4 ± 14.5
Inhaled corticosteroid use (%) 65 64
Long-acting ß-agonists use (%) 46 45
Education level (%)
Low 68 59
moderate 21 23
High 11 18
# All variables were measured at baseline unless otherwise stated
* Mean values were based on 122 and 118 patients in the intervention and control group respectively
Table 1. Baseline Characteristics of the Two Treatment Groups#
Self-management Control Treatment effect#
baseline 6 month 12 month baseline 6 month 12 month ∆ 95% CI
Utility 0.81
(0.017)
0.81
(0.018)
0.81
(0.018)
0.82
(0.017)
0.80
(0.021)
0.80
(0.022)
0.018 -0.023; 0.059
Total SGRQ score 37.2
(1.6)
37.3
(1.6)
37.4
(1.7)
38.1
(1.5)
38.6
(1.5)
37.7
(1.6)
-0.6 -2.8; 1.7
* Results were obtained with repeated measurements analyses with Proc Mixed (SAS)
#
 Self-management minus Control, adjusted for baseline difference
Table 2 Mean (Se) EuroQol-5D Utility- and SGRQ Total Scores at Each Study Time Point and
Mean Difference Between Both Treatment Groups*
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0.81 (SD 0.19). As we did not find any difference in QALYs between groups and
no cost-effectiveness ratios can be calculated, we will describe a cost-analysis only.
Cost-analysis
The self-management programme specific costs amounted to € 642 per patient
(see Table 3). Physiotherapist visits and patient time costs (for the education
course and fitness programme) constituted the major part of the programme spe-
cific costs (17 and 65%, respectively). The probability of using antibiotics for an
exacerbation was 0.59 in the self-management group and 0.57 in the usual care
group. Mean costs for an exacerbation was € 31.42 in the self-management group
and € 30.66 in the usual care group.The average number of limited activity days
during exacerbation recovery was 4.1 (SD 4.2) in the self-management group
and 5.3 (SD 5.3) in the usual care group: the associated mean indirect cost per
patient per exacerbation was € 337 and € 436, respectively.The average number
of hospital days was 11.4 (SD 6.0) days for both groups. There were no admis-
sions on the intensive care unit. The mean costs for a hospital stay including
patient time was € 3,751.
In the base-case cost analysis, the total annual costs were substantially higher
for patients in the self-management group than for patients in the usual care
group (€ 1,643 versus € 805), largely because of cost incurred by the programme
itself. So, the associated incremental costs amounted to € 838 per patient per year
in favour of usual care (see Table 4). The incremental costs of self-management
relative to usual care for direct medical care alone were € 179 per person per
year. When productivity costs were excluded, the incremental annual costs of
self-management relative to usual care were € 193 per person per year.
Sensitivity analysis
The results from the cost minimisation analysis were not sensitive to realistic
changes in the assumptions upon which they were based.Varying the probability
of a hospitalisation, a limited activity day, the costs of a limited activity day and
time costs did not alter the treatment decision, but these parameters influence the
cost difference most (see Table 5). If time costs for the fitness programme were
set to zero, the incremental costs for self-management reduced to € 542 per per-
son per year.
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Components of costs Source unit
valuation
Unit Mean cost
 per unit
Mean cost
per patient
education course$
respiratory nurse time # hours 50 80
education booklet * piece 5 5
travel costs ✝ km 0.12 8.40
parking costs ✝ visit 1.15 5.75
rent for office space Ψ hours 12.5 15.63
patient time ✝ hours 8 120
fitness programme$
physiotherapist visit ✝ unit 18 110.88
patient time ✝ hours 8 295.68
# Source used for unit valuation: based on the gross hourly wage of respiratory nurses in 2002
* Source used for unit valuation: retail prices
✝ Source used for unit valuation: standard cost prices as specified by current Dutch guidelines on good
pharmaco-economic practice (16)
$ Group education and group fitness training consisted of 8 patients and 4 patients on average, respectively.
Patients attended the fitness programme on average 32 times during a year. 77% of the patients participated
in the fitness programme.
Ψ Source based for unit valuation: based on actual cost in our hospital
Table 3 Breakdown of the Mean Costs per Patient of the Self-management 
Education Course and Fitness Programme 
Base-case estimate (€) Incremental costs (€)Mean annual cost per patient
Self-management Control
Self-management education course 235 - 235
Weekly fitness training 407 - 407
Medication for exacerbations 59 22 37
Hospitalisation costs 432 513 - 81
Health care contact for exacerbation 22 27 - 5
Limited activity days during exacerbation 489 242 247
Total 1643* 805* 838*
* Due to rounding the sum of the costs differ from the total
Table 4 Summary of Important Cost Data in the Base-case Analysis
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Discussion
This economic evaluation showed that the COPE self-management programme
is not a cost-efficient treatment option for COPD patients with regard to improv-
ing HRQoL.The programme was twice as expensive as usual care (€ 1,643 ver-
sus € 805) and had no measurable beneficial effects on HRQoL.The majority of
the difference in societal costs could be attributed to the costs for the self-man-
agement education course and the weekly fitness training. If only direct medical
costs were included, the incremental costs for self-management relative to usual
care reduced significantly to € 179 per patient per year.
As we take into account the cost for regular prescription medication and the
scheduled physician visits, the costs generated by the control population will be
slightly higher than the mean annual costs for COPD  (€ 1024) estimated by the
Confronting COPD survey in the Netherlands (17).The more severe outpatient
COPD population can explain the slightly higher annual costs per patient in our
study. So, we are confident that our study population resembles the general
COPD outpatient population in the Netherlands.
Patient time costs for the fitness programme constituted about one third of the
incremental costs of a self-management patient. Inclusion of time costs and val-
uation of these costs led to much discussion among health economists (5;18). We
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Cost difference
in sensitivity analysis
Base-case (range
 
in
sensitivity analysis)
lower upper
Probability of hospitalisation†*
. Self-management group 0.13 (0; 0.5)
 
726 1157
. Usual care group 0.20 (0; 0.5) 1254 214
Probability of a limited activity day
. Self-management group 0.77 (0.5; 1)
 
666 983
. Usual care group 0.77 (0.5; 1)
 
923 766
Cost of a limited activity hour (€) 8 (4; 16) 723 1067
Time cost per hour+ 8 (0; 16)
 
422 1254
# Difference in annual cost per patient. A positive difference favours the control group.
† This probability is based on patients with at least one exacerbation
*Varied over the probability range from 0 to 0.5. The probability of 0.5 is based on the probability of at
least one exacerbation in the usual care arm of the Bourbeau study (26)
Costs varied from 50% to 200%.
+ Time costs for the self-management education course and fitness programme (opportunity costs of leisure)
Table 5 Sensitivity Analysis of Cost Difference# between Treatment Groups 
(base-case difference = € 838 ) 
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did not measure how individuals value the time spent in the fitness programme.
If patients value time spent exercising equivalent to time spent in other leisure
activities, then the time cost should be valued as zero (5).As the results of a qual-
itative study (19) indicate that our patients were very enthusiastic about the fit-
ness programme and attendance to the programme was voluntary, we feel that
neglecting these time costs might be justified. The sensitivity analysis revealed
that, if time costs for the fitness programme were set to zero, the opportunity
costs for self-management diminished (€ 542).
In COPD, we are aware of one other randomised controlled trial analysing the
costs- and cost-effectiveness of self-management in patients with COPD (20).
This study (the Gallefoss study) concluded that patient education reduced costs
and improved outcomes.The relevance of the selected effectiveness measures, i.e.
a GP independent patient, satisfaction with GP-care and reduced use of rescue
medication might be discussed.The cost savings ($ 1329 in 1994) in the Gallefoss
study are in contrast to the expenses in our study.This might partly be explained
by the fact that reduced absenteeism from work (48% (n=27) was employed)
explained most of the difference in total costs.These results should be considered
in the light of small numbers and skewed cost distribution: only three out of 14
and two out of 13 in the intervention and usual care group respectively, report-
ed on absence from work. So, the two patients reporting absence from work in
the usual care group were major cost drivers due to a high number of lost pro-
ductivity days. A limitation of our study is that we did not collect productivity
data in stable state. If we assume that our self-management group experienced
less limited activity days beyond exacerbation periods than the usual care group,
i.e. because of increased exercise capacity or better coping behaviour, the cost dif-
ference between the groups will diminish.
Another explanation for the expenses in our study is the two fold higher exac-
erbation frequency in the self-management group (due to self-treatment) com-
pared to usual care. The reduced number of health care contacts for exacerba-
tions did not outweigh the increased medication costs for exacerbations. As it is
very unlikely that the difference in exacerbation frequency is a real effect of par-
ticipating in the self-management programme, the question remains whether the
difference in reported exacerbation frequency was induced by underreporting in
the usual care group or overreporting and thus overtreatment in the self-man-
agement group. If the latter is the case, future self-management programmes
should probably incorporate more individualised (21) self-treatment action plans,
so the medication costs and potential side effects of self-treatment will diminish.
Since studies have shown that in developed countries the primary cost driver
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for CODP is hospital care for exacerbations (22-25), prevention of hospitalisation
is an important outcome in economic studies in COPD. However, in our fairly
well stabilised moderate to severe COPD population, the number of hospitalisa-
tions was small and no ICU admissions were necessary. So, the room for subse-
quent cost savings by preventing hospitalisations due to the self-management pro-
gramme is limited.A self-management programme including more severe COPD
patients might yield savings in hospitalisation costs. A self-management study of
Bourbeau et al. (26) found a 40% reduction in hospital admissions for exacerba-
tions in a group of more severe and less stable COPD patients, already admitted
once before entering his study.
Another limitation of this evaluation is the relatively short time horizon since
some study effects might change during longer follow-up. For example, excessive
self-treatment might fade out when patients gain more experience in self-treat-
ment. Furthermore, the difference in limited activity days and hospitalisations
might become more pronounced.
Although we did not find differences on HRQoL and QALYs, we are not will-
ing to conclude that the self-management programme had no beneficial effects
on patients well-being. To understand the striking discrepancy between subjec-
tive positive signals of the self-management patients and the objective HRQoL
data in the COPE study, we have performed a qualitative study (19).This quali-
tative study indicated several positive effects of the self-management programme
on i.e. exercise capacity, symptom control, coping behaviour, disease-specific self-
confidence, and acceptation of energy conservation measures. The qualitative
interviews suggest that the SGRQ and possibly other existing HRQoL instru-
ments might fail to capture the full experience of patients in self-management
studies.
The final point of discussion is whether self-management programmes for
COPD patients in general will be a future treatment option, taking in consider-
ation health effects and costs. In COPD, several studies on the efficacy of self-
management education have been published. A recent Cochrane Review (27),
including 8 studies of self-management education for patients with COPD, con-
cluded that the available evidence is inconclusive due to different study designs,
methodological limitations and a wide variation of reported outcome measures.
The Bourbeau study (26), published after the Cochrane Review, reported a
reduction of exacerbations (18%), emergency room visits and hospitalisations for
exacerbations (40%) in the self-management group.This study did not find a dif-
ference between groups in HRQoL measured by the SGRQ total score.
However, a difference on the impact subscale was observed.Taking into account
CHAPTER 7
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the results from the Bourbeau study and the COPE study in relation to the results
of the Cochrane review, we are still unable to pronounce sentence upon the
effectiveness of self-management programmes in COPD. If beneficial effects of
self-management programmes are established, new economic evaluations should
be performed.
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Abstract
Objective: This study assessed the efficacy of an individual, minimal contact,
smoking cessation programme in COPD patients, using a pre-test post-test
design.
Methods: The study was part of a large ongoing investigation into the effica-
cy of self-management in patients with COPD (the COPE study). In total, the
participants received three 15-to-30 minutes home-based counselling sessions.
Additionally, patients were provided with a written self-help manual. On the
patient’s request, the chest physician prescribed bupropion or nicotine replace-
ment therapy. Cessation rates after 9 months were based on self-report and after-
wards confirmed by salivary cotinine analysis. Patients were biochemically classi-
fied as smoker if their cotinine levels exceeded 20 ng/ml.
Results: At baseline, one third of the 269 patients in the COPE study were
active smokers (according to self-report). Almost 70 percent (n=64) of these
patients were willing to participate in the smoking cessation programme. After 9
months follow-up, 23 (36.5%) patients self-reported abstinence. However, the
cotinine validated abstinence rate was much lower: 12.7 % (n = 8), implying that
the actual abstinence rate is severely overestimated by self-report in this study.
Conclusions: The results suggest that the (validated) effectiveness of this inter-
vention is probably in line with that of comparable programmes for “healthy”
persons. However, considering the urgent need for quitting in COPD patients, a
more intensive programme resulting in higher quit rates seems to be required for
this high-risk population.
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Introduction
Chronic Obstructive Pulmonary Disease (COPD) is the result of many years of
accelerated decline in pulmonary function due to heavy cigarette smoking (1;2).
Smoking cessation is the most important intervention in the management of
COPD because it reduces the decline in pulmonary function and improves the
prognosis for the COPD patient (3;4). Furthermore, quality of life improves when
smokers become non-smokers (5). As COPD patients generally have a long
smoking history, they are considered strongly addicted to smoking, both physi-
cally and psychologically.A study of Jimenez and colleagues (6) found that smok-
ers with COPD have higher tobacco consumption and higher dependence on
nicotine.This different smoking pattern for COPD patients is likely to require a
specific smoking cessation programme.
In many countries, physicians indicate that they are reluctant to discuss smok-
ing cessation with their patients. This might be explained by lack of training in
the management of nicotine addiction in clinical practice and lack of routinely
available smoking cessation programmes (7). Currently, various smoking cessation
programmes that include pharmacological or behavioural elements have been
developed, but these are often unstructured and, more important, not especially
tailored to COPD patients. In the Netherlands, the minimal contact smoking ces-
sation programme (MIS) for “healthy” smokers has been disseminated in 1995
among general practitioners (GP) (8). In a trial involving subjects with GP con-
tacts largely unrelated to smoking, a 13.4% self-reported abstinence rate among
patients receiving the MIS was observed, compared to 7.3% in a usual care con-
trol group (9). A recent survey indicated that 28% of the general practitioners in
the Netherlands are using the MIS (10).This implies that at present only a minor-
ity of Dutch COPD patients will be exposed to this intervention.
We modified the MIS into a slightly more intensive intervention for COPD
patients, administered by pharmacy assistants.The modified MIS was tested in the
smoking population of a large randomised controlled trial of self-management
education in COPD (the COPE study).We assessed the efficacy of the modified
MIS on the basis of a one group pre-test post-test design, using both self-report-
ed and biochemically validated cessation rates.
113
bw-monninkhof&valk  02-12-2003  08:59  Pagina 113
The Intervention 
Theory
The MIS is based on a frequently applied behavioural change theory: the ASE-
model (11-13). This model describes the determinants of both behaviour and
behavioural change.The determinants of behavioural change in the ASE-model are
Attitude, Social support and self-Efficacy. Attitude represents the outcome expec-
tations of a person with regard to the intended behaviour (for example, smoking
cessation) based on a balance of pros and cons. Social support represents the pos-
itive or negative incentives from the person’s social environment. Attitude and
social support together determine the person’s motivation and intention to stop
smoking. Self-efficacy expectations refer to the belief in one’s capabilities to exe-
cute the intended behaviour successfully.The person needs to increase general and
smoking specific self-efficacy expectations and outcome expectations, and the per-
son’s environment needs to provide adequate social support, in order to strength-
en the person’s determination to quit smoking. For example, an individual may be
convinced that quitting smoking is beneficial with regard to pulmonary complaints
and exercise capacity (high outcome expectations), but at the same time this per-
son may not consider himself capable of abstaining from cigarettes in stressful sit-
uations (low self-efficacy). Most important in the ASE-model are the self-efficacy
expectations because these can directly change behaviour.The internal relations of
the determinants of the ASE-model are shown in Figure 1.
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Figure 1 Attitude Social Support self-Efficacy -Model 
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Smoking cessation is not a single event but a comprehensive process. Prochaska’s
Transtheoretical model describes this process in six stages of motivational change
(14).The counselling strategy in this study is tailored to the smoker’s motivational
stage in order to obtain points of departure for efficient and effective counselling.
Furthermore, the MIS is intended to increase both the outcome expectations and
self-efficacy expectations of the patient. Counselling in the MIS is personalised
and consisted for a large part of problem solving strategies for expected difficult
moments in order to increase self-efficacy expectations.
Practice
In preparation for the execution of the modified MIS, 14 pharmacy assistants
from local pharmacies and a respiratory nurse received 4 hours of skills training,
which consisted of education about the theoretical background of smoking ces-
sation, information about COPD, COPD specific problems in smoking cessation,
and training of counselling skills. In addition, the counsellors were supplied with
a written manual that described the procedure of the MIS in detail.
The smoking cessation programme was offered to the current smokers includ-
ed in the COPE study.When motivated to quit (i.e. smoking cessation contem-
plators according to the stages of change model), the pharmacy assistant con-
tacted the patient to arrange a first session. If the patient’s pharmacy was not
involved in the study, our respiratory nurse performed the counselling.The inter-
vention took place at the patient’s home to increase the involvement of family
members in the smoking cessation process (increase of social support).
Additionally, home counselling gives counsellors more insight in the social bar-
riers for smoking cessation, allowing them to anticipate problems better.
In total, the participants received three 15-to-30 minutes home-based coun-
selling sessions. The goal of the first session was to analyse the determinants of
the ASE-model specific for smoking cessation. Problems and barriers were dis-
cussed, and the patients were provided with a written self-help manual. During
this first session, the counsellor arranged a quitting date with the patient. On the
patient’s request, the chest physician prescribed bupropion sustained release (SR)
(Zyban®) or nicotine replacement therapy.The first follow-up session was sched-
uled 2 weeks after the quitting date and the second session after 6-8 weeks.The
goal of the second and third session was to keep the patient motivated and to
support the quitting process.
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Methods
The smoking cessation programme was one group pre-test post-test comparison
nested in the COPE study.The hospital’s ethical committee approved the proto-
col for the COPE study, and written informed consent was obtained from all par-
ticipants.
The study population consisted of current smokers included in the COPE
study. These were outpatients with a clinical diagnosis of stable COPD of the
department of pulmonary medicine of Medisch Spectrum Twente in Enschede,
the Netherlands. All patients were aged between 40 and 75 years.We confirmed
the diagnosis of COPD by spirometry (ratio of FEV1 to FVC ≤ 60 %) and
absence of a bronchodilator response (∆FEV1% predicted following inhalation of
80 µg of ipratropium bromide ≤ 12%) (15). Patients were excluded if they had
asthma as primary diagnosis, medical conditions with a low survival rate, or other
diseases that might influence compliance, bronchial symptoms or lung function
(e.g. alcoholism, cardiac insufficiency, and sarcoidosis.) 
At baseline, we obtained information about demographic variables, nicotine
dependency, smoking history and behavioural determinants. The patients com-
pleted a modified version of the Fagerström questionnaire (16) to study the
degree of physical nicotine dependency. This questionnaire consists of 8 items
summing up to a maximum score of 8 points.
At baseline and after 9 months follow-up, smoking habits were assessed by 
an interview by a lung function technician. Two questions were asked: “Do 
you smoke cigarettes? Yes/No”, and, if yes, “What is the average daily cigarette
consumption?” Additionally, a salivary sample was collected for cotinine assess-
ment. The samples were frozen until assayed. Cotinine is the major metabolite 
of nicotine with a half-life in the body of about 20 hours. It takes about 
four days of abstinence from smoking for the cotinine level to decrease to 
that of a non-smoker (17).The laboratory of our hospital assayed cotinine from
the salivary samples using a gas chromatography technique (GC-MS) (18).
The accuracy and precision of the method was checked by means of reference
samples.
Prevalence rates of self-reported and biochemically validated smoking cessa-
tion at baseline and 9 months follow-up were estimated with corresponding 95%
confidence intervals (CI). Patients were biochemical classified as smokers if their
salivary cotinine level exceeded 20 ng/ml (19). Saliva samples were considered
to be invalid if less than 500 µl saliva was available, and the cotinine concentra-
tions were between 20 and 100 ng/ml.The proportion of patients who misstat-
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ed their smoking habits, in the literature referred to as “smoking deceivers”, was
assessed (20;21).
Statistical analyses were performed using SPSS version 10 (22).
Results
Two hundred sixty-nine (269) COPD patients were enrolled in the COPE study
of whom 90 (33%) self-reported to be current smokers. At baseline, we obtained
saliva samples of 197 (73%) patients: 126 patients reported to be non-smokers
and 71 to be smokers. Cotinine concentrations of 9 saliva samples were invalid,
leaving 188 valid cotinine samples.Table 1 illustrates the calculation of the pro-
portion of expected smokers at baseline using the patients with valid cotinine
samples. Of the 118 patients with self-reported non-smoking, 16 (13.6%) were
classified as smokers based on their cotinine levels. Assuming that the subgroup
with valid cotinine values is representative for the study population, we calculate
that about 45% (84/188) is a smoker at baseline.
Of the patients who admitted smoking, 64 (64/90;71%) were willing to partici-
pate in the smoking cessation programme. The baseline characteristics of this
population are shown in Table 2.
About half of the patients (n=29) used nicotine replacement therapy (NRT)
(n=23) and/or bupropion SR (Zyban®)(n=9).
Of the 64 patients who were enrolled in the smoking cessation programme,
63 could be followed for 9 months. At that time, 23 patients reported abstinence
(36.5%). However, cotinine levels exceeding 20 ng/ml were detected in 12 out
of these reported quitters, and in another 3 no saliva could be obtained. So, the
actual abstinence rate is between 12.7% (8/63) and 13.3% (8/60) depending on
the interpretation of the missing values.
An attempt to discriminate between successful (n=8) and unsuccessful patients
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 Smoker
cotinine > 20 ng/ ml
Non-smoker
cotinine ≤ 20 ng/ ml
 
Self-reported smoker 68 2 70
Self-reported non-smoker 16 102 118
 84 104 188
# based on the patients with valid saliva samples
Table 1 Smoking Status according to Cotinine Levels at Baseline#
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(n=55) on the basis of the baseline characteristics described in Table 2 did not
show any predictors.
Discussion
This study has two main findings. First, disappointingly few COPD patients actu-
ally quit smoking after 9 months follow-up. Second, biochemical validation is
essential in smoking cessation programmes. In this study, 12 (52%) of the self-
reported non-smokers were not truthful about their smoking status. Both find-
ings need to be discussed.
Effectiveness of smoking cessation programme
Our success rate may appear to be low when compared with two other behav-
ioural smoking cessation studies in patients with COPD published after 1990 :
33% and 35% success in the intervention groups, respectively (23;24). Several rea-
sons might explain this. The smoking interventions in both studies were more
intensive and, in fact, it is stated that the intensity of cessation counselling has a
strong dose-response relation with effectiveness (25). Another reason can be the
timing of the intervention. In the study of Pederson and colleagues, counselling
occurred while the patients were in hospital. Hospitalisation can be an opportune
CHAPTER 8
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Male (%) 55 (85.9)
Age (mean ± sd; years) 62.6 ± 7.1
Body Mass Index (mean ± sd; kg/m2) 26.4 ± 4.7
Education level (%)  
 Low 41 (64.1)
 Intermediate 15 (23.4)
 High 7 (10.9)
FEV1% predicted (mean ± sd; litres) 49.4 ± 14.9
Pack-years (mean ± sd) 44.3 ± 16.8
Daily cigarette consumption (mean ± sd) 16.5 ± 12.4
Fagerström score (mean ± sd) (n=55) 3.1 ± 2.1
Quit attempts (%) (n=48)  
 0 14 (28)
 1-2 16 (32)
 2-4 9 (18)
 5+ 9 (18)
Table 2 Baseline Characteristics of COPD Patients who
Entered the Smoking Cessation Programme 
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Effects of the smoking cessation programme
time to intervene with smoking because patients can be more motivated to quit
by the perceived vulnerability related to hospitalisation for their COPD.
However, only a minority of the self-reports in this study were confirmed by
COHb analysis in blood. In the Lung Health Study, participants had mild (symp-
tom free) COPD and this population can be more sensitive to smoking inter-
ventions than those with symptomatic disease as in our study, as they probably
constitute a ‘negative’ selection of patients.
In ”healthy” smokers the MIS is considered as an effective and easy applicable
smoking cessation intervention. The proportion of adults who self-report absti-
nence at 12 months follow-up is twice that of the reference rate without inter-
vention (13% versus 6 %) (9). With this result, the MIS can compete interna-
tionally with other smoking intervention abstinence proportions (26).
Although in our population of COPD patients the efficacy of the modified
MIS was studied without randomised comparison, the biochemically validated
abstinence rate is at least in line with that of comparable programmes. It should
be noted that COPD patients who still smoke form a highly selected group
because they probably have resisted many urgent advises to quit smoking when
they contacted their physician because of their COPD symptoms (27). Also,
patients in this study can be considered highly motivated because they participate
in a time-intensive self-management trial for three years and can be considered
to be in the preparation phase of the Stages of Change Model (14).
As the urgency for quitting is much greater for COPD patients than for
“healthy” smokers, and there is no indication yet, for which COPD patient a
smoking cessation intervention is especially effective, these minimal interventions
should be supplemented or intensified in order to increase the success rates.
Biochemical validation 
Self-reports of smoking abstinence in special subgroups with smoking related dis-
eases are considered to be less reliable than in “healthy” smokers (20;28;29). As
symptomatic smokers feel more pressure to quit smoking whilst at the same time
they are unable to achieve this goal.Additionally, reporting bias will occur when a
health worker in a clinical setting inquires after smoking habits (30). Literature sug-
gests proportions of smoking deceivers varying from 4 to 24% in patients with
coronary heart disease, not participating in smoking cessation trials (20;21;31-34).
Little is known about deception in patients with COPD. One major study report-
ed 6.5% smoking deceivers using saliva cotinine in patients with early stage COPD
(35). In another large smoking cessation trial in patients with smoking related dis-
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ease (80% COPD), about 26% dishonest self-reports were found.We found a much
higher percentage of deception in our COPD patients (52%), indicating a much
higher degree of social desirable response. COPD patients realise that smoking ces-
sation is the most indisputable option to improve their health status.
We learned from this experience that in smoking cessation studies in general,
but especially when COPD patients are involved, biochemical assessment of
abstinence rates is essential.
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Abstract
Objective: To evaluate the effects of optimisation of pulmonary status on FEV1
and health related quality of life (HRQoL) in patients with moderate to severe
chronic obstructive pulmonary disease (COPD).
Methods: A total of 269 moderate to severe COPD outpatients were recruit-
ed. After inhalation instructions and a smoking cessation program for current
smokers, pulmonary status was optimised in a four-month period by bron-
chodilators and high dose inhaled fluticasone propionate. Disease specific
HRQoL was measured by the St George’s Respiratory Questionnaire and gener-
ic HRQoL by the EuroQol Visual Analogue Scale. For both clinical and research
purposes, we used FEV1 and HRQoL as primary outcome measure respectively.
Results: Overall, no change in FEV1 after the four months optimisation peri-
od was observed. Patients with a clinically relevant improvement in FEV1 (≥
200ml and ≥ 12% from baseline) after 4 months showed a clinically significant
improvement in disease specific HRQoL compared to patients without improve-
ment in FEV1. Baseline FEV1 was lowest in patients with an improvement in
FEV1 and highest in patients with a worsening in FEV1.Analysis of the results in
patients divided over the disease specific HRQoL subgroups (improvement, no
change, worsening) did not show a relationship with change in FEV1.. A down-
ward trend in generic HRQoL for the disease specific HRQoL and FEV1 sub-
groups (improvement, no change, worsening, respectively) was observed.
Conclusions: This optimisation programme did not demonstrate an effect on
both pulmonary status and HRQoL. A possible explanation for the lack of an
optimisation effect could be that our patients were already at their optimum and
the disappointingly low proportion of patients that quit smoking. Furthermore
there was evidence of regression to the mean using FEV1 as an outcome mea-
sure.
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Introduction
Chronic obstructive pulmonary disease (COPD) constitutes a major public health
burden worldwide.The World Health Organization predicts that by 2020 COPD
will be the fifth most prevalent disease worldwide and the third most common
cause of death (1;2).Although COPD has its primary effects in the lungs, COPD
is now seen as a systemic inflammatory disease and besides not fully reversible
respiratory impairment, systemic defects such as skeletal muscle impairment and
involuntary weight loss are prominent features (3).The goals of effective COPD
management are to prevent disease progression, relieve symptoms, improve exer-
cise tolerance, improve health status, prevent and treat complications, prevent and
treat exacerbations, and reduce mortality (4). The management strategy is based
on an individualized assessment of disease severity and response to various ther-
apies (4;5). In order to reach this, an individual treatment plan should address the
following important elements: smoking cessation, optimisation of pulmonary sta-
tus by pharmacotherapy including compliance with inhaled medication, physical
activity, nutrition, education on coping behaviour and sufficient knowledge about
COPD and its provoking factors. The first steps should be optimisation of pul-
monary status by appropriate up-to-date drug treatment, inhalation instructions
for a correct use of their inhalers and medications (6) and a smoking cessation
attempt if applicable.These interventions should be maintained or repeated dur-
ing follow-up for stabilisation of the disease, symptom control and increase or
maintenance of optimal quality of life (5). Although there is no generally agreed
definition for stable COPD, stable COPD can be characterized analogous to a
recent definition of exacerbations in COPD, as a condition that includes normal
day-to-day variation without any worsening of symptoms that are acute in onset
and may need additional treatment (7). Patients that are target for optimisation
of pulmonary status are newly diagnosed patients as well as patients in follow-
up, who have had optimisation before, but of which the effects might have faded
away. Taking into account the above mentioned goals of effective COPD man-
agement, we used forced expiratory volume in one second (FEV1) and health
related quality of life (HRQoL) as primary outcome measures.
Although there is a plethora of research on COPD, we are not aware of the
effect of optimisation of pulmonary status in so-called stable COPD patients on
lung function and HRQoL.This paper describes the effects of a four-month opti-
misation programme in moderate to severe COPD patients. The results will be
presented and discussed from the perspectives of both clinical practice and
research.
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Methods
Subjects
From May 1999 through March 2000, all patients were recruited from the out-
patient pulmonary clinic of the Medisch Spectrum Twente: an 1150 bed teaching
hospital in Enschede, The Netherlands. To be eligible for the study the patients
had to meet the following criteria: 1) a clinical diagnosis of COPD, as defined by
American Thoracic Society criteria (8); 2) no history of asthma; 3) no exacerba-
tion in the month prior to enrollment; 4) current or former smoker; 5) age
between 40-75 years; 6) baseline pre-bronchodilator FEV1 25- 80% of predicted;
7) pre-bronchodilator ratio FEV1 inspiratory vital capacity( IVC) value of  60%
or less; 8) reversibility of FEV1 post inhalation of 80 µg of ipratropium bromide
via metered dose inhalator with an aerochamber 12% of predicted value or less
(9); 9) total lung capacity (TLC) greater than the TLC predicted minus 1.64*SD;
10) no maintenance treatment of oral steroids or antibiotics; 11) no medical con-
dition with low survival or serious psychiatric morbidity (e.g. cardiac insufficien-
cy, alcoholism); 12) absence of any other active lung disease (e.g. sarcoidosis); and
13) use of medication such as nasal corticosteroids, theophyllines, chronic use of
acetylcysteine and all other bronchodilators was allowed.
The hospital’s medical ethical committee approved this study. All patients pro-
vided written informed consent.
Study design
Eligible patients entered a four-month period, which contained three visits (Table
1) during which pulmonary status was optimised by the inhaled corticosteroid
(ICS) fluticasone propionate (FP) (Flixotide®; GlaxoWellcome Inc; Zeist,
Netherlands) via Discus/Accuhaler (GlaxoWellcome Inc; Zeist, Netherlands) 500
µg twice daily and inhaled ipratropium bromide (Atrovent®; Boehringer
Ingelheim Inc; Alkmaar; Netherlands) 40 µg four times a day. Short acting β2-
CHAPTER 9
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Visit Time Content of the visit
1 Baseline Baseline measurements, including lung function and HRQoL measured by the
SGRQ and EQ-VAS
2 2-3 weeks Instruction on inhalation techniques, change to study medication and possibility to
enter the smoking cessation programme
3 4 months Measurement of long function and HRQoL measured by the SGRQ and EQ-VAS
Table 1 Content of the Visits
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agonists were used as rescue medication. If used more than twice a day, a long
acting β2-agonist was added.This pharmacological optimisation was based on the
Dutch General Practitioner’s-guidelines (10).These guidelines are congruent with
the later published global initiative for chronic obstructive lung disease (GOLD)
standard on managing stable COPD (4). All patients received instructions in the
correct use of their inhaled medications in small-group sessions given by a res-
piratory nurse. First, the respiratory nurse explained and showed patients the cor-
rect use of their inhaled medication. Subsequently, the inhalation techniques of
all patients were individually judged and corrected in the group session (Visit 2).
Current smokers were offered a smoking cessation programme by means of a
modified version of the Minimal Intervention Strategy (MIS), consisting of three
15-30 min home-based counselling sessions (11). On patient’s request, the chest
physician prescribed bupropion-sustained release (SR) (Zyban®; Glaxo Welcome
Inc; Zeist, Netherlands) or nicotine replacement therapy. Smoking cessation was
biochemically validated. During the optimisation phase patients visited the hos-
pital three times.
Outcome Measures
Lung function parameters (FEV1 post bronchodilation) and HRQoL were the
primary outcomes and were measured at baseline and at visit 3, after four
months. The Dutch version of the St. George’s Respiratory Questionnaire
(SGRQ) and the EuroQol visual analogue scale (EQ-VAS) measured disease spe-
cific and generic HRQoL, respectively.The SGRQ is divided into three domains:
symptoms, activity and impacts (12). Scores on the SGRQ range from 0 (no dis-
turbance of health-related quality of life) to 100. Lower scores represent better
quality of life.A difference of four units indicates a clinically relevant effect (13).
The EQ-VAS scale records the respondent’s self-rated generic health status from
0 (worst imaginable health state) to 100 (best imaginable health state).
Lung function parameters were measured by spirometry. Well-trained lung
function technicians performed spirometry on water sealed spirometers
(Sensormedics Inc; Bilthoven, Netherlands) according to standardized guidelines
and FEV1 and IVC were measured until three reproducible recordings (less than
5% difference) were obtained. Highest values were used for analyses. A clinical-
ly relevant increase in FEV1 was defined as an increase of 200 ml or more and
an increase of 12 % or more from baseline value (14). A clinically relevant
decrease was defined as the opposite of increase.
127
bw-monninkhof&valk  02-12-2003  08:59  Pagina 127
Statistical Analysis
Baseline results are expressed as means (SD) or percentages. We categorised
change in FEV1 and disease specific HRQoL (SGRQ) as follows: no improve-
ment, relevant increase, relevant worsening. Comparison of subgroups for change
in FEV1 and SGRQ were performed by a one-way analysis of variance (ANOVA)
combined with a post-hoc test (Tukey) in case of normally distributed data.
Otherwise a non-parametric test for independent samples (Kruskall-Wallis) was
performed. Between group comparisons of nominal or ordinal variables like
smoking status were performed by Chi-square tests.
CHAPTER 9
128
Excluded
N= 106 (17.5%)
Transport/mobility problems: 19
Refused to participate: 54
Other reasons: 33
Excluded
N= 123 (24.2%)
Transport/mobility problems: 10
Refused to participate: 93
Problems with change in medication: 20
Patients not meeting entry criteria at visit 1
(lung function + general criteria)
N= 117 (30.3%)
Reversibility: 49 TLC:8
FEV1 : 25 FEV /VC:19
Other reasons: 16
Withdrawn between visit 1 and 2
N= 6 (2,2%)
Dead: 1 Failure to return: 4
Lobectomy: 1
Withdrawn between visit 2 and 3
N= 19 (7,2%)
Dead: 4 Failure to return: 7
Other: 3
Visit 2
N= 263
Visit 3
N= 249
Written informed consent
N= 386
Patients included at visit 1
N= 269
Eligible patients
N= 509
Base population
N=615
1
Figure 1 Flow Diagram of Subject Progress through the COPE Study
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Furthermore, we analysed additional factors that might influence FEV1: the
number of exacerbations prior to this study (0, 1 through 3 and more than 3
times), smoking cessation, use of ICS and seasonal influences during the study
period. Seasonal influence was studied by comparing the group of patients that
participated more versus less than 75% of the study in winter period (October
till March) (15).
All statistical analyses were performed using SPSS version 11.5.
Results
Baseline characteristics
Of the 509 eligible patients, a total of 269 patients participated in the study
(Figure 1). Excluded patients were mostly patients that refused to participate and
patients that did not meet the lung function entry criteria. The baseline charac-
teristics of the patients in this study are shown in Table 2.The mean age (SD) of
the patients was 64.0 (7.2). The mean FEV1 % predicted after bronchodilation
was 50.2 (14.0). According to the GOLD criteria this represents moderate to
severe COPD (4). Between the first and second visit, 6 patients (2.2%) were lost
to follow-up: one patient died, one had a lobectomy and four patients failed to
return. Of the remaining 263 patients, 19 (7.2%) were lost between visit 2 and
3: four patients died of causes that were not COPD related, six left the study
because of intolerance to FP, and seven patients failed to return (see Figure 1).
Figure 2 shows the change in medication as a result of the COPD study of the
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Mean (N= 269)
Age in years (SD) 64.0  (7.2)
Male in % 83.3
Body mass index in kg/m2 (SD) 26.9  (4.2)
Smoking status in %
    current
    former
33.5
66.5
Lung function after bronchodilation
    FEV1 in L (SD)
    FEV1 % predicted (SD)
    IVC in L (SD)
    FEV1/VC in % (SD)
    TLC in L (SD)
1.71  (0.55)
50.2  (14.0)
3.86  (0.91)
44.2  (9.9)
7.14  (1.46)
Total score SGRQ (SD) 37.1  (16.2)
Total score EQ-VAS (SD) 69.6  (11.8)
Table 2 Baseline Characteristics of the Patients 
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department of pulmonary medicine Enschede (COPE) study protocol. Substantial
changes occurred in the proportion of patients that used anticholinergics and
short acting β2- agonists (from 50-60% to nearly 100%).
Differences in FEV1 subgroups 
We observed no overall change in FEV1 after four months.The mean difference
in disease specific HRQoL, measured by SGRQ score, between visit 1 and visit
3 is -0.5 (95%CI: -1.8; 0.7). Patients with a clinically relevant improvement in
FEV1 at visit 3 showed an improvement in disease specific HRQoL of 4.3 (95%
CI:1.0;7.5 ) (Table 3) while no change in HRQoL was observed in patients with-
out improvement or worsening in FEV1. Generic HRQoL, measured by the EQ-
VAS score, did not change in patients with an improvement in FEV1 but
decreased in patients with no change in FEV1 (-3.7 (95%CI:-5.4;-2.1)). This
decrease was even more prominent in patients with a worsening in FEV1 (-8.4
(95%CI:-13.4;-3.4)) (Figure 3). However, the differences between the subgroups
were not significant.
There is a significant difference in baseline FEV1 values between the FEV1 sub-
groups. Patients with an improvement in FEV1 had the lowest baseline FEV1 (1.46
L) while patients with a worsening in FEV1 had the highest baseline value (1.91
L), indicating regression to the mean (see Figure 4).The same trend was also visi-
ble for baseline IVC, where we observed an IVC of 3.70 L (improvement), 3.88 L
(no change) and 4.20 L (worsening) in the three subgroups, respectively.
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Figure 2 Medication Use prior and after Visit 2
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Inhaled corticosteroid use prior to this study was similar in all FEV1 subgroups.
The participation in the winter period was similar in all FEV1 subgroups.
Differences in disease specific HRQoL subgroups
The results for the HRQoL subgroups are displayed in Table 4. In this table, we
show the changes in lung function and generic HRQoL (EQ-VAS) for the groups
with and without disease specific HRQoL changes (SGRQ). There was no
change in FEV1 or IVC observed for the disease specific HRQoL subgroups.The
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-9
-8
-7
-6
-5
-4
-3
-2
-1
0
improvement no change worsening
Ô    FEV1
 HRQoL
0.5
1
1.5
2
2.5
improvement fev1 (n=34) no change fev1 (n=191) worsening fev1 (n=24)
Ô FEV1 at visit 1
  FEV1 at visit 3
Figure 3 Differences in EQ-VAS Score between FEV1 and HRQoL Subgroups 
The FEV1 subgroups consist of 34, 187 and 24 patients in respectively the subgroups  improvement,
no change and worsening in FEV1. The HRQoL subgroups consist of respectively 82, 93 and 70
patients for the subgroups improvement, no change and worsening in HRQoL
Figure 4 Change in FEV1 for the Different Subgroups
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generic HRQoL decreased in all disease specific HRQoL groups, although not
significantly in patients that observed an increase in disease specific HRQoL
(Figure 3). The group of patients with a worsening of disease specific HRQoL
showed the largest decrease (5.7 (95%CI:2.8;8.5)).
Effects of smoking cessation
One third of the patients reported to be current smokers. Almost 70% (n=64)
were willing to participate in the smoking cessation program. Disappointingly
few COPD patients actually quit smoking (cotinine validated) after 9 months fol-
low-up (13%; n=8). In patients that quit smoking, FEV1 remained unchanged or
improved. FEV1 in patients that did not succeed, changed in all directions. The
same was true for HRQoL.
Discussion
This study reported for the first time the results of an optimisation programme
in moderate to severe COPD patients before entering a COPD study. It has two
main findings. Firstly, no overall effect of optimisation in stable moderate to
severe outpatients of a pulmonary clinic was found. Secondly, an indication of
regression to the mean was observed using FEV1 as outcome measure. Both find-
ings need to be discussed in the perspective of clinical practice and research.
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Improvement
FEV1 (95%CI)
n = 34
No change 
1(95%CI)
n = 191
Worsening 
FEV1(95%CI)
n = 24
SGRQ score (∆)*
VAS score (∆)**
IVC in L (∆)
-4.26 (-7.55;-1.10)
-2.3 (-6.4;1.7)
0.23 (0.11;0.35)
-0.25 (-1.10;1.59)
-3.7 (-5.4;-2.1)
-0.07 (-0.11;-0.02)
-1.56 (-6.44;3.31)
-8.4 (-13.4;-3.4)
-0.34 (-0.49;-0.19)
FEV1 in L  visit1
FEV1 in L visit 3
IVC in L visit 1
IVC in L visit 3
1.46 (1.33;1.59)
1.85 (1.70;2.00)
3.70 (3.47;3.93)
3.93 (3.70;4.16)
1.75 (1.67;1.83)
1.74 (1.66;1.82)
3.88 (3.75;4.01)
3.82 (3.70;3.94)
1.91 (1.68;2.13)
1.54 (1.36;1.73)
4.20 (3.81;4.58)
3.85 (3.44;4.27)
* A negative SGRQ score means an improvement in and a difference of four units indicates a clinically relevant
effect. A negative EQ-VAS score means a deterioration.
** Respectively 34, 187 and 24 patients of the FEV1 subgroups, improvement, no change and worsening in
HRQoL, measured EQ-VAS.
FEV 
Table 3 Differences between FEV1 Subgroups
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No effect of optimisation
To be eligible for the study, patients were supposed to have stable moderate to
severe COPD, which may have led to a selection of patients already at their opti-
mum.This selection and the disappointingly low proportion of patients that quit
smoking may explain the negative results of this study.
A management programme for COPD patients may contain many different
elements like compliance with inhaled medication, inhalation technique, optimi-
sation of pulmonary status by pharmacotherapy, smoking cessation, physical activ-
ity, nutrition, education on coping behaviour, and providing sufficient knowledge
about COPD and its provoking factors. We focused on inhalation technique,
adjustment of pulmonary pharmacotherapy and a smoking cessation program,
preceding a self-management intervention that contained the other above-men-
tioned elements of management of COPD.
The data suggest that the room for improvement in both inhalation technique
and pulmonary medication was very limited. Repeated training of inhalation
technique in the study region might be already common practice since the pub-
lication of Van der Palen et al. for COPD patients (16). Moreover, prescription
levels of ICS and long acting β2-agonists of which an effect on lung function and
HRQoL might be expected (7;17-19;20) , were not substantially changed. Pre-
study, ICS treatment was almost maximal in our patients. Long acting B2-ago-
nists were not added to pre-study treatment because at start of our study the
added value of this treatment to short-acting B2-agonists was not clear.
Additionally, prescription of anticholinergics (ipratropiumbromide) and short act-
ing β2-agonists as rescue medication were the major changes in pulmonary treat-
ment in this study.The Lung Health study showed a relatively small improvement
in FEV1 in the first year of the study, due to the use of ipratropiumbromide, that
appeared to be reversed after the drug is discontinued (21). However, in our study
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Improvement 
HRQoL
n = 94
No change 
n = 82
Worsening 
HRQoL
n = 73
FEV1 L (∆) 0.02 (-0.03;0.08) 0.02 (0.02;0.07) -0.03 (-0.07;0.02)
IVC L(∆) -0.03 (-0.10;0.03) -0.10 (-0.17;0.04) -0.02 (-0.13;0.09)
EQ-VAS (∆)* -2.2 (-4.6;0.1) -4.5 (-7.0;-2.1) -5.7 (-8.5;-2.8)
*     Respectively 82, 93 and 70 patients of the HRQoL subgroups, improvement, no change and
  worsening in HRQoL, measured EQ-VAS.
HRQoL
Table 4 Differences between SGRQ Subgroups
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we observed an even smaller improvement in FEV1. A possible explanation for
the differences in effect might be that we included patients with a clinical diag-
nosis of moderate to severe COPD while the Lung Health Study included only
“healthy” smokers who probably did not use any pulmonary medication prior to
the study. Therefore, the room for improvement might be much larger in the
Lung Health Study.
In addition, a minimal contact smoking cessation programme that has shown
to be effective in healthy smokers might not be effective enough in populations
of stable COPD patients who already have been trying to stop smoking several
times.
This study, therefore, may not be interpreted as evidence against optimisation
in general.Although an optimisation or run-in period is common practice in asth-
ma studies, such a run-in period may not be very useful in situations where sta-
ble, moderate to severe COPD patients are included, conditioned on high quali-
ty of inhalation technique and pharmacotherapy according to standards. In less
favourable situations and in studies with more severe COPD patients, the effects
of optimisation might be substantial. In addition, effective smoking cessation pro-
gramme should be developed to help COPD patients quit smoking. Furthermore,
in behavioural research, smoking cessation should not be part of a (new) inter-
vention. As smoking cessation itself might have several beneficial effects, net
results of the intervention cannot be determined.
Regression to the mean
There was evidence of regression to the mean using FEV1 as an outcome mea-
sure. This phenomenon leads to overestimation of treatment effects and is com-
mon in studies where the outcome measure have a relative large intra-individual
variability, like FEV1. Attempts to reduce variability (in duplicate or in triplicate
measurements) might reduce regression to the mean. However, without a prop-
er control group, regression to the mean is a serious threat to these kind of stud-
ies. To monitor FEV1 without much variability, it is more efficient to monitor
longer than more frequent (22). Another guard against regression to the mean
can be the use of a control group (23). This study has shown that the effect of
interventions in COPD might be overestimated in studies without a proper con-
trol group.
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COPE Discontinuation of ICS Study
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Abstract
Objective: The aim of this double blind single centre study (the COPE study)
was to investigate the effect of discontinuation of the inhaled corticosteroid flu-
ticasone propionate (FP) on exacerbations and Health-Related Quality of Life
(HRQoL) in patients with Chronic Obstructive Pulmonary Disease (COPD).
Methods: After 4 months of treatment with FP (1000 µg /day), 244 patients
were randomised to either continue FP or to receive placebo for 6 months: 123
patients continued FP (FP-group) and 121 received placebo (placebo group).
Results: In the FP-group, 58 (47%) patients developed at least one exacerba-
tion compared to 69 (57%) in the placebo group.The hazard ratio of a first exac-
erbation in the placebo group compared to the FP-group was 1.5 (95% CI 1.1-
2.1). In the placebo group 26 patients (21.5%) experienced rapid recurrent exac-
erbations and were subsequently unblinded and prescribed FP compared to 6
patients (4.9 %) in the FP-group (Relative Risk = 4.4; 95% CI 1.9-10.3). Over
a 6-month period, a significant difference in favour of the FP-group was observed
in the total score (+ 2.48 95% CI 0.37-4.58), activity domain (+4.64 95% CI
1.60-7.68) and symptom domain (+4.58 95% CI 1.05-8.10) of the St George’s
Respiratory Questionnaire.
Conclusions: This study indicates that discontinuation of FP in COPD patients
is associated with a more rapid onset and higher recurrence risk of exacerbations
and a significant deterioration in aspects of HRQoL.
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Introduction
Chronic Obstructive Pulmonary Disease (COPD) constitutes a major public
health burden worldwide (1). The World Health Organization (2) (WHO) esti-
mates COPD to be the world’s fifth most common disease and fourth leading
cause of death. Both prevalence and mortality are expected to increase in the
coming decades (3;4).
Smoking cessation (5) and bronchodilator therapy (5;6) are the mainstay of the
management of COPD. Born from the idea that both asthma and COPD result
from chronic inflammation, and that inhaled corticosteroids (ICS) are remarkably
effective in controlling inflammation in asthma, there is an intense discussion
whether or not ICS are beneficial in COPD (7;8). Inevitably, clinicians have pre-
scribed ICS in COPD. However, the inflammatory pattern in COPD differs
markedly from that in asthma (9;10), and the safety of long-term, high-dose ICS
has not been well established (11).
Beneficial clinical effects of ICS were observed in recent randomised con-
trolled trials: amelioration of respiratory symptoms (12), persistent improvement
in airways reactivity (12), decreased frequency (13) or severity (14) of exacerba-
tions, diminished use of healthcare resources (12), and improved health-related
quality of life (HRQoL) (13). One observational study (15) suggested that ICS
therapy is associated with reduced COPD related morbidity and mortality in
elderly patients. Of the above mentioned outcome parameters in COPD, exacer-
bations are most relevant for HRQoL, but in all reported studies these were only
measured as secondary outcomes, which were poorly defined.
Inhaled corticosteroids have been shown to be ineffective in arresting long-term
decline in FEV1 as recently reported in five major studies (12;13;16-18).A remark-
able finding reported in two of these studies (13;17) was that treatment with ICS
improves FEV1 slightly in the first 3-6 months, an effect that is maintained during
follow-up treatment.This led to the idea that this initial improvement in lung func-
tion due to ICS is worth pursuing, but the overall effect of prolonged ICS treat-
ment is not yet clear. Only two studies have investigated the effect of withdrawal
of ICS: one observational, non randomised, study (19) as part of the run-in phase
of the ISOLDE study (13) and a small, underpowered crossover study with a short
follow-up and no wash-out period (20). As most of the newly diagnosed COPD
patients receive initial trial treatment for several months, and many of them will
show the initial improvement in FEV1, they will be prescribed ICS for life.
Therefore, there is an urgent need for large randomised controlled studies on dis-
continuation of ICS treatment.
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We investigated the effect of discontinuing maintenance therapy with high
doses (1000 µg/day) of inhaled fluticasone propionate (FP) in a randomised, dou-
ble blind, placebo controlled study (COPE study), on time to first exacerbation
and rapid recurrence of well-defined exacerbations in patients with moderate to
severe COPD.
Methods
Patients
All patients were recruited from one outpatient pulmonary clinic, from May 1999
till March 2000. To be eligible for the study the patients had to meet the fol-
lowing criteria: • a clinical diagnosis of stable COPD, as defined by American
Thoracic Society criteria (21) • no history of asthma • no exacerbation in the
month prior to enrolment • current or former smoker • age between 40-75 years
• baseline pre-bronchodilator FEV1 25- 80% of predicted • pre-bronchodilator
ratio FEV1 / IVC ≤ 60% • reversibility of FEV1 post inhalation of 80 µg of ipra-
tropium bromide via metered dose inhalator with an aerochamber ≤ 12% of pre-
dicted (22) • TLC greater than the TLC predicted minus 1.64*SD • no mainte-
nance treatment of oral steroids or antibiotics • no medical condition with low
survival or serious psychiatric morbidity (e.g. cardiac insufficiency, alcoholism) •
absence of any other active lung disease (e.g. sarcoidosis) • use of medication
such as nasal corticosteroids, theophyllines, chronic use of acetylcysteine and all
other bronchodilators was allowed.
The hospital’s medical ethical committee approved this study. All patients pro-
vided written informed consent.
Trial design
This study was a randomised, double blind, parallel group single centre study that
comprised of 4 months run-in, 6 months active treatment or placebo, with fol-
low-up visits at 3 and 6 months. In the run-in phase, all patients were prescribed
FP via Diskus/Accuhaler 500 µg twice daily and ipratropiumbromide 40 µg four
times daily to optimise lung function. All patients were prescribed short-acting
ß2-agonists (salbutamol) as rescue medication. Patients using rescue medication
more than twice daily were offered a long-acting ß2-agonist.All patients received
inhalation instruction in small group sessions at the start of the study. Current
smokers were offered an individual smoking cessation programme (23).
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Basepopulation
n = 615
Excluded
n= 106;  17.5%
Transport/mobility problems: 19
Refused to participate: 54
Other reasons: 33
Written informed consent
n= 386
Excluded
n= 123;  24.2 %
Problems with change in medication: 20
Transport/mobility problems: 10
Refused to participate: 93
Patients included
n= 269
Patients not meeting entry criteria at visit 1
(lung function + general criteria)
n= 117;  30.3 %
Reversibility  : 49 TLC: 8
FEV1 : 25 FEV /VC: 19
Other reasons: 16
Open label study medication
(visit 2)
n= 263
Withdrawn between visit 1 and 2.
n=6;  2.2%
Dead: 1
Lobectomy: 1 Failure to return: 4
Randomised (visit 3) n=244
FP-group n=123
Placebo group n=121
Eligible patients
n=509
Withdrawn between visit 3 and 5
n=2  0.8 %
Dead due to cancer: 1 (FP group)
CVA: 1 (placebo group)
End double blind phase (visit 5)
Placebo group n=120
End double blind phase (visit 5)
FP-group n=122
Withdrawn between visit 2 and 3
n=19;  7.2 %
Reasons:
Dead: 4    Failure to return: 7
Intolerance FP: 6    Other: 2
1
Figure 1 Flow Diagram of Subject Progress through the COPE Study
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After the four months, eligible patients were randomly assigned to continue FP
500 µg twice daily or to receive placebo administered via the Diskus inhalation
device for 6 months. Randomisation was performed in blocks of 6 by computer
generated allocation. Follow-up visits were scheduled 3 and 6 months post ran-
domisation. Spirometry at regular follow-up visits was measured under post bron-
chodilation medication, and only when the patient was in a stable condition. If the
patient was using a short course of oral steroids or antibiotics or was experiencing
an exacerbation at the time of the follow-up visit, this visit was postponed 4 weeks.
If patients experienced any worsening of their respiratory symptoms, they were
instructed to contact the COPE study personnel by telephone.They were subse-
quently invited to attend the hospital within 12 hours for spirometry measure-
ments and consultation by one of the study physicians who subsequently decid-
ed either to continue the trial or to prescribe FP 500 µg twice daily unblinded.
The latter was allowed according to the benefit of the doubt principle in case
patients experienced rapid recurrent exacerbations. This was defined as either
twice an objective increase in respiratory symptoms within a 3-month period,
defined as more than 20% or 300 ml decrease in FEV1, compared with stable lung
function at randomisation, or three times a subjective increase of respiratory
symptoms in a 3-month period as experienced by the patient regardless of the
above mentioned criteria.
Outcome measurements
Primary outcome measures were first and second exacerbation, and the occur-
rence of rapid recurrent exacerbations, as well as HRQoL. Exacerbations were
defined as worsening of respiratory symptoms that required treatment with a
short course of oral corticosteroids or antibiotics as judged by the study physi-
cian. A short course of oral corticosteroids was defined as 30 mg prednisolone
for a period of 10 days. First choice of antibiotics was amoxicillin/clavulanic acid
625 mg four times daily for a period of 10 days. Second choice was doxycycline
100 mg daily for a period of 10 days. Exacerbations were followed actively as
described under the heading “Trial design”.
Patients with rapid recurrence of exacerbations were those who had to be pre-
scribed FP unblinded due to safety reasons as mentioned above. HRQoL was mea-
sured immediately prior to randomisation, and after 3 and 6 months follow-up, by
means of the Dutch version of the St George’s Respiratory Questionnaire (SGRQ)
and the EuroQol 5D including a Visual Analogue Scale (VAS).The SGRQ is a dis-
ease specific instrument composed of 76 items that are weighted to produce
CHAPTER 10
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domain scores: “symptoms”, “activity” and “impact”. The total score is calculated
from all items and provides a global view of the patient’s respiratory health. The
scores range from 0 to 100, a score of 100 indicating maximum disability (24). A
difference of four units indicates a small clinically relevant effect.The EuroQol-5D
visual analogue scale (VAS) records the respondent’s self-rated health status from 0
(worst imaginable health state) to 100 (best imaginable health state).
Secondary outcome measures were lung function parameters and exercise tol-
erance. Spirometry was assessed immediately prior to randomisation, and after 3
and 6 months follow-up. Well-trained lung function technicians performed
spirometry on water sealed spirometers according to standardised guidelines (25)
FEV1 and IVC were measured until three reproducible recordings (less than 5%
difference) were obtained. Highest values were used for analyses. Exercise toler-
ance was measured at randomisation and after 6 months follow-up by the stan-
dardised six minute walking test (6MW). Oxygen saturation, heart rate and the
Borg-scale of breathlessness by means of an 11-point scale were recorded pre test
and after every minute (26). The performance of the test was standardised:
patients performed a practice walk, were instructed pre test, and no encourage-
ment was used during the test (27). A change of 54 meter in walking distance is
considered clinically important (28).
Use of health care facilities was registered during the study: hospitalisations,
emergency room visits, scheduled and emergency outpatient visits, and exacer-
bations treated by the patient’s general practitioner. Pharmacists reported all
drugs used during the study period.
Patients were asked to complete a two-week diary prior to each follow-up visit
and during periods of increased respiratory symptoms. In the diary, data on
breathlessness, cough, sputum volume, sputum colour, and use of rescue ß2-ago-
nists was collected. Every week patients graded their health status from 1-10. At
each visit patients were questioned about possible adverse events.
Statistical analyses
We calculated that 192 patients (96 per treatment group) were required to detect
a hazard ratio of a first exacerbation of 1.50 (FP compared to placebo) with 80%
power and a two-sided 0.05 α-level test (29).
Baseline characteristics are reported as means ± SD or as percentages within
groups. Analyses were performed according to the intention-to-treat principle.
The effect of discontinuing FP on the subsequent exacerbation risk (the prima-
ry outcome) was assessed using Cox proportional hazard analyses. Between-
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group differences in the proportion of patients with rapid recurrences of exacer-
bations were assessed by means of Chi-squared -tests.
Between-group differences in continuous variables (Quality of Life scores, lung
function parameters) were assessed by analyses of repeated measurements using
Proc Mixed (mixed models approach) from SAS (30). Linear regression analysis was
used to assess between-group differences for the distance walked in 6 minutes.
Within-patient comparisons were done by the paired T-test (normal distribu-
tion) or the Wilcoxon Signed Rank Test (non-Normal distribution).We adjusted
the analyses for potential confounding variables if these variables were not equal-
ly distributed at randomisation.
We performed subgroup analyses for the patients with a FEV1<50% predict-
ed according to the GOLD recommendations for ICS prescription (1).
Except for the repeated measurements analyses, all statistical analyses were per-
formed using SPSS version 10 (31).
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Placebo
Number of patients 123 121
Age (mean ± sd; years) 64.1 ± 6.8 64.0 ± 7.7
Male (%) 85.4 83.5
Body Mass Index (mean ± sd; kg/m2) 26.9 ± 4.0 26.9 ± 4.1
Number of exacerbations in preceding year (mean ± sd) 1.31 ± 1.50 1.36 ± 1.66
Smoking status (%)
Ex-smokers 78.0 66.9
Current smokers 22.0 33.3
Pack years 38.2 ± 26.6 37.3 ± 21.7
Previous use of inhaled corticosteroids (%) 86.2 80.2
Use of long-acting ß-agonists (%) 59 (48%) 53 (44%)
Lung function post bronchodilation (mean ± sd)
FEV1 (L) 1.78 ± 0.53 1.69 ± 0.53
FEV1 % predicted of normal 57.5 ± 14.1 56.1 ± 14.8
VC (L) 3.89 ± 0.85 3.77 ± 0.84
Total score SGRQ (mean ± sd) 34.3 ± 15.5 38.2 ± 16.7
Six Minute Walk (mean ± sd; meters) 458 ± 77 435 ± 87
Table 1. Baseline Characteristics of the Two Treatment Groups
bw-monninkhof&valk  02-12-2003  08:59  Pagina 146
Discontinuation of inhaled corticosteroids in COPD
Results
Baseline characteristics 
Of the 509 eligible patients, a total of 269 were enrolled (Figure 1). The mean
age of the participants was 64.0 ± 7.2 years. Table 1 shows the baseline charac-
teristics of the study population stratified by treatment group. Except for smok-
ing, the two treatment groups were similar with respect to the known prognos-
tic variables. Eighty-three percent (203/244) of the patients had used ICS at least
6 months before entering the study. In the year preceding the study, patients
experienced a mean number of 1.3 exacerbations per year (median =1). Long-
acting β-agonists were used by 48% of the patients in the FP-group and 44% of
the patients in the placebo group.This difference is not statistically significant.
During the four months run-in phase 263 patients received FP 500 µg twice
daily. Of these, 244 patients were randomised; 123 received FP 500 µg b.i.d. and
121 placebo during a period of 6 months. In the run-in phase 19 patients (7%)
had to be withdrawn (Figure 1), 6 because of intolerance to FP. During the dou-
ble blind phase, two patients died; one in the FP group (from cancer) and the
other in the placebo group from a cerebrovascular accident (Figure 1).
Exacerbations
Of the 244 patients, 117 (48%) did not have any exacerbation. 127 (52%) devel-
oped at least one exacerbation: 58 (47.2%) in the FP-group and 69 (57.0%) in
the placebo group.The hazard ratio of a first exacerbation in the placebo group
(adjusted for smoking status) was 1.5 (95% CI 1.05-2.1) compared to the FP-
group (Figure 2). Mean difference in time to first exacerbation, adjusted for
smoking status, between the FP-group (75.2 days) and the placebo group (42.7
days) was 34.6 days (95% CI 15.4-53.8) in favour of the FP-group. The hazard
ratio of a second exacerbation adjusted for smoking status in the placebo group
compared to the FP-group was 2.4 (95% CI 1.5 -3.9).
In the placebo group, 26 patients (21.5%) experienced rapid recurrent exacer-
bations and were thus prescribed FP in an open way in contrast to 6 patients (4.9
%) of the patients in the FP-group (Relative Risk = 4.4; 95% CI 1.9-10.3).
Five of the six patients (83%) in the FP-group who were prescribed FP in an
open way continued to have exacerbations over the remaining trial period in con-
trast to 38 % (10/26) in the placebo group.
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Subgroup analysis
Analysis of the prognostic variables at baseline indicated that the placebo sub-
group with recurrent exacerbations had a slightly higher exacerbation rate pre-
trial, a worse health status and walked less in 6 minutes.The lung function of this
subgroup did not differ from the overall study population. Analysis of the sub-
group of patients with a FEV1 <50% predicted (low FEV1 group) suggests that
the difference in time to first exacerbation between groups is driven by this sub-
set.The hazard ratio was 2.1 (95% CI 1.1-3.6) and 1.2 (95% CI 0.8-2.0) in the
low and high FEV1 group, respectively.
Health Related Quality of Life
Adjusted for baseline scores, smoking status, and time effects a statistically sig-
nificant difference was observed between both groups in the total score (+ 2.48
95% CI 0.37-4.58), in the activity domain (+4.64 95% CI: 1.60-7.68) and the
symptom domain (+4.58 95% CI: 1.05-8.10) over 6 months. No difference was
seen in the impact domain. The results are summarized in Figure 3.Adjusted for
baseline differences, smoking status, and time effects, a small but statistically sig-
nificant difference in mean Euroqol-5D VAS-score of 3.1 points (95% CI 0.8-5.3)
in favor of the FP-group was observed.
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Figure 2 Time to First Exacerbation Curve (Cox Regression) Adjusted 
for Smoking Status for Patients Assigned to FP and Placebo
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Lung function and exercise capacity
During the four-month run-in period, FEV1 did not change. Adjusted for base-
line values, smoking status, and time effects an almost statistically significant dif-
ference of 38 ml in post bronchodilation FEV1 was observed in favour of the FP-
group. Mean distance walked in 6 minutes and mean Borg score of breathless-
ness remained unchanged (Table 2).
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Figure 3 Difference between Placebo and FP-Group in SGRQ-Scores over 6 Months adjusted
for Time Effects, Smoking Status and Baseline Value
Outcome parameter FP
(mean ± SE)
Placebo
(mean ± SE)
Difference #
(95% CI)
P-value
Change in FEV 1  (ml) after -4.6 ± 1.6
n=122
-22.9 ± 1.7
n=120
- 38 (-79.5; 1.6)Ψ 0.056
Six minute walk (meters) -11.0 ± 4.8
n=87*
-0.2 ± 5.2
n=85*
9.37 (-4.47; 23.21)† 0.18
Change in Borg-score (units) -0.07 ± 0.2
n=88*
-0.29 ± 0.2
n=85*
0.29 (-0.13; 0.71) † 0.17
FEV1=forced expiratory volume in one second (litres)
# Analysis of treatment differences were adjusted for smoking status and baseline values.
Ψ Based on repeated measurements analyses with Proc Mixed.
† Based on linear regression analysis.
* numbers are smaller than randomised population for 6MW-distance and Borg score because of practical problems not
all patients performed a 6MW. Patients were randomly assigned to a do a 6MW.
bronchodilator
Table 2 Effect of Treatment by Placebo relative to FP on FEV1, Six Minute Walk (6MW) and
Borg-score of Breathlessness
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Safety
In concordance with the primary outcome results, the frequency of serious
adverse respiratory events (mainly hospital admissions for exacerbations of
COPD) was higher in the placebo group (Table 3).There was no indication that
FP caused serious or non-serious adverse events.
Discussion
This randomised placebo controlled study demonstrated that discontinuation of
FP (1000µg/day) after 4 months of maintenance therapy induced a more rapid
onset and higher recurrence risk of exacerbations in moderate to severe COPD
patients.
The study was motivated by the observation in two earlier studies (13;17)
showing that ICS produces a small initial improvement in FEV1 without addi-
tional reduction in lung function loss in subsequent years. Prior to enrolment in
the present study, 85% of the COPD patients were receiving ICS, which may
explain the lack of the improvement in FEV1 during the run-in period.
The increased risk of exacerbations following withdrawal of ICS is in accor-
dance with the limited evidence available (19;20). In the run-in phase of the
ISOLDE study (19), ICS were withheld from patients already using these med-
ications. In the first 7 weeks post withdrawal, 38 % of patients previously treated
with ICS experienced an exacerbation compared to 6% of those who had not
previously received ICS. Although the patients in the ISOLDE study were more
severe, the higher frequency of exacerbations seen in the COPE study after with-
drawal of ICS might be explained by a prospective and complete registration of
exacerbations. In agreement with the ISOLDE study, the majority of exacerba-
tions in our study occurred in the first seven weeks. The study by O’Brien et
al.(20) demonstrated that withdrawal of ICS in elderly patients with COPD led
to deterioration in ventilatory function and increased exercise-induced dyspnoea
and showed a trend towards an increased frequency of exacerbations. However,
results of this small cross-over study should be viewed with caution as only 15
of the 24 patients completed the study, and follow-up was only 12 weeks.
Moreover, lung function varied considerably (range of FEV1 between 0.73 and
2.42 litres), and the only three patients with exacerbations were withdrawn.Also
our own results with regard to the larger decline in FEV1 in the placebo group
should be viewed with caution. The difference of 38 ml seems relevant, but is
based only on 3 measurements in a period of 6 months.
It should further be stressed that in most studies on effects of ICS in COPD
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(including the two studies dealing with effects of ICS withdrawal), exacerbations
were only considered a secondary outcome and hence were poorly defined,
described, or measured (13;14). By contrast, the COPE study was designed to
investigate the effect of discontinuing ICS on first and second exacerbation and
occurrence of rapid recurrence of well-defined exacerbations. The exacerbation
data of our study can be considered very reliable since all patients were instruct-
ed to call and visit the COPE centre as soon as they experienced any serious
worsening of their respiratory condition, in order to clinically verify the suspi-
cion of an exacerbation. In all of these instances, lung function tests were per-
formed within 12 hours. In addition, all diaries, week reports, hospital records
(hospitalisations, emergency department visits), and records from the patient’s
general practitioner and pharmacists were searched for additional information on
exacerbations.
Assessment of the HRQoL, which is an important outcome in COPD studies
(10), provided us with a comprehensive picture of the overall impact of FP treat-
ment withdrawal in COPD (32).This study showed a significant deterioration in
the total score, symptoms and activity domains of the SGRQ in the placebo
group.This suggests that discontinuation of FP affects distress, due to respiratory
symptoms and disturbance of physical activity, but does not affect the overall
impact on daily living and well being. These findings are in line with the study
by Spencer et al (33).Their results suggest that FP has greatest influence on dete-
rioration in physical aspects of health rather than psychosocial functions.Another
study assessing the effect of exacerbations on HRQoL in COPD, however,
showed worse SGRQ total and domain scores in patients with frequent exacer-
bations (34). Based on this study, one expects worse health status in our patients
in the placebo group because of their higher rate of exacerbations. However, it
should be noted that the patients with frequent exacerbations in the COPE study
received open FP treatment for safety reasons most times already before the first
follow-up visit, and this may have lead to dilution of the effect upon HRQoL.
We did not find relevant differences in the EuroQol-5D VAS score within and
between treatment groups, a finding concordant with the view that a global
assessment of patients’ health underestimates the impact of airways disease on
patients’ perceived health (32).
Further research is needed to analyse the clinical intangible factors of sensi-
tivity to ICS as it is still not well understood why patients with COPD would
benefit from ICS. In addition, it should be stressed that patients treated at a chest
clinic in the Netherlands may have another manifestation of COPD compared to
those treated by the general practitioner.This should lead to caution in extrapo-
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lating the results of this study to the group of COPD patients treated in prima-
ry care.
A hypothetical explanation for ICS sensitivity could be the inclusion of COPD
patients who also have asthma features. Although patients with a history of asth-
ma or reversible bronchial obstruction were excluded, some patients might have
hidden asthma-like characteristics and thus were probably prone to develop an
exacerbation after discontinuation of FP. In this context, it might be relevant that
the subgroup experiencing rapid recurrent exacerbations had slightly more
advanced disease prior to enrolment.
Our study demonstrated that discontinuation of high doses of FP in patients
with moderate to severe COPD induced a more rapid onset and higher recur-
rence risk of exacerbations. However, as 40% of the patients have no untoward
effect from the withdrawal of ICS there is an urgent need to identify which sub-
group of COPD patients responds well to prolonged ICS therapy. Moreover,
there is need for further studies to investigate the efficacy and safety of long-term
use of ICS for the management of COPD.
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To the Editor:
We read with interest the Cope study, which determined that there is an increased
COPD exacerbation rate when subjects are taken off of high dose inhaled corti-
costeroids (1).The COPD subjects in the study all had an FEV1 between 25-80%
predicted with a prebronchodilator FEV1/IVC ratio of 60% or less.
Reversibility of FEV1 for inclusion in the Cope study needed to be less than
12% of predicted after 80 ug of ipratropium bromide via a metered dose inhaler
with aerochamber. Traditionally, significant reversibility is defined using β2-ago-
nist inhalation and at least a 12% improvement in FEV1 from baseline and at least
a 200 ml improvement in absolute FEV1 (2;3). Using less than 12% of predicted
as a bronchodilator response could include some subjects who would be greater
than 12% of baseline using the American Thoracic Society guidelines (2-4). In
addition, it is possible some subjects would respond differently with the use of a
β2-agonist instead of an anticholinergic. This suggests that some of the Cope
study patients probably have a significant degree of reversibility if classically
defined.Therefore, it is possible that some of the patients had asthmatic charac-
teristics that would predispose them toward an exacerbation of lung disease on
withdrawal from inhaled corticosteroids as is seen in the asthmatic population.
Given the above, we were wondering why reversibility was not determined
with β2-agonist therapy, since that is the traditional method.Are there studies val-
idating that anticholinergic reversibility give the same or similar information as
β2-agonist reversibility?
Gene R. Pesola, Sanjay Dogra, Harlem Hospital Center, Columbia University, New York
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Comment on discontinuation of ICS study
From the authors:
We appreciate the comments of Dr. Pesola and Dr. Dogra regarding our article
in the November 2002 issue of the AJRCCM (1) and would like to address their
concerns.
Their first concern pertains to our use of a cut-off point for reversibility of
12% of predicted, compared to 12% of baseline, which they state is used in the
American Thoracic Society (ATS) guidelines (2). Use of the first would lead to
a higher probability to include patients with asthmatic characteristics.
The European Respiratory Society lung function guidelines (3) follow the
study of Brand et al. (4), which compared different expressions of bronchodila-
tor response with respect to dependence on initial FEV1.They conclude that the
∆FEV1 predicted is the most useful method of expressing bronchodilator
response, both for clinical and research purposes. Also, the ATS statement (2)
mentions that expressing the change in FEV1 as percentage of predicted deserves
further study as it has been reported to have advantages over current methods.
Moreover, the change in FEV1 after bronchodilation compared to baseline level
increases in patients with a low initial FEV1. The use of the test with reversibili-
ty of 12% of baseline would have lead to overestimated bronchodilator response
and so to inappropriate exclusion of real COPD patients. Additional analysis of
two subgroups of reversibility in FEV1 according the ATS guidelines showed that
the risk to develop a first exacerbation in COPD after discontinuation of fluti-
casone does not change substantially and is even more prominent in the low
reversibility group (see Table 1).
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Reversibility FEV1 Hazard
Ratio
95% CI N
ERS guidelines# 1.5 1.1-2.1 244
ATS guidelines*
Subgroup 1: only patients with
reversibility <= 12%
1.7 1.02-2.7 152
Subgroup 2: only patients with
reversibility >12%
1.3 0.7-2.4 92
#reversibility of the FEV1 is calculated as percentage of the predicted value:
FEV1post- FEV1 pre bronchodilator/ FEV1 predicted
# reversibility of the FEV1 is calculated as percentage of the baseline value:
FEV1 post- FEV1 pre bronchodilator/ FEV1 prebronchodilator
Table 1 Subgroup Analysis of Time to First Exacerbation
according to Reversibility Guidelines of the ERS and ATS,
respectively
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Their second concern is related to the use of ipratropium bromide for testing
reversibility, instead of a ß-2 agonist. In a study of Hadcroft and Calverley (5), no
significant differences were found in the magnitude of change in FEV1 after
either salbutamol or ipratropium given singly or in combination in COPD
patients. One recent study in asthmatics (6) concluded that both salbutamol and
ipratropium are effective bronchodilators in patients with asthma although the
overall response to salbutamol appears to be superior in asthma. However, in
older patients there was less difference in the reaction to one or other of the two
drugs. Since the patients in our study are relatively old (mean age 64), the type
of bronchodilator seems to be less important. Furthermore, all our patients had
a clinical diagnosis of stable COPD, as defined by ATS criteria without a history
of asthma as checked in their hospital records.We choose to test reversibility after
inhalation of a high dose of ipratropium bromide via a metered dose inhaler with
aerochamber since ipratropium is the first bronchodilator of choice in COPD in
the Netherlands as it is virtually without systemic side effects. As mentioned by
Pesola and Dogra, it is possible that some subjects would respond differently to
the use of a β2-agonist compared to an anticholinergic, but this is also the case
vice versa. Even when asthma is excluded, clinical COPD will always include
some asthmatic features, which are hard to detect by simple reversibility testing.
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Abstract
Background: In Chronic Obstructive Pulmonary Disease (COPD) inhaled cor-
ticosteroids (ICS) are often prescribed, but evidence with regard to their effec-
tiveness and safety is inconclusive.The objective of the current evaluation was to
determine the cost-effectiveness  of withdrawing the ICS fluticasone propionate
(FP) in outpatients with COPD.
Methods: The cost-effectiveness analysis was based on a randomised, double
blind, placebo controlled FP withdrawal study with a follow-up of 6 months (the
COPE study). A decision analytic model with a time perspective of six months
evaluated the short-term incremental cost-effectiveness of the ICS versus ICS-
withdrawal strategy, expressed as cost per exacerbation or cost per hospitalisation
prevented. One-way sensitivity analyses and a Monte Carlo simulation were per-
formed to evaluate the robustness of the findings.To extend the limitation of the
short-term findings, we designed a Markov model with six health states and
monthly transition probabilities for lifetime costs and effects.A Monte Carlo sim-
ulation was conducted to explore the variation in the cost per Quality Adjusted
Life Years (QALY).
Results: The 6-month incremental cost-effectiveness of the FP strategy com-
pared to placebo was € 110 per exacerbation prevented and € 1,286 per hospi-
talisation prevented. The lifetime Markov modelling showed that the FP-with-
drawal strategy resulted in a negligible increase in life expectancy of 0.0133 years
and a cost saving of € 5,029 per patient. It therefore dominates the FP strategy.
Conclusions: Over a six-month period the FP strategy is quite cost-effective.
The lifetime modelling showed that the FP withdrawal strategy is dominant with
a negligible gain in QALD but with large associated cost savings. In the long run,
the dominant strategy is withdrawing inhaled steroids, combined with close fol-
low-up of patients to return those with recurrent exacerbations on inhaled
steroids. Pre-screening patients, e.g. excluding those with a FEV1 <50% predict-
ed, is highly recommended.
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Economic evaluation of discontinuation of ICS
Introduction
Chronic Obstructive Pulmonary Disease (COPD) is a common disease that
affects up to 24 million people in the USA and leads to substantial disability and
death. Patients with COPD have about 3 exacerbations of their disease per year,
many of which result in unscheduled visits to a physician or emergency depart-
ment and to hospitalisation. Clinicians regularly prescribe long-term inhaled cor-
ticosteroids (ICS) for the management of COPD as ICS are effective in control-
ling inflammation in asthma, and both asthma and COPD result from chronic
inflammation. However, the inflammatory pattern of COPD is different from that
of asthma, and evidence with regard to the effectiveness and safety of ICS in
COPD is contradictory (1-5). A recent meta-analysis that included 3571 adults
with COPD who had participated in 6 different studies of long-term use of ICS
showed them to be ineffective in arresting the long-term decline in FEV1 in
COPD. Effects of inhaled steroids on symptoms, numbers of exacerbations, and
adverse effects were inconclusive. Tradeoffs between potential clinical benefits
and harms remain unclear (6). However, the GOLD COPD guidelines recom-
mend that in patients with a FEV1 percent predicted of less than 50% and fre-
quent exacerbations ICS be prescribed (7).
Only three studies have investigated the effect of withdrawal of ICS in COPD:
1) an observational, non randomised, study as part of the run-in phase of the
ISOLDE study (8), 2) a small, underpowered cross-over study with a short fol-
low-up and no wash-out period, (9), and 3) our own study, the COPE study (10).
In the run-in phase of the ISOLDE study ICS were withheld from patients
already using these medications. In the first 7 weeks post withdrawal 38 % of
patients previously treated with ICS experienced an exacerbation compared to
6% of those who had not previously received ICS. Similarly, in the COPE study
the majority of exacerbations also occurred in the first seven weeks. The cross-
over study by O’Brien et al. demonstrated that withdrawal of ICS in elderly
patients with COPD led to deterioration in ventilatory function and increased
exercise-induced dyspnoea and showed a trend towards an increased frequency
of exacerbations. However, results of this small cross-over study should be viewed
with caution as only 15 of the 24 patients completed the study, and follow-up
was only 12 weeks. Clinical results of the COPE study are published in detail
elsewhere (10). In brief, the following results were reported. After 4 months of
treatment with fluticasone propionate (FP), 244 patients were randomised to
either continue FP or to receive placebo for 6 months: 123 patients continued FP
and 121 received placebo. In the FP-group, 58 (47%) patients developed at least
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one exacerbation compared to 69 (57%) in the placebo group.The hazard ratio
of a first exacerbation in the placebo group compared to the FP-group was 1.5
(95% CI 1.1-2.1). In the placebo group 26 patients (21.5%) experienced rapid
recurrent exacerbations and were subsequently unblinded and prescribed open
FP compared to 6 patients (4.9 %) in the FP-group (Relative Risk = 4.4; 95%
CI 1.9-10.3). Five of the six patients (83%) in the FP-group who were prescribed
FP in an open way continued to have exacerbations over the remaining trial peri-
od in contrast to 38 % (10/26) in the placebo group. During the double blind
phase, two patients died; one in the FP-group (from cancer) and the other in the
placebo group from a cerebrovascular accident.
The objective of the current economic evaluation was to assess the cost-effec-
tiveness  of withdrawing the ICS fluticasone propionate (FP) 500 µg twice daily
in outpatients with COPD based on the six months of follow-up in the COPE
study.We utilised decision modelling techniques to assess differences in total costs
as well as cost per exacerbation and hospitalisation prevented over the six month
trial timeframe. Modelling allowed us to explore variation in parameters to
enhance generalisability.
The second objective of this study was to project the lifetime clinical and eco-
nomic effects of steroid withdrawal. To extend the short-term timeframe of the
trial, we employed Markov modelling for lifetime costs and effects, expressed as
cost per quality adjusted life year (QALY) gained.
Methods
Clinical data
The COPE study was a randomised, double blind, parallel group single centre
study that comprised of 4 months run-in and 6 months active treatment or place-
bo, with follow-up visits at 3 and 6 months.The inclusion criteria and design have
been described previously and is summarised briefly below (10). In the run-in
phase all patients were prescribed FP via Diskus 500 µg twice daily, and iprat-
ropiumbromide 40 µg four times daily to optimise lung function. After the four
months, eligible patients were randomly assigned to continue FP 500 µg twice
daily or to receive placebo administered via the Diskus inhalation device for 6
months. Randomisation was performed in blocks of 6 by computer-generated
allocation. Follow-up visits were scheduled 3 and 6 months post randomisation.
CHAPTER 11
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Figure 1 Decision Analytic Model with Probabilities of Exacerbations and Hospitalisations for
the Inhaled Corticosteroid Strategy and the Placebo Strategy
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If patients experienced any worsening of their respiratory symptoms, they were
instructed to contact the COPE study personnel by telephone.They were subse-
quently invited to attend the hospital within 12 hours for spirometry measure-
ments and consultation by one of the study physicians who subsequently decid-
ed either to continue the trial or to prescribe FP 500 µg twice daily unblinded.
The latter was allowed according to the benefit of the doubt principle in case
patients experienced rapid recurrent exacerbations. This was defined as either
twice an objective increase in respiratory symptoms within a 3-month period,
defined as more than 20% or 300 ml decrease in FEV1, compared with stable lung
function at randomisation, or three times a subjective increase of respiratory
symptoms in a 3-month period as experienced by the patient regardless of the
above mentioned criteria. For patients who were already on FP, therapy did there-
fore not change; only the blinding was gone.
Short-term economic evaluation using a decision analytic model
A decision analytic model with a time perspective of six months was developed
to evaluate the short-term (incremental) cost-effectiveness of the ICS versus
withdrawal strategy. Figure 1 depicts the decision analytic model.Table 1 presents
the base-case probabilities with the associated 95% Confidence Intervals (95%
CI) for each step in the model. All data come from the COPE study.
Base-case cost-effectiveness  analyses were performed according to the U.S. panel
on CEA guidelines (11-13). However, indirect costs, such as lost productivity dur-
ing usual daily activities, were excluded from the base-case analyses, thus, assum-
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Base-case value (95% CI)
FP Placebo
Probability of rapid recurrent exacerbations .049 (.023 - .102) .215 (.151 - .296)
Probability of further exacerbations when returned to open FP .833 (.436 - .970) .385 (.224 - .575)
Probability of at least one hospital admission in patients that continue to
experience exacerbations following use of open FP
.400 (.118 - .769) .300 (.108 - .603)
Probability of at least one hospital admission during the six month trial
period in patients that are free of exacerbations following use of open FP
.000 (.000 - .793) .063 (.011 - .283)
Probability of at least one exacerbation in patients not experiencing
recurrent exacerbations
.445 (.358 - .535) .453 (.356 - .553)
Probability of at least one hospitalisation in patients not experiencing
recurrent exacerbations
.135 (.067 - .253) .116 (.051 - .245)
Table 1 Base-case Values of Probabilities of Exacerbations and Hospitalisations with 95% CI
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ing the health care payer’s perspective.The cost-effectiveness  ratio was calculat-
ed as cost per exacerbation prevented and cost per hospitalisation prevented,
respectively. One-way sensitivity analyses were performed to evaluate the relative
impact of the various parameters in the decision analytic model. Cost compo-
nents with the exception of hospital costs were varied over a range of 50 – 150%
of the actual cost.The probabilities of experiencing exacerbations, hospitalisations
and the costs associated with hospital admissions were varied between the lower
and upper 95% CI as derived from the COPE trial data. A Monte Carlo simula-
tion with 1000 iterations was done to explore the variation in the total costs as
well as cost per exacerbation and hospitalisation prevented when cost parameters
and probabilities were varied simultaneously over their ranges and associated 95%
CI. For the cost of exacerbations and FP, triangular distributions were used.The
reason for varying the cost of FP in the model was to facilitate generalisation to
situations where inhaled corticosteroids are cheaper or more expensive. For the
cost of a hospitalisation a Normal distribution was used, while a logistic-normal
distribution was used for all probabilities (14).
Resources and cost
Health care resource use was prospectively recorded during the COPE study by
active follow-up of the patients’ records, both in-patient and outpatient, with
regard to hospitalisations, emergency room visits, scheduled and emergency out-
patient visits.At each visit patients were questioned about possible adverse events
and health care contacts.We also contacted all the patients’ general practitioners
to enquire about treated exacerbations of COPD at the end of the six month fol-
low-up. Pharmacists reported all drugs used during the study period.
Current Dutch guidelines on good pharmaco-economic practice specify that
costs estimated at a national average level should be used as much as possible
(15). Resource use, including the salary of the pulmonary physicians and lung
function technicians was multiplied with 2002 unit prices (16;17). Medication
cost for FP, prednisolone and amoxicillin/clavulanate were based on market
prices and included a €6 dispensing fee added for each 6-month period. During
the trial, 21.5% of patients in the placebo group experienced recurrent exacer-
bations and they resumed open FP for the remainder of the trial. On average they
used FP for 50% (91 days) of the entire trial period of 6 months.
Where applicable, Dutch guilders were converted into Euros (1 Euro (€) =
NLG 2.20). For conversion to U.S. dollars, costs in euros should be multiplied by
a factor of 0.934, based on the 2002 Purchasing Power Parities as issued by the
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organisation for Economic Co-operation and Development (www.oecd.org). Due
to the short-time perspective, costs and effects were not discounted for time pref-
erences.
Long term projection using Markov modelling
To extend the limitation of the short-term decision analytic model, we employed
Markov modelling for long-term costs and effects.The most important long-term
side effect of FP that has a possible impact on mortality, costs, and quality of life
is the increased risk of hip fractures by 19% (18).Also, it must be considered that
courses of oral steroids for treatment of exacerbations will decrease bone miner-
al density and hence increase the risk of hip fractures (19).
At the conclusion of the six months follow-up of the COPE study, four types
of patients could be identified: 1) patients in whom FP was withdrawn and who
did not experience repeated exacerbations as a result (78.5%), 2) patients in
whom FP was withdrawn and who experienced repeated exacerbations as a
result, and who subsequently resumed FP (21.5%), 3) patients who continued
using FP and who did not experience repeated exacerbations (95.1%), and 4)
patients who continued using FP and who experienced repeated exacerbations
(4.9%).We assumed that following recommencement of ICS, patients will expe-
rience a similar course of COPD related events as patients who remained on ICS
throughout the trial. Therefore, for the Markov model three types of patients
were modelled: 1) COPD without ICS, 2) COPD with ICS, and 3) COPD with
ICS and with recurrent exacerbations. Furthermore, the model allowed for gen-
der differences because of the different probabilities with regard to the risk of hip
fractures and mortality.To account for this, a Markov Model with six health states
and monthly transitions was constructed, with a starting age of 50 years (Figure
2).The base state was stable COPD, without exacerbations, hospitalisations or hip
fractures. From this state patients could transition on a monthly basis into a state
where they experienced an exacerbation of COPD, a hospitalisation due to an
exacerbation of COPD, or a hip fracture. For hip fractures a tunnel state was cre-
ated, assuming that the majority of the cost associated with a hip fracture were
accrued in the first month, followed by a state of ‘post hip fracture’, in which
patients remained until death. All states could always lead to death. Disease pro-
gression was not incorporated in the model.
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Monthly transition probabilities were derived from the six months of follow-up
in the COPE study where possible. Following the steroid withdrawal trial, all
patients entered a two-year randomised controlled study on the effects of a self-
management programme. Data on hospitalisations associated with exacerbations
were obtained from the self-management trial data. Furthermore, transition prob-
abilities were obtained from published literature. Conversion of e.g. one-year
probabilities to monthly probabilities was done using the formula of Briggs and
Sculpher (20).
Table 2 describes the transition probabilities as well as the sources. For the
probability of a hip fracture, equations for the Dutch population stratified by gen-
der were used (21).The probability of a hip fracture was increased by 19% when
using ICS, based on a population based case-control study including 16,341 cases
of hip fracture, by Hubbard et al. (18). In clinical practice, exacerbations are treat-
ed with oral corticosteroids that increase the risk of osteoporosis and therefore
hip fracture.We assumed that every course increased the risk of a hip fracture by
167
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Figure 2 Markov Model with Six Health States
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2%, based on extrapolation of data from two studies (19;22). The probability of
an exacerbation in the six-month follow-up in the COPE study was 45% for
those without repeated exacerbations. For patients who kept having repeated
exacerbations after being put back on open FP, the 6-month exacerbation rate
was 83%. During the trial and also in the two-year follow-up in the COPE study,
following the trial, 8.5% of all exacerbations resulted in a hospitalisation.
Data on the probability of a rehospitalisation come from the literature. The esti-
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Parameter Base-case Low High Source
Mortality rate Dutch
population
Age &
gender
specific rates
Central Bureau of Statistics of the
Netherlands
Probability of a hip fracture
Dutch population
Age &
gender
specific rates
De Laet, Van Hout, et al. 1997 (21)
Relative risk of a hip fracture
with ICS-use
1.19 1.10 1.28 Hubbard, Smith, et al. 2002 (18)
Relative risk of a hip fracture
with each course of oral
steroids due to an exacerbation
1.02 1.01 1.04 Walsh, Lewis, et al. 2002(22); Dubois,
Roder, et al. 2002 (19)
Probability of an exacerbation
for patients without recurrent
exacerbations
9.5% 4.75% 19% COPE study
Probability of an exacerbation
for patients with recurrent
exacerbations
25.6% 12.8% 51.2% COPE study
Probability of a hospitalisation
due to an exacerbation
8.5% 4.25% 17% COPE study & two-year prospective
follow-up of the same patients in the
self/management trial
Probability of a
rehospitalisation
5.6% 2.8% 11.2% Sin & Tu 2001 (23), Connors, Dawson, et
al. 1996 (24) Almagro, Calbo, et al.(25),
Niewoehner, Erbland, et al. 1999 (26)
Probability of death following
a hospitalisation due to an
exacerbation
1.4% 0.7% 2.8% Sin & Tu 2001 (23), Connors, Dawson, et
al. 1996 (24) Almagro, Calbo, et al.(25),
Niewoehner, Erbland, et al. 1999 (26),
Fuso et al. 1995 (36), Brandli et al. 1988
(37), Vestbo et al. 1998 (28) Weiss et al.
1994 (38), Seneff et al. 1995 (27)
Mortality rate in first month
following a hip fracture
6% 3% 12% Berglund-Roden, Swierstra, et al. 1994
(29), Boereboom, Raymakers, et al. 1992
(30) Koot, Peeters, et al. 2000 (31)
RR for men of dying after first
month following a hip
fracture, compared to overall
mortality rate
1.8 1.4 2.2 Forsen, Sogaard, et al. 1999 (32)
RR for women of dying after
first month following a hip
fracture, compared to overall
mortality rate
1.5 1.25 1.75 Forsen, Sogaard, et al. 1999 (32)
Table 2 Transition Probabilities. Conversion of e.g. one-year probabilities to monthly probabi-
lities was done using the formula of Briggs and Sculpher.(20)
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mates vary from 25% readmitted within one year to 74% (23-26). For the base-
case analysis, it is assumed that 50% of patients will be readmitted within one year.
Mortality rates following hospitalisations vary considerably, from11% to 59% in one
year, and age seems to be a determining factor (23-28). It is assumed that the one-
year risk of death following hospitalisation is 15% for a person aged 50 years, and
that every year after age 50 this risk increases by 0.5%. Mortality rates following
hip fractures were obtained from the literature. These rates vary by age and gen-
der, and they remain elevated for many years.There are two hip fracture states in
the present model: one in which patients have just experienced the hip fracture,
and where the majority of cost is made, and another where they remain as patients
who have experienced a hip fracture in the past. They remain in this latter state
until death. It is assumed that following a hip fracture, patients will not incur any
other COPD related cost, except the maintenance regimen of ICS. The reported
risk of death within the first month following a hip fracture in the Netherlands
varies from 6% to 9% (29-31).We assumed that in the first month both for men
and women the risk of death following a hip fracture is 6% for a person aged 50
years, and that every year after age 50 this risk increases by 0.25%. In the subse-
quent years, the RR for men of dying is assumed to be 1.8-fold compared to men
without a hip fracture. Similarly, the RR for women is estimated to be 1.5 (32).
The number of QALYs is derived by the adjustment of modelled survival data
for utilities.Weights for these utilities were obtained from the Euroqol-5D ques-
tionnaire (33).The utility of living with COPD (0.81) was assessed in the COPE
trial population by the EuroQol-5D. Utilities of experiencing exacerbations or
hospitalisations were not elicited and could not be found in the literature. They
were estimated to be 0.4 for exacerbations and 0.2 for hospitalisations.The util-
ity for living with a hip fracture was estimated at 0.6 (34).The utility for the first
months is assumed to be 0.2.The discount rate was set at 3% both for costs and
effects. In a sensitivity analysis this was set at 0% and 6%, respectively.
A Monte Carlo simulation was conducted to explore the variation in the cost
per Quality Adjusted Life Years (QALY) when cost parameters and probabilities
were varied simultaneously over their ranges and associated 95% CI. Cost com-
ponents with the exception of hospital costs were varied over a range of 50 –
150% of the actual cost. The costs associated with hospital admissions were var-
ied between the lower and upper 95% CI as derived from the COPE trial data.
The probabilities of experiencing exacerbations, hospitalisations and hip fractures
were varied over the ranges specified in Table 2. The cost with their associated
ranges are specified in Table 3.
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Results
Base-case cost-effectiveness analysis of the trial
The 6-month cost and effect data are presented in Table 4. The average patient
with COPD in the FP-group generated € 511 direct medical cost, including €
238 for FP. The cost of the placebo strategy was € 456. The higher direct drug
cost of € 212 per patient in the six months of follow-up of the FP strategy com-
pared to the placebo group was partially offset by a € 157 lower exacerbation
and hospitalisation cost.
In the base-case cost-effectiveness  analysis, the 6-month incremental cost-
effectiveness of the FP strategy compared to placebo was € 110 per exacerbation
prevented and € 1,286 per hospitalisation prevented.The corresponding Number
Needed to Treat (NNT) to prevent one exacerbation is 2 while the NNT to pre-
vent one hospitalisation is 24.
CHAPTER 11
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Base-case cost Low value High value
Exacerbation € 68 € 34 € 136
Hospitalisation € 2,912 € 1,456 € 5,824
Hip fracture month 1 € 10,000 € 5,000 € 20,000
Hip fracture other months € 150 € 75 € 300
FP, cost per month € 40 € 20 € 80
Table 3 Cost Parameters with their Ranges or Confidence Interval
FP strategy Placebo strategy Difference
Cost per patient
Fluticasone Propionate 500 µg b.i.d. 1 238 26 212
Exacerbation cost 2 59 93 -34
Hospitalisation 3 214 337 -123
Total direct medical cost 511 456 55
Effect per patient
Number of exacerbations 0.87 1.37 -0.50
Number of hospitalisations 0.073 0.116 -0.043
1 includes 6 pharmacy cost/prescription
2 includes salary cost of pulmonary physician and lung function assistant, as well as cost for courses of oral
steroids and antibiotics, including 6 pharmacy cost/prescription
3  average of 10.5 hospital days
Table 4 The Six Month Cost (€) and Effects of Withdrawal of Fluticasone Propionate
500 µg b.i.d. versus Placebo in Outpatients with COPD, using 2002 Cost Prices
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Sensitivity analysis of the decision analytic model
The results from the cost-effectiveness analysis with regard to cost per exacerba-
tion and hospitalisation prevented were sensitive to change in various parameters
(Figure 3,Tornado diagram).When the RR of recurrent exacerbation decreases
to the lower limit of the 95% CI (HR 1.9), the FP strategy exceeds a cost of €
1000 per exacerbation prevented. At a RR of 5.4 both alternatives are equally
costly.The same is true if the cost of FP is reduced to 75% of the base-case cost
at € 177 per six months.The results are also sensitive to the probability of a hos-
pitalisation in those who develop recurrent exacerbations following FP with-
drawal but remain without exacerbations following use of open FP. At the upper
limit of the 95% CI, with a probability of a hospitalisation of 28%, the FP strat-
egy would save € 571 per exacerbation prevented. Furthermore, the results are
sensitive, but to a lesser degree, to the probability of a hospitalisation in those
who develop recurrent exacerbations following FP withdrawal and continue to
have subsequent exacerbations following use of open FP (range of cost per exac-
erbation prevented from € 264 to a saving of € 134) and in those who only have
an occasional exacerbations following FP withdrawal (range of cost per exacer-
bation prevented from € 245 to a saving of € 157). Finally, the results are sensi-
tive to the probability of a hospitalisation in those who remain on FP and only
have an occasional exacerbations (range of cost per exacerbation prevented from
€ 402 to a saving of € 57).
A Monte Carlo simulation with 1000 iterations reached convergence and Figure
4 shows the results of the simulations in cost per exacerbation prevented.The medi-
an cost per exacerbation prevented was € 127 (interquartile range -€ 52 to € 331).
Figure 5 shows the cost per hospitalisation prevented.The median cost per hospi-
talisation prevented was € 122 (interquartile range -€ 1411 to € 3069).
Results from Markov modelling
The undiscounted life expectancy for men and women without recurrent exacer-
bations was 17.5 and 18.7 years, respectively. For men and women with recurrent
exacerbations, despite FP treatment, the life expectancy was reduced to 12.1 and
12.4 years, respectively. The main results of the Markov Model are presented in
Table 5, which includes the discounted overall life expectancy for both strategies.
The strategy to withdraw FP in all COPD patients and to return only those who
experience recurrent exacerbations (21.5%) resulted in an increase in life expectan-
cy of 0.0133 years (4.86 quality adjusted days of life) and a cost saving of € 5,029
per patient (discounted at 3%). It therefore dominates the FP strategy.The men and
171
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-700% -500% -300% -100% 100% 300% 500% 700% 900%
RR of recurrent exacerbations
Prob (hospitalization | no FP, A & B)
Prob (hospitalization | FP, D)
Cost of FP
Prob (hospitalization | no FP, D)
Prob (hospitalization | no FP, A & C)
Prob (exacerbation | FP, D)
Prob (exacerbation | no FP, D)
Prob (exacerbation | no FP, A)
Prob (hospitalization | FP, A & C)
Cost of a hospitalization
Prob (exacerbation | FP, A)
Cost of an exacerbation
Prob (hospitalization | FP, A & B)
% Change from Base Value
A: recurrent exacerbations leading to use of open FP
B: no further exacerbations following use of open FP
C: further exacerbations following use of open FP
D: occasional exacerbation, not leading to use of open FP
Figure 3 Tornado Diagram for Cost per Exacerbation Prevented
A positive change from base value favours the placebo strategy.
-€ 600
-€ 500
-€ 400
-€ 300
-€ 200
-€ 100
€ 0
€ 100
€ 200
€ 300
€ 400
€ 500
0 0,2 0,4 0,6 0,8 1 1,2
Difference in exacerbations
Figure 4 Results of a Monte Carlo Simulation on Cost per Exacerbation Prevented
A positive €-amount favours the placebo strategy. A positive difference in number of exacerba-
tions favours the FP-strategy.
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women without recurrent exacerbations (95%) experienced 19 and 20 exacerba-
tion during their lifetime, respectively. For those with recurrent exacerbations,
these numbers were 34 and 35, respectively. Hip fractures are associated with a
considerable loss in utility, but only a very small amount of time is spent in this
state because it is so rare.The average time spent varies from 5 days in men with
repeated exacerbations, to an average of 20 days for women with ICS but with-
out repeated exacerbations.
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Figure 5: Results of a Monte Carlo Simulation on Cost per Hospitalisation Prevented
A positive €-amount favours the placebo strategy. A positive difference in nr of exacerbations
favours the FP-strategy.
Life expectancy1
(years)
Cost for health
events 1,2
Cost of FP
treatment 1,3
Total direct medical
cost
No FP strategy 13.355 €   4,936  €   1,294  €  6,230
FP strategy 13.342 €    4,952     € 6,306  €  11,259
Difference 0.0133 €  16 €  5,012 €  5,029
1 Discounted at 3%
2 Includes cost for exacerbations, hospitalisations and hip fractures
3 In the no FP strategy 21.5% of patients are returned on FP within 6 months
Table 5. Lifetime Cost and Effect Parameters
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Sensitivity analysis of the Markov model
A Monte Carlo simulation was run, using the transition probabilities from Table
1 and the costs from Table 2, and their associated upper and lower bounds. The
simulation was run for 1000 iterations to reach convergence. Figure 6 shows the
cost plotted against Quality Adjusted Life Days (QALD) gained. In all cases, the
FP withdrawal strategy was the dominant strategy.The difference in QALD var-
ied from 1 to 13 days, while the cost-difference varied from € 2200 to € 8000,
both in favour of the FP withdrawal strategy.The difference in QALD was most
sensitive to the probability of an exacerbation, the Relative Risk of a hip frac-
ture when using ICS and the probability of a hospitalisation following an exac-
erbation.The difference in costs was mainly sensitive to the price of FP and to a
much lesser extend to the probability of an exacerbation.
Discussion
In the base-case cost-effectiveness  analysis, the 6-month incremental cost-effec-
tiveness of the FP strategy compared to placebo was € 110 per exacerbation pre-
vented and € 1.286 per hospitalisation prevented, which makes it a quite cost-
effective treatment option.The lifetime modelling showed that the FP withdraw-
al strategy is dominant with a negligible gain in QALD but with a large associ-
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Figure 6 Results of a Monte Carlo Simulation Plotting the Cost against the
Difference in Quality Adjusted Life Days
A negative €-amount favours the placebo strategy. A positive difference in Quality adjusted
Life Days favours the placebo strategy.
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ated cost saving of € 5029 per patient. Although the FP strategy seems reason-
ably cost effective over a short follow-up period of six months, in the long run
it is the more costly approach with no associated long-term benefits. Also, the
short-term results are quite sensitive to the risk of repeated exacerbations when
withdrawing FP, and to the probability of a hospitalisation, while the long-term
modelling is robust in its findings, with the observed cost difference driven main-
ly by the use of FP.
The beneficial effects of ICS have been investigated previously in COPD
patients, and a recent meta-analysis showed them to be ineffective in arresting the
long-term decline in FEV1 in COPD and their influence on symptoms, exacer-
bations, and adverse effects were inconclusive (6).The current study is in agree-
ment with this analysis in that it does not show long-term benefits of treating all
COPD patients with ICS.
Sensitivity analyses showed that the short-term results are sensitive to the risk
of recurrent exacerbations when withdrawing FP.When the risk of exacerbations
with the withdrawal of FP becomes relatively low, the FP strategy becomes very
expensive. In practice, a sizable proportion of COPD patients also has asthma-
like characteristics. It is likely that especially these patients are most sensitive to
the positive effects of ICS.Withdrawing inhaled steroids in a COPD population
where patients with these asthma-like characteristics have been screened out,
would probably reduce the risk of repeated exacerbations and will make the cost-
effectiveness ratio much less favourable for the FP strategy. Conversely, in a reg-
ular outpatient population where ‘pure’ COPD patients and patients with symp-
toms of both asthma and COPD are more mixed than in our trial setting, where
a serious attempt was made to exclude patients with asthma-like symptoms, the
opposite will be true.The FP withdrawal strategy will result in a higher risk, with
FP becoming the dominant strategy when the RR exceeds 5.4.
Given the sensitivity of the cost-effectiveness ratio to the risk of recurrent
exacerbations when withdrawing FP, it is important to identify patients with
COPD in whom withdrawing FP is likely to be safe or not.The GOLD COPD
guidelines recommend that in patients with a FEV1 percent predicted of less than
50% and frequent exacerbations ICS be prescribed (7). Analysis of the subgroup
of patients with a FEV1 <50% predicted in the COPE ICS withdrawal study sug-
gested that the difference in time to first exacerbation between groups was dri-
ven by this subset (10).
The results were also sensitive to the cost of FP.The sensitivity analysis of the
trial results also shows that the FP strategy becomes very expensive if the cost of
FP is doubled.This, however, is not very realistic because the patients in the study
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already received 1000 µg per day, which is considered to be the maximum dose
patients should be prescribed as maintenance therapy. If the cost of FP would be
reduced to below 75%, the FP strategy becomes dominant. If this reduction in
monthly cost is achieved with the same dosage of 1000 µg per day, this holds
true. However, it is unlikely to be achieved by reducing the dosage to e.g. 500 µg
per day as lower doses of ICS have shown to be ineffective in COPD (35).
The unfavourable effects of withdrawing FP manifest themselves at an early
stage.Among patients that were returned on open FP, the average time it took to
develop two objective exacerbations was exactly 3 months, from the moment FP
was withdrawn.When patients are subsequently returned on FP, it is assumed that
they will have a similar future risk of adverse events as patients who remained
on FP. The long-term effect of withdrawing ICS in COPD patients and only
resuming ICS in those with rapid recurrent exacerbations has been modelled in
this study but warrants further investigation.
In summary, withdrawing FP in a pre-selected trial population of COPD patients
led to absolute cost-savings but with a higher exacerbation and hospitalisation rate.
However, in the long run, withdrawing inhaled steroids and close follow-up of
patients to return those with recurrent exacerbations on inhaled steroids, is the
dominant strategy. Pre-screening patients is highly recommended, both to prevent
unnecessary harm to patients, as to prevent an unnecessary high workload for the
physician.
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Abstract
Objective: The aim of this study was to investigate the effect of bacterial coloni-
sation during stable disease on time to first exacerbation in patients who either
discontinued or continued fluticasone propionate (FP).
Methods: In a randomised controlled trial, 244 COPD patients either contin-
ued using FP or received placebo for 6 months, after 4 months of treatment with
FP. Sputum samples were collected at randomisation and during exacerbations.
We calculated the time to development of an exacerbation in colonised com-
pared to non-colonised patients in relation to ICS use.
Results: At randomisation, we collected sputum samples of 209 patients, of
which 36% were colonised with potentially pathogenic microorganisms. We did
not find effect modification by FP status (FP or placebo), but effect modification
by FEV1 was present. The adjusted hazard ratio of a first exacerbation in
colonised compared to non-colonised patients was 1.29 (95% CI 0.76-2.20) and
1.01(95% CI 0.56; 1.81) in patients with a FEV1 ≥ 50%, and FEV1 <50%, respec-
tively.
Conclusions: Bacterial colonisation in moderate to severe COPD patients is
not an independent risk factor for the development of acute exacerbations.There
is no interaction between colonisation and discontinuation of ICS on time to first
exacerbation.
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Bacterial colonisation and risk of exacerbations
Introduction
The clinical course of chronic obstructive pulmonary disease (COPD) is one of
gradual progressive impairment, which despite optimal pharmacological treat-
ment may lead to substantial functional limitations and eventually to respiratory
failure (1;2). Morbidity and mortality among patients with COPD are for the
most part related to acute exacerbations of COPD (3;4) which occur on average
one to three times a year (5).The clinical effects of inhaled corticosteroids (ICS)
on exacerbations in COPD observed in recent studies were a more rapid onset
and higher recurrence-risk of exacerbations after discontinuation of ICS (6), and
a decreased frequency (7) or severity (8) of exacerbations. ICS affect airway
inflammation in COPD, which may explain the decrease in exacerbations (9).
However, many issues related to exacerbations remain unclear or controversial
including the role of microorganisms in the airways of the COPD patient (10-
12). A significant proportion of patients with COPD have lower airway bacterial
colonisation with a spectrum of pathogens including non- typeable Haemophilus
influenzae, Streptococcus pneumoniae, and Moraxella catarrhalis (13;14). Simple
bronchial colonisation or overgrowth of potentially pathogenic microorganisms
(PPM) may promote bronchial inflammation (15) hence promoting bronchial
injury and consequently, by higher sputum levels of inflammatory mediators,
exacerbations (16;17). Recent longitudinal studies compared for the first time the
role of bacterial colonisation in COPD exacerbations and in stable state (18-20).
These have clearly demonstrated that especially the acquisition of a new bacter-
ial strain promoted the development of a bacteriological proven exacerbation
(19). Since ICS affect airway inflammation in COPD, discontinuation of these
corticosteroids in colonised patients might have profound effects on the acquisi-
tion of new bacterial strains and so promoting exacerbations.
The aim of this single center prospective study was to investigate the effect of
bacterial colonisation during stable disease on time to first exacerbation in
patients who either discontinued or continued the inhaled steroid fluticasone pro-
pionate (FP) in a randomised double blind fashion.
Patients and Methods
Patients
From May 1999 through March 2000, patients were recruited from the outpa-
tient pulmonary clinic of the Medisch Spectrum Twente: an 1150 bed teaching
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hospital, in Enschede, The Netherlands. To be eligible for the study the patients
had to meet the following criteria: 1) a clinical diagnosis of stable COPD, as
defined by American Thoracic Society criteria (21); 2) no history of asthma; 3)
no exacerbation in the month prior to enrolment; 4) current or former smoker;
5) age between 40-75 years; 6) baseline pre-bronchodilator FEV1 25- 80% of pre-
dicted; 7) pre-bronchodilator ratio FEV1 inspiratory vital capacity ( IVC) value
of  60% or less; 8) reversibility of FEV1 post inhalation of 80 µg of ipratropium
bromide via metered dose inhalator with an aerochamber 12% of predicted value
or less (22); 9) Total Lung Capacity (TLC) greater than the TLC predicted minus
1.64*SD; 10) no maintenance treatment of oral steroids or antibiotics; 11) no
medical condition with low survival or serious psychiatric morbidity (e.g. cardiac
insufficiency, alcoholism); 12) absence of any other active lung disease (e.g. sar-
coidosis); and  13) use of medication such as nasal corticosteroids, theophyllines,
chronic use of acetylcysteine and all other bronchodilators was allowed.
The hospital’s medical ethical committee approved this study. All patients pro-
vided written informed consent.
Trial design
This study was designed as a randomised, double blind, parallel group single cen-
tre study that comprised of 4 months run-in, followed by 6 months of active
treatment or placebo (6). In the run-in phase all patients were prescribed the
inhaled corticosteroid, fluticasone propionate (FP) via Diskus/Accuhaler 500 µg
twice daily, and bronchodilators to optimise lung function. After 4 months
patients were randomly assigned to continue FP 500 µg twice daily or to receive
placebo for 6 months. Randomisation was performed in blocks of 6 by comput-
er-generated allocation. Sputum samples were collected at randomisation at 4
month and at exacerbation. Only patients producing sputum at randomisation
were included in this analysis. Follow-up visits were scheduled only when the
patient was in a stable condition at 4, 7 and 10 months post baseline.At the reg-
ular follow-up visits data were collected, spirometry was performed post bron-
chodilation, and sputum was collected for analysis. At any time patients experi-
enced any worsening of their respiratory symptoms they were instructed to con-
tact the study personnel by telephone.They were subsequently invited to attend
the outpatients department within 12 hours for spirometry measurements, spu-
tum collection and consultation by one of the study physicians.
Exacerbations were defined as worsening of respiratory symptoms that
required treatment with a short course of oral corticosteroids or antibiotics as
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Basepopulation
n = 615
Excluded
n= 106;  17.5%
Transport/mobility problems: 19
Refused to participate: 54
Other reasons: 33
Written informed consent
n= 386
Excluded
n= 123;  24.2 %
Problems with change in medication: 20
Transport/ mobility problems: 10
Refused to participate: 93
Patients included
n= 269
Patients not meeting entry criteria at visit 1
(lung function + general criteria)
n= 117;  30.3 %
Reversibility  : 49 TLC: 8
FEV1: 25 FEV /VC: 19
Other reasons: 16
Open label study medication
(visit 2)
n= 263
Withdrawn between visit 1 and 2.
n=6;  2.2%
Dead: 1
Lobectomy: 1 Failure to return: 4
Randomised (visit 3) n=244
FP-group n=123
Placebo group n=121
Eligible patients
n=509
Patients without sputum sample
at visit 3
n = 35
Colonised patients
n=76 (36%)
Non-colonised patients
n=133 (64%)
Withdrawn between visit 2 and 3
n=19;  7.2 %
Reasons:
Dead: 4    Failure to return: 7
Intolerance FP: 6    Other: 2
1
Figure 1 Flow Diagram of Subject Progress through the Study.
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judged by the study physician.The type of an exacerbation was expressed by the
Anthonisen scores type I, II, III (23). A short course of oral corticosteroids was
defined as 30 mg prednisolone for a period of 10 days. First choice of antibiotics
was amoxicillin/clavulanic acid 625 mg four times daily for a period of 10 days.
Second choice was doxycycline 100 mg daily for a period of 10 days. In order to
differentiate between an ongoing and a new or recurrent exacerbations all
patients’ clinical and pharmacy records were collected and analysed. In order to
avoid the impact of treatment with antibiotics on lower airway colonisation, we
only analysed the time to the first exacerbation of COPD.
Sputum samples 
The laboratory technicians processing the sputum samples were unaware of the
clinical condition of the patients. Spontaneously expectorated sputa were col-
lected in sterile vials and processed in the laboratory within 4 hours. Sputa were
homogenised by incubation at 37o C for 15 minutes with an equal volume of 0,1
percent dithiothreitol. Appropriate dilutions of homogenised sputum samples
were placed on blood, chocolate, CLED and saboroud agar plates. Bacterial and
mycological isolation and identification was performed with the use of standard
techniques (24). Streptococcus pneumoniae, Haemophilus influenzae or Moraxella
catarrhalis, Pseudomonas aeruginosa, Staphylococcus aureus, Aspergillus and Candida
species and other gram-negative rods were considered to be potentially pathogenic
microorganisms (PPM). Other bacterial species were classified as normal flora.
Bacterial colonisation was defined as the demonstration of bacteria in cultures
of lower respiratory tract sample in a clinically stable COPD patient without
symptoms attributable to infection (16).
Statistical analysis
We calculated that 192 patients (96 per treatment group) were required to detect
a hazard ratio of a first exacerbation of 1.50 (colonised compared to non
colonised) with 80% power and a two-sided 0.05 α-level test (25). Baseline char-
acteristics are reported as means ± SD or as percentages stratified by colonisa-
tion at baseline yes or no.The effect of colonisation on time to first exacerbation
(the primary outcome) was assessed using multivariate Cox proportional hazard
analyses. We adjusted for potential confounding variables, including age, sex,
smoking status, number of exacerbations in preceding year and FEV1% predict-
ed.We forced all of these variables in the final model(s) because they have been
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demonstrated to be associated with exacerbations or risk of bacterial colonisa-
tion.The presence of effect modification by ICS (FP or placebo) and FEV1 (con-
tinuous) was investigated by adding the product terms to the multivariate Cox
proportional hazard model. If the p-value of the product term was lower than
0.1, further analyses were stratified by subgroups of the tested variable. For the
stratified analysis, FEV1 was dichotomised into patients with a relatively low
(FEV1< 50%) and high FEV1 (FEV1 ≥ 50%) according to the GOLD criteria (1).
Furthermore, we analysed time to a first Anthonisen type I, II and III exacer-
bations for colonisation (yes or no) in the parsimonious model.
All statistical analyses were performed using SPSS version 10 (26).
Results
Of 509 eligible patients, 269 were enrolled as described in an earlier publication
(6) (see Figure 1). After 4 months of treatment with fluticasone propionate (FP),
244 COPD patients were randomised to either continue using FP (FP-group) or
to receive placebo for 6 months (placebo group).At randomisation, sputum sam-
ples could be collected in 209 patients, 106 in the FP and 103 in the placebo
group.The mean age (± SD) of the participants was 64.0 ± 7.2 years. During the
double blind phase, two patients were withdrawn from the study; one in the FP
group due to cancer and the other in the placebo group due to a cerebrovascu-
lar accident. Table 1 shows the baseline characteristics of the study population
stratified by colonisation (yes or no) in stable state.
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Colonised Non colonised
Number of patients 76 133
Mean age in years (SD) 65 (7) 64 (8)
Male (%) 86 87
Mean number of exacerbations in preceding year (sd) 1.7 (1.8) 1.2 (1.6)
Smoking status (%)
Ex-smokers 67 74
Current smokers 33 26
Placebo (%) 54 47
Lung function post bronchodilation (SD)
FEV1 in litres 1.6 (0.5) 1.8 (0.6)
FEV1 % predicted of normal 54 (15) 58  (15)
Table 1 Baseline Characteristics of the Patients with Sputum Samples at Randomisation 
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The excluded patients without sputum sample at baseline (n=35) experienced
slightly fewer exacerbations in the preceding year (0.9 ± 0.9), contained fewer
current smokers (20%) and more women (30%) compared to the study popula-
tion with a sputum sample at baseline.
At randomisation, 76 (36%) of the 209 patients were colonised. Haemophilus
influenzae was observed in 50 patients, Streptococcus pneumoniae in 22 and Moraxella
catarrhalis in 19 patients. In the colonised group, 47 (62%) of the patients devel-
oped at least one exacerbation compared to 67 (50%) in the non-colonised
group. At exacerbation predominantly new PPM were isolated compared to sta-
ble state COPD.
The crude hazard ratio of a first exacerbation in colonised patients compared
to non-colonised was 1.30 (95% CI 0.89-1.89). Adding the product term (ICS*
colonisation) to the multivariate model, including age, sex, FEV1, number of
exacerbations in preceding year and smoking status, did not indicate effect mod-
ification by discontinuation of ICS (p=0.85). However, adding the product term
(FEV1 * colonisation) to this model, suggests effect modification by FEV1
(p=0.038). We therefore stratified the analysis by patients with a relatively low
(FEV1< 50%) and high FEV1 (FEV1 ≥ 50%) according to the GOLD criteria (1).
The adjusted hazard ratio of a first exacerbation in colonised compared to non-
colonised patients was 1.01 (95% CI 0.56-1.81) in patients with a low FEV1 and
1.29 (95% CI 0.76-2.20) in the patients with a high FEV1 (see Table 2).
Analysis for the different types of exacerbation revealed that colonisation
increased the risk of a first Anthonisen type I exacerbation in the low FEV1
group: adjusted HR 4.42 (95% CI 1.20-16.25) (see Table 3). No hazard ratio’s
for the risk of a first type III exacerbation could be calculated because of an
insufficient number of cases. The type of the exacerbations differed significantly
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FEV1 < 50%
HR (95% CI)
FEV1 > 50%
HR (95% CI)
Colonisation at randomisation (yes versus no) 1.01 (0.56; 1.81) 1.29 (0.76; 2.20)
Treatment (placebo versus FP)) 2.14 (1.14; 4.03) 1.35 (0.81; 2.26)
Smoking status at baseline (yes versus no) 0.32 (0.15; 0.68) 0.70 (0.37; 1.29)
FEV1% predicted 1.00 (0.96; 1.04) 0.98 (0.96; 1.01)
Gender (male versus female) 1.61 (0.51; 5.08) 0.65 (0.36; 1.19)
Age (years) 0.97 (0.93; 1.01) 0.99 (0.95; 1.02)
Number of exacerbations in preceding year 1.30 (1.11; 1.52) 1.45 (1.25; 1.69)
Table 2 Adjusted Hazard Ratios of the First Exacerbation for Colonisation and other Risk
Factors Stratified by FEV1
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between colonised and non-colonised patients. Colonised patients experienced
predominantly type I exacerbations: 53% (18/34) compared to 25% (13/52) in
the non-colonised patients. In the non-colonised patients, a type II exacerbation
occurred most often (39% 20/52) (see Table 4).
Discussion
This study revealed three important new findings. First, in contrast to our hypoth-
esis no interaction between colonisation and discontinuation of ICS on the time
to first exacerbation was found. Second, different from recent literature, bacteri-
al colonisation in moderate to severe COPD patients was not shown to be an
independent risk factor for the development of acute exacerbations. Third, as
already indicated in an earlier publication (6), patients with a FEV1< 50% had a
prominent increased risk of exacerbation following withdrawal of ICS while such
increased risk was not found in patients with a FEV1 of 50% or higher.
This is the first study longitudinally investigating the effects of bacterial
colonisation on well-documented exacerbations in moderate to severe COPD in
relation to discontinuation of ICS.The lack of effect of bacterial colonisation on
the development of exacerbations is in contrast to the findings of the Sethi study
and a study of the East London Cohort (19;20), which both reported that bac-
terial colonisation in stable state modulated frequency of COPD exacerbations.
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Outcome FEV1 < 50%
HR (95% CI)
FEV1 > 50%
HR (95% CI)
Colonisation and risk of type I exacerbation 4.42 (1.20-16.25) 1.23 (0.42-3.61)
Colonisation and risk of type II exacerbation 0.75 (0.13- 4.28) 0.89 (0.32-2.47)
*No hazard ratio’s for the risk of a first type III exacerbation could be calculated because of an insufficient number 
of cases
Table 3. Adjusted Hazard Ratios for Colonisation (yes/no) of the First Anthonisen Type I
and II Exacerbation Stratified by FEV1*
Type 1 Type 2 Type 3
Colonised*         n(%) 18 (53%) 8 (23%) 7 (21%)
Non colonised#   n(%) 13 (25%) 20 (39%) 12 (23%)
*Information was available in 34 exacerbations; 1 exacerbation did not fulfil the
 Anthonisen criteria
#Information was available in 52 exacerbations; 7 exacerbations did not fulfil the
 Anthonisen criteria
Table 4 Distribution of Exacerbation Types According to Anthonisen
Criteria in the Colonised and Non Colonised Patients
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Both studies suggest that colonisation is a risk factor for exacerbations, but they
did not report the results corrected for potential confounders indicating the
severity, like FEV1, smoking, and age. Since we assumed FEV1 is not an inter-
mediate between colonisation and exacerbation, we considered FEV1 as a poten-
tial confounder or effect modifier.Although in our study unadjusted Cox regres-
sion analysis showed a trend of increased risk in colonised patients, after correc-
tion for potential confounding factors no increased risk was found.The sugges-
tion that an outgrow of colonizing bacteria prompts an exacerbation (20) is dis-
puted by the study of Sethi et al. (19) indicating that the increased exacerbations
risk in colonised patients is caused by newly acquired bacteria. In the latter study,
the relative risk of an exacerbation for colonised patients in stable state was 1.44,
and rose to a maximum of 2.15 if a new strain of a bacterial pathogen was iso-
lated. Similarly, we found in our study that most bacteria at exacerbations were
different compared to those seen in stable state.
Since patients with bacterial colonisation in the low FEV1 group experienced
predominantly Anthonisen type I exacerbations and hence have a high chance to
be treated with antibiotics at exacerbation (23), new studies on the effects of fre-
quent use of antibiotics in this subgroup of COPD patients are warranted.
The increased risk of exacerbations following withdrawal of ICS was already
reported in our recent publication (6) and is in accordance with other limited
evidence available (27;28).There is still debate whether or not ICS are beneficial
in airway inflammation in COPD (29;30) following reports of conflicting results
on the effects of ICS on markers of inflammation (31-34). In a recent study, the
inhaled corticosteroid FP (9) showed beneficial effects on airway inflammation in
bronchial biopsies in COPD, which may explain the decrease in exacerbations
seen in long-term studies with FP.We are not aware of a study investigating the
interaction of ICS with lower airway bacterial colonisation.We found that bac-
terial colonisation is not a risk factor for a more rapid onset of exacerbations in
patients who discontinue ICS.We now feel that ICS merely influence the non-
bacterial part of the airway inflammation in accordance to the lack of effect on
neutrophils or derived enzymes reported in a study of a similar regimen of ICS
on airway inflammation in COPD patients with comparable disease severity (9).
Although we did not study colonisation and infections with viruses and atyp-
ical bacteria, some non-differential sampling errors might have occurred and
minimal oropharyngeal contamination of the sputum samples cannot be exclud-
ed, we feel confident about the following conclusions: bacterial colonisation in
moderate to severe COPD is not an independent risk factor for new bacterial
exacerbations and colonised patients do not benefit more from the preventive
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effects of ICS in reducing the frequency and severity of exacerbations than non-
colonised patients.
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Abstract
Background: The wide use of antibiotic therapy in the treatment of exacerba-
tions in COPD lacks evidence, efficacy is debatable, and verification of bacterial
involvement in an exacerbation is difficult.The aim of this prospective study was
to identify factors, which can help to estimate the probability that a microorgan-
ism is involved in the exacerbation and hence predicts success of treatment with
antibiotics.
Methods: Clinical data and sputum samples of an exacerbation of 116 COPD
patients were collected. Bacterial infection was defined by the abundant presence
of one or more potential pathological microorganisms in relation to the normal
flora in sputum.
Results: Of 116 exacerbations, 22 (19%) had bacterial involvement.The com-
bination of a negative Gram’s stain of the sputum, a non clinical relevant decrease
in lung function compared to baseline measurements, and less than 2 exacerba-
tions in the previous year were 100% predictive for a non-bacterial origin of an
exacerbation.The presence of all these three clinical characteristics gave a posi-
tive predictive value of 67% for a bacterial exacerbation.
Conclusions: Patients presenting with an exacerbation with a negative Gram’s
stain of the sputum, without a clinical relevant decrease in lung function and less
than 2 exacerbations in COPD in the previous year do not need antibiotic treat-
ment. A treatment protocol taking into account these variables might lead to a
5-24% reduction of unnecessary treatment with antibiotics, depending on actual
prescription rates.
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Introduction
The clinical course of chronic obstructive pulmonary disease (COPD) is, despite
optimal pharmacological treatment, one of gradual progressive impairment,
which may lead to substantial functional limitations and eventually to respirato-
ry failure (1;2). Morbidity and mortality among patients with COPD are for the
most part related to acute exacerbations in COPD (3) which occur on average
one to three times a year (4).The definition of an acute exacerbation in COPD
is a major point of criticism in many of the studies dealing with that issue (5;6).
Recently, an acute exacerbation in COPD was redefined as a sustained worsen-
ing of patient condition, from stable state and beyond normal day-to-day varia-
tions, that is acute in onset and may warrant additional treatment in a patient
with underlying COPD (6;7).
The aetiology of exacerbations is heterogeneous and still under discussion.
Recent studies stated that at least one third of the COPD exacerbations might
be triggered by viral infections (8;9). Undoubtedly, also bacteria play a role in
exacerbations in COPD (10).The prevalence of relevant bacteria in sputum sam-
ples at exacerbation in COPD is estimated up to 50% (11-14).
The management of exacerbations is usually empirical and includes corticos-
teroids and often antibiotics. Recent studies showed a course of oral corticos-
teroids to be superior to placebo in treatment of exacerbations in hospitalised and
outpatient’s setting (15;16).The wide use of antibiotics in exacerbations, howev-
er, lacks evidence, and efficacy is debatable.The prediction of a bacterial cause of
an exacerbation in COPD is difficult (17;18).
For a physician, it is hard to decide on clinical grounds whether or not to pre-
scribe antibiotics at presentation of the patient with an exacerbation in COPD.
Recently, Ewig proposed that antibiotic treatment of acute exacerbations in
COPD should only regularly be applied to patients meeting at least two of the
Winnipeg criteria of increased dyspnoea, sputum volume and purulence (19;20),
or to patients with 4 exacerbations during the last year and/or significant car-
diopulmonary co morbidity (21) and patients presenting with severe airway
obstruction or severe respiratory failure at presentation requiring ventilatory sup-
port (18). Evidence for these criteria and the diagnostic value of many diagnos-
tic tools (e.g. sputum purulence, gram stain, X-ray, CRP and lung function para-
meters) in predicting a bacteriological origin in exacerbations are still under
debate (13;17;20;22-27). Furthermore, microbiological analyses of sputum are
often not performed and if so, microbiological criteria for the interpretation of
the results are often poorly defined and reported to have little impact on treat-
195
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ment because the test results are not available at presentation of the exacerbation
(28).
The aim of this prospective study was to identify predictive factors for exac-
erbations caused by bacteria for which treatment with antibiotics is indicated by
correlating clinical signs, symptoms and rapid available laboratory data on pre-
sentation of an acute exacerbation of COPD, using clear-cut definitions for inter-
pretation of bacterial cultures.
Patients and Methods
Patients
From May 1999 through March 2000, patients were recruited from the outpa-
tient pulmonary clinic of the Medisch Spectrum Twente: an 1150 bed teaching
hospital in Enschede, the Netherlands. To be eligible for the study the patients
had to meet the following criteria: 1) a clinical diagnosis of stable COPD, as
defined by American Thoracic Society criteria (29); 2) no history of asthma; 3)
no exacerbation in the month prior to enrolment; 4) current or former smoker;
5) age between 40-75 years; 6) baseline pre-bronchodilator FEV1 25- 80% of pre-
dicted; 7) pre-bronchodilator ratio FEV1 inspiratory vital capacity (IVC) value of
60% or less; 8) reversibility of FEV1 post inhalation of 80 µg of ipratropium bro-
mide via metered dose inhalator with an aerochamber of 12% of predicted value
or less (30); 9) Total Lung Capacity (TLC) greater than the TLC predicted minus
1.64*SD; 10) no maintenance treatment of oral steroids or antibiotics; 11) no
medical condition with low survival or serious psychiatric morbidity (e.g. cardiac
insufficiency, alcoholism); 12) absence of any other active lung disease (e.g. sar-
coidosis); and 13) use of medication such as nasal corticosteroids, theophyllines,
chronic use of acetylcysteine and all other bronchodilators was allowed.
The hospital’s medical ethical committee approved this study. All patients pro-
vided written informed consent.
Study design
This study was part of a randomised, double blind single centre study, investigat-
ing the role of inhaled corticosteroids in COPD (31). From this study, patients
were recruited at presentation of the first exacerbation of COPD. At any time
patients experienced worsening of their respiratory symptoms, they were instruct-
ed to contact the study personnel by telephone.They were subsequently invited
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to attend the outpatients department within 12 hours for spirometry measure-
ments, sputum collection and consultation by one of the study physicians. Lung
function data and sputum samples were collected. Staff doctors registered in a
standardised exacerbation report the presence of “major” symptoms (increase in
dyspnoea, cough, increase in sputum volume, sputum purulence) or ”minor”
symptoms (nasal discharge/congestion, wheeze, sore throat, cough, fever, need of
extra bronchodilator) (19) and the treatment prescribed. Furthermore, the study
physician reported his/her clinical judgment about the severity of the exacerba-
tion (no exacerbation; mild, moderate, severe), before being informed about the
results of the lung function and Gram’s stain tests.
Clinically, exacerbations were defined as worsening of respiratory symptoms
that made the patient contact the study office. Classification of the type of an
exacerbation was expressed by the Anthonisen score (19). Lung function was
measured by spirometry. Well-trained lung function technicians performed
spirometry on water sealed spirometers according to standardised guidelines.
FEV1 and IVC were measured until three reproducible recordings (less than 5%
difference) were obtained. Highest values were used for analyses. A clinical rele-
vant decrease in FEV1 was defined as a decrease of more than 12 % and 200 ml
from baseline (32).The most recent result of the lung function in stable state was
used as baseline value to calculate the decrease in FEV1 at exacerbation. Body
mass index was computed as weight (kg) divided by the height-squared (m2). In
COPD, a poor nutritional status is indicated by a body mass index (BMI) below
22 kg/m2.
Sputum samples 
The laboratory technicians processing the sputum samples were unaware of the
clinical condition of the patients. Spontaneously expectorated sputa were collected
in sterile vials and processed in the laboratory within 4 hours. Sputa were
homogenised by incubation at 37o C for 15 minutes with an equal volume of 0,1
percent dithiothreitol. Gram’s stained sputum samples were judged microscopically
and had to contain less than 105∗mL-1 epithelial cells to be considered representa-
tive bronchial samples.Appropriate dilutions of homogenised sputum samples were
placed on blood, chocolate, CLED and saboroud agar plates. Bacterial and myco-
logical isolation and identification was performed with the use of standard tech-
niques of the American Society of Microbiologists (ASM) (33). Streptococcus pneu-
moniae, Haemophilus influenzae, Moraxella catarrhalis, Pseudomonas aeruginosa,
Staphylococcus aureus, Aspergillus and Candida species were considered to be poten-
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tially pathogenic microorganisms (PPM). Other bacterial species were classified as
normal flora (non-PPM).
A bacterial exacerbation was defined in two ways: according to the primary
criteria as used in pneumonia (33) by the abundant presence (more than 107
colony-forming units per ml (cfu∗mL-1)) of one or more PPM in excess (one log
or more) to the normal microbiological flora in sputum. As these criteria are
debated in exacerbations in COPD, a secondary analysis was performed using the
following secondary criteria for a bacterial exacerbation in COPD: PPM’s were
regarded as significant if they reached an absolute growth of  > 106 cfu∗mL-1,
except for Streptococcus pneumoniae where growth of > 105 cfu∗mL-1 was deemed
sufficient, irrespective of the presence of non-PPM (13).
Statistical analyses
Baseline characteristics are reported as means ± SD for continuous variables or
as percentages for categorical or dichotomous variables stratified by a bacterial
exacerbation yes or no.
In order to avoid dependency between exacerbations, we included only the
first exacerbation of which a sputum sample was obtained.
First, univariate logistic regression analyses were performed to identify the sub-
set of independent variables that were associated with a bacterial exacerbation.
The a priori list of potential predicting variables included: Gram’s stain (posi-
tive/negative), relevant decrease of FEV1, clinical judgment (moderate - severe;
mild - no exacerbation), BMI (≤ 22; >22), number of exacerbations in preceding
year before the study (0-1; ≥ 2), sex, smoking status, fever, sore throat, nasal dis-
charge, increase in sputum volume, sputum colour, dyspnoea and Anthonisen
score (type 1; other) (19). Only those variables with significance at or below p=
0.15 were considered as candidate variables for the multivariate logistic regres-
sion analysis. For the development of the predictive model, we started with all
candidate variables (full model). Subsequently, we eliminated the variables step-
by-step with the highest p-value until the model fit decreased significantly (based
on likelihood-ratio test).
Finally, we calculated positive and negative predictive values for the variables
in the final multivariate regression model (separately and combined).
For the secondary analysis, the same statistical procedure was applied. In this
analysis, only the microbiological criterion for a bacterial exacerbation was
changed as described above.
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Results
In total, 123 sputum samples at presentation of the first acute exacerbations in
COPD were collected. From 116 of these 123 exacerbations, the presence of a
bacterial infection could be analysed. According to the primary criteria as used
in pneumonia (33), 22 (19%) patients had a bacterial exacerbation and 94 (81%)
did not. Table 1 shows the baseline characteristics of the patients stratified by a
bacterial exacerbation yes or no.
The following variables were associated with a bacterial exacerbation according
to the primary criteria in univariate analysis: Gram’s stain, relevant decrease of
FEV1, clinical judgment, BMI and number of exacerbations in preceding year.
These were included in a multivariate logistic regression model (see Table 2).This
analysis revealed that Gram’s stain, decrease of FEV1 and number of exacerbations
in preceding year together predicts best the existence of a bacterial exacerbation
(final model).Table 3 shows the positive and negative predictive values of all com-
binations of these variables together and separately.The positive predictive value of
these variables together is 67% 95% CI [36-97] while the negative predictive value
if all three are absent was 100%. The second best combination (Gram’s stain and
number of exacerbations in the year preceding the study) reduced the positive pre-
dictive value to 63% and the negative predictive value to 97%.
Analysis of the prescription of antibiotics by chest physicians showed that only
in 28% (14 out of 50) of the exacerbations antibiotics were given correctly based
on our microbiological criteria of a bacterial exacerbation. Moreover, 36% (8 out
of 22) of the bacterial exacerbations were not treated with antibiotics (see Table
4).
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Bacterial Non bacterial
Number of patients 22 94
Mean age in years (SD) 64 (6) 64 (7)
Male (%) 82 78
Mean number of exacerbations in preceding year (sd) 2.3 (2.2) 1.4 (1.8)
Smoking status (%)
Ex-smokers 73 65
Current smokers 27 35
Lung function post bronchodilation (SD)
FEV1 in litres (baseline) 1.6 (0.5) 1.6 (0.5)
FEV1 % predicted of normal (baseline) 54 (16) 55  (15)
*according to the primary criteria
Table 1 Baseline Characteristics of the Patients Stratified by Bacterial Exacerbation (yes/no)*
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If the variables Gram’s stain (negative), reduction of FEV1 (no) and exacerbations
(0-1) in the preceding year were taken into account 40% (11 out of 28) of the
exacerbations were unnecessarily treated with antibiotics. Table 5 shows the
implications of the combinations of all three predictors for antibiotic therapy.
Only 35% of the positive Gram’s stain tests of the sputum at presentation of
the exacerbation resulted in a positive culture. Furthermore, in 59% of the posi-
tive sputum cultures Gram’s stain was positive.
Analysis using secondary criteria for a bacterial exacerbation
Using the secondary criteria for a bacterial exacerbation, the prevalence increased
from 19% using the primary criteria to 46% (56/123). Forty percent of these so
classified bacterial infections had also a positive Gram’s stain.The variables signif-
icantly associated with a bacterial exacerbation in univariate analysis were: Gram’s
stain, clinical judgment, BMI, number of exacerbations in preceding year, sputum
colour and increase in sputum volume. These were included in a multivariate
logistic regression model.This analysis revealed that Gram’s stain, and number of
exacerbations in preceding year together predicted best the existence of a bacte-
rial exacerbation according to the less strict criteria.The positive predictive value
of these variables together is 75% 95% CI [54-96] and the negative predictive
value 62% 95% CI [55-69].
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Bacterial Non bacterial
Number of patients 22 94
Lung function post bronchodilation (SD)
FEV1 in litres (at exacerbation) 1.4 (0.5) 1.5 (0.5)
Relevant decrease in FEV1 (%) 57* 31
ψ
Type 1 exacerbation Anthonisen (%) 46 37
Clinical judgment exacerbation moderate/severe (%) 36 16
Increased sputum volume (%) 81* 68#
Purulent sputum (%) 41 32#
Fever (%) 18 21φ
Nasal discharge (%) 46 46#
Sore throat (%) 41 27#
Positive Gram’s stain (%) 59 26
BMI <22 (%) 5 10
Fluticasone propionate use at exacerbation (%) 68 63
$ Using primary criteria of exacerbation
* Based on information of 21 patients
# Based on information of 93 patients
φ Based on information of 92 patients
ψ Based on information of 91 patients
Table 2 Exacerbation Characteristics of the Patients Stratified by Primary Bacterial
Exacerbation (yes/no)$
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Discussion
The most common decision a doctor has to make in managing a patient with an
acute exacerbation in COPD is whether or not to prescribe antibiotic therapy.
We are not aware of a study combining the above mentioned clinical signs, symp-
toms and rapid available laboratory data on first presentation as predictors of an
acute bacterial exacerbation in COPD. This study, investigating the clinical pre-
dictors for bacterial involvement of an exacerbation in moderate to severe
COPD, revealed four important new findings. First, we found a 100% negative
predictive value for non-bacterial involvement with a combination of a negative
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Positive predictive value
% (95% CI)
Negative predictive value
% (95% CI)
Gram’s stain (Gram’s) 35 (20-50) 89 (82-96)
Relevant decrease of FEV1
# (FEV1) 30 (16-44) 88 (80-96)
No. exacerbations preceding the study
(Exa)
32 (19-45) 90 (83-97)
Gram’s & FEV1& Exa 67 (36-97) 100
Gram’s & FEV1 50 (26-75) 92 (69-115)
Gram’s & Exa 63 (49-78) 97 (93-101)
FEV1 & Exa 43 (27-59) 89 (81-97)
# A clinical relevant decrease in FEV1 was defined as a decrease of more than 12 % and 200 ml from baseline
* According to the primary criteria of a bacterial exacerbation
Table 3 Positive and Negative Predictive Values for the Three Variables (and Combinations of
these) in the Final Multivariate Logistic Regression Model*
Bacterial (%) Non bacterial (%) Total
Antibiotics 14 (64%) 36 (38%) 50
No antibiotics 8 (36%) 58 (62%) 66
Total 22 94 116
* According to primary criteria
Table 4 Prescription of Antibiotics in Relation to a
Bacterial Exacerbation Yes or No
Bacterial (%) Non bacterial (%) Total (%)
Three predictors + 6 (67) 3 (33) 9
Three predictors - 0 (0) 28 (100) 28
Other 16 (20) 63 (80) 79
Total 22 (19) 94 (81) 116
Table 5 Implications of the Combination of all Three Predictors for
Antibiotic Use
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Gram’s stain of sputum, a clinically non-relevant decrease in lung function com-
pared to baseline measurements and less than 2 exacerbations in the previous
year. Second, the best positive predictive value for a bacterial exacerbation of
COPD was a combination of presence of a positive Gram’s stain of sputum, a
clinically relevant decrease in lung function and 2 or more exacerbations in the
previous year.Third, the classic Anthonisen type I criteria (dyspnoea, sputum vol-
ume and sputum purulence) were no predictors for bacterial origin of an exac-
erbation. Last, using the solid definition of a bacterial infection according to the
ASM criteria for pneumonia in COPD exacerbations this study found that only
19 % of the primary exacerbations originated of a bacterial infection.
It takes about 45 minutes to obtain the results of a Gram’s stain and basic
spirometry. The 100% negative predictive value for a non-bacterial origin of an
exacerbation, occurring in 25% of all exacerbations in this study, might help
physicians in deciding to forego unnecessary treatment. Also the combination of
negative Gram’s stain of sputum and the history of less than 2 exacerbations in
the previous year results in a high negative predictive value. This study demon-
strated once again that more objective criteria for use of antibiotic therapy in
exacerbations of COPD are needed to prevent overuse of antibiotics (25;34).
In our population about 40% of the exacerbations in moderate to severe COPD
were treated with antibiotics, a figure that represents the Dutch practice fairly well.
Use of this prediction rule would reduce this percentage to 35%, an absolute reduc-
tion of 5%.As regular prescription rates for this kind of patients in other countries
are much higher, the potential savings by applying this prediction rule might
increase to 24% in situations where every exacerbation is treated with antibiotics
(see Figure 1).
The positive predictive value of a bacterial exacerbation for these variables
(positive Gram’s stain of the sputum, a relevant decrease in lung function and
more than 2 exacerbations in the previous year) was 67%, raising the likelihood
of a bacterial exacerbation of 19 % by 48%. Unfortunately, this only pertains to
8% of the exacerbations.
The yield of Gram’s stains has proven to be highly dependent on a skilled
investigator applying strict criteria (35). In a study of nocosomial pneumonia the
negative predictive value for Gram’s stain of endotracheal aspirate was reported
as high as 94%, comparable to our results using the primary exacerbation crite-
ria (36). In our study, similar to other studies (23), the presence of a positive
Gram’s stain test of the sputum at presentation does not predict a positive cul-
ture, and on the other hand also a positive culture was not a predictor of a pos-
itive Gram’s-stain of the sputum. Prior measurements of lung function are report-
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ed to be useful for comparison with those made during an acute exacerbation
(1), but the importance of change in baseline spirometry as a tool for predicting
a bacterial cause of an exacerbation has not yet been demonstrated before.
Historically, based on the results of the Anthonisen study, patients presenting
with type I criteria of dyspnoea, change in sputum characteristics (increased vol-
ume or purulence) are almost always treated with antibiotics (19).Although these
criteria define a type of exacerbation, they do not define its (bacterial) aetiolo-
gy.We found no association between bacterial exacerbations and Anthonisen type
1 exacerbations.
Since we included less severe COPD patients compared to the Anthonisen
study, the prevalence of PPM at exacerbation is expected to be lower (13) and
might explain the lack of above mentioned association in our study between bac-
terial exacerbations and Anthonisen type 1 exacerbations (5;13;37;38).
In contrast to the study of Stockley et al.(17), sputum purulence was not a pre-
dictor for a bacterial exacerbation.This means that not only patients with mucoid
sputum production at exacerbation are known to improve without antibiotic
therapy (17), but also patients with purulent sputum at exacerbation might not
be candidates for antibiotic treatment.
In conclusion, we feel that patients presenting at exacerbation in COPD with
a negative Gram’s stain of the sputum, without a clinical relevant decrease in lung
function compared to baseline measurements and a history of less than 2 exac-
erbations in COPD in the previous year do not need additional treatment of an
exacerbation. More studies are needed to determine whether other subgroups of
COPD patients exist in which bacteria are likely to play an important role and
hence antibiotic treatment is indicated.
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The main objective of this thesis was to study the effect of a comprehensive self-
management programme including self-treatment of exacerbations and a fitness
programme on clinical outcomes (e.g. health-related quality of life and exacerba-
tions) and costs in moderate to severe Chronic Obstructive Pulmonary Disease
(COPD) patients (GOLD stage II (1)). Secondary objectives were: 1) to assess the
effects of optimisation of pulmonary status by appropriate up-to-date drug treat-
ment, inhalation instructions and smoking cessation; 2) to obtain more insight into
the effects of discontinuation of Inhaled Corticosteroids (ICS) on exacerbations
and Health-Related Quality of Life (HRQoL); 3) to investigate the effect of bac-
terial colonisation during stable disease on time to first exacerbation in patients
who either discontinued or continued ICS and 4) to search for clinical factors that
can predict the need for antibiotic therapy in exacerbations in COPD patients.
As the COPE study was designed as a combination of two substudies (discon-
tinuation of ICS study and self-management study), we will discuss the method-
ological issues, directions towards further research, and future therapeutic implica-
tions of the above mentioned objectives under the headings of these substudies.
Self-management study
Effect of the self-management programme
The COPE self-management programme consisted of a self-management educa-
tion course including self-treatment of exacerbations and a low-intensity near-
home fitness programme. The content of the fitness programme was based on
important elements of pulmonary rehabilitation programmes.The goal of the self-
management programme was to obtain long-term beneficial health effects by
behaviour modification. However, the COPE self-management programme led to
(unexpected) disappointing results. First, we did not find an effect on HRQoL as
measured by the St Georges Respiratory Questionnaire (SGRQ) and walking dis-
tance measured by the six-minute walk (6MW) test (Chapter 4). Second, the self-
management group reported a two-fold higher exacerbation frequency compared
to usual care. The majority of these exacerbations, however, were self treated
(Chapter 5).Although self-managing patients had a reduced number of doctor con-
sultations for exacerbations, these effects did not outweigh the other societal costs
of the self-management programme (Chapter 7). The results of the COPE self-
management study should be considered in light of some methodological aspects.
First, our study population, although by lung function definitions moderate to
severe, appeared to have relatively mild disease with relatively high HRQoL
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scores. So, the room for improvement was limited. Second, the outcome measures
used may not have been sensitive enough to pick up self-management specific
changes.To measure HRQoL and exercise capacity, we used the SGRQ and 6MW,
respectively. Our qualitative study (Chapter 6) revealed that the SGRQ might fail
to capture the full experience of patients in self-management interventions. At
least three elements of HRQoL, reported by patients as very important aspects of
well-being, namely self-confidence, feeling safe, and social isolation are not ade-
quately captured by the SGRQ. Since the qualitative interviews also suggest an
increased exercise capacity, we feel that the 6MW test might not reflect small but
important changes in exercise capacity as a result of the fitness programme.
With these limitations in mind, we cannot exclude that self-management is
beneficial for moderate to severe stable COPD patients. Such an effect is suggest-
ed from the results of our qualitative study indicating that the exercise programme
induced positive effects on physical and social functioning and that the self-man-
agement programme induced psychological reinforcement. From the interviews,
we deduce that the fitness programme might have been the most important com-
ponent of the COPE self-management programme as it does not only influence
physiological aspects (i.e. exercise capacity) but also social functioning of the
patients. This might explain the discrepancy between studies showing beneficial
outcomes after pulmonary rehabilitation (2) and our systematic review showing
no real benefit for self-management education (3). Although the self-treatment
component might have contributed to disease-specific self-confidence and self-
determination, the increased frequency of reported exacerbations due to self-treat-
ment indicates overtreatment.As short causes of prednisolone might cause serious
side effects (4-7), we do not recommend self-treatment with these drugs in regu-
lar COPD care in the way it was done in this study, until it has been determined
whether patients in the intervention group overtreated themselves or whether
COPD patients under regular care underreported exacerbations. In order to
reduce systemic side-effects of prednisolone, a future option for self treatment in
order to reduce systemic side-effects might be a shorter duration of prednisolon
courses (8) and more supervision in case of repeated exacerbations.
Is self-management a treatment option for more severe COPD patients?
Having discussed the primary results, the question has to be raised whether self-
management might be a treatment option for more severe COPD patients
(GOLD stage III). We are inclined to answer this question negatively. First,
because of a higher level of systemic disease and substantial co-morbidity, the
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dropout rate in a weekly fitness programme of these patients will be high.
Second, fitness training once a week is not intensive enough to reach beneficial
health effects in these patients. These severe patients probably need more inten-
sive programmes with more individual supervision, like pulmonary rehabilitation
programmes.The relatively short duration of pulmonary rehabilitation will prob-
ably not lead to a permanent change in exercise behaviour and consequently the
effects will deteriorate over time (9-11). So, aftercare programmes might be nec-
essary to prevent patients to revert again to a sedentary lifestyle and to establish
long-term benefits.
Comprehensive self-management programmes might be typically designed for
moderate to severe COPD patients (GOLD stage II) with more impairment than
the patients in our study. Bourbeau et al.(12) found beneficial effects (reduction
in hospital admissions and unscheduled physician visits) of self-management com-
pared to usual care in a more severe group of patients (also GOLD stage II) with
at least one hospitalisation in the preceding year. These patients might be more
in need of self-management education than a group of stable COPD patients
with relatively low impairment, and interventions will likely be more cost-effec-
tive.
Should the self-management programme be intensified? 
An additional point of discussion is whether the intensity of the self-management
education course and fitness programme should be enhanced. Increasing the fre-
quency of visits to a physiotherapist to three times a week and a higher exercise
intensity as suggested by Casaburi and co-workers (13), do not fit into the con-
cept of self-management. A programme of e.g. 3 times a week intensive super-
vised exercise training resembles a pulmonary rehabilitation programme. Self-
management is directed to incorporate exercise in daily life and reach behavioural
change. Some intensification of the programme might be reached by addition of
home-exercise to the group fitness programme. Furthermore, the frequency of
group fitness might be increased to twice a week. Besides general exercise train-
ing, functional training might increase the effectiveness.
The intensity of the self-management education course might be enhanced by
follow-up calls by trained respiratory nurses. The use of telephone-based or e-
mail interventions have gained increased attention as a viable alternative to con-
ventional counselling in behavioural medicine and may be particularly attractive
in the maintenance phase after acquisition of a new health behaviour (14). For
instance Ries et al.(15) evaluated the effects of a 12-month maintenance program
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of weekly telephone calls and monthly supervised sessions (including 1,5 hour
exercise) after pulmonary rehabilitation.This study indicated that COPD patients
need a continuous maintenance programme in order to maintain or reach bene-
ficial health effects.
Is pre-trial optimisation of pulmonary status worthwhile?
To prevent optimisation bias, we included an optimisation period prior to actual
randomisation. Efforts focussed on optimisation of pulmonary status by improv-
ing inhalation technique, appropriate up-to-date drug treatment, and a smoking
cessation programme.
Overall, this optimisation period did not result into favourable effects on FEV1
and HRQoL (Chapter 9), probably due to the fact that our patients were already
well stabilised before inclusion in the study, and the poor results of the smoking
cessation programme. Of course this does not imply that optimisation of phar-
macological treatment is ineffective in everyday clinical practice and before the
start of any COPD study because a substantial number of COPD patients might
be not stable.
Is the minimal contact smoking cessation programme suitable for COPD patients?
The impact of smoking cessation on pulmonary status and HRQoL is well estab-
lished.
In the COPE study, one third of the patients reported to be current smokers.
Around 70% of them were willing to participate in an individual, minimal con-
tact, smoking cessation programme (MIS). Disappointingly few COPD patients
(13%) actually quit smoking after 9 months of follow-up. Furthermore, about half
of the self-reported non-smokers were not truthful about their smoking status at
the time of evaluation (Chapter 8).
Apparently the minimal contact smoking intervention strategy is not suitable
for this group of COPD patients and more effective intervention strategies should
be developed.
Recommendations
Because this thesis fails in demonstrating a positive effect of self-management in
COPD, the risk for overtreatment might be substantial and the costs are consid-
erable, such a programme is not recommended before more research is done.
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First, a more effective self-management programme should be developed based
on the results of this thesis; e.g. the self-management education course might be
improved by incorporating the themes anxiety and feeling safe. Communication
with the chest physician can be omitted because it did not contribute to positive
effects or behavioural change. Since the risk of involuntary weight loss and being
underweight for COPD is very important, we feel that this item should still be
addressed, in another way, despite the lack of demonstrated impact in our study.
To diminish the risk of overtreatment and the potential side effects of excessive
prednisolone use, future self-management programmes might incorporate more
individualised self-treatment action plans (16). Furthermore, the self-management
education course and exercise programme may be intensified by telephone fol-
low-up by case-managers and inclusion of home-exercise prescriptions in addi-
tion to twice-a-week group fitness, respectively.
Second, this improved programme should be evaluated by an enhanced design
e.g. by including a more severely impaired COPD population and better outcome
measures. Inclusion criteria might be at least two or more exacerbations or one
hospitalisation in the year preceding study entry.
Outcome instruments that explicitly reflect psychological and social dimen-
sions should be used to measure changes in health status.To measure changes in
exercise capacity adequately, future studies should include measurements with
more incentives to reach (sub) optimum intensity levels like for example a shut-
tle walk test for COPD patients.
Implementation of self-management strategies in regular clinical practice
should only be considered after the studies described above have demonstrated
the (cost) effectiveness of the newly developed programmes.
We strongly recommend biochemical validation of abstinence rates for future
smoking cessation studies in general, but especially when COPD patients are
involved. Smoking cessation rates reported in the literature based on self-report
should be mistrusted since these rates might highly overestimate true quit rates.
Future studies should identify the most effective elements of cessation pro-
gramme for COPD patients.
Discontinuation of ICS study
Effect of discontinuation of ICS
Earlier studies observed beneficial clinical effects of ICS in COPD patients on
lung function, HRQoL and exacerbations (17;18). As only short term, but sus-
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taining, effects of ICS on FEV1 were observed (17;19), we investigated the effects
of discontinuation of inhaled corticosteroids (ICS) on exacerbations and HRQoL
in patients with COPD. This study led to important, partly unexpected results
(Chapter 10). First, discontinuation of fluticasone propionate (FP) in patients with
moderate to severe COPD induced a more rapid onset and higher recurrence risk
of exacerbations, compared to patients who remained on FP, especially among
patients with a FEV1 <50% predicted. Second, placebo treatment showed a trend
towards deterioration in aspects of HRQoL in contrast to continued FP treat-
ment. However, about half of the patients had no untoward effect from the with-
drawal of ICS with respect to exacerbations and probably also with respect to
HRQoL (since HRQoL is predominantly related to the occurrence of exacerba-
tions (20)). Although the continued use of ICS for the whole group of COPD
patients was quite cost-effective over a six-month period, in the long run the
dominant strategy is withdrawing ICS in all COPD patients and resuming ICS
only in those patients who develop rapid recurrent exacerbations (Chapter 11).
The results of the discontinuation of ICS study should be considered in light
of some methodological aspects. First, defining an acute exacerbation in COPD
is difficult and a major point of criticism or controversy in many of the studies
dealing with that issue (21;22). Even GOLD (1) does not provide a clear defini-
tion of an exacerbation.We defined an exacerbation as worsening of respiratory
symptoms that made the patient contact the study office resulting in a prescrip-
tion of oral corticosteroids or antibiotics. This definition is comparable to the
recent definition of an exacerbation by Burge and Wedzicha (23). Historically, the
different types of exacerbations, based on the results of the Anthonisen study
(24), were used as severity criteria. However, this classification indicates the type,
not the severity of exacerbations (23). Both in the discontinuation of ICS study
as well as in our self-management study, we found differences in severity of exac-
erbations extracted from symptom diaries which were not reflected by the
Anthonisen criteria.
Secondly, we used reversibility after bronchodilation as a criterion to exclude
asthma in our study population. Although this is a widely used diagnostic tool,
the definition of reversibility according to American Thoracic Society (ATS) is
different from that of the European Respiratory Society (ERS) lung function
guidelines and subsequently can lead to considerably different study populations.
We used a cut-off point for reversibility of 12% of FEV1 predicted, as put forward
in the ERS guidelines. The ATS guidelines, however, propose 12% of baseline
FEV1. Using the ERS guidelines might lead to including more patients with asth-
matic characteristics. On the other hand, the ATS guidelines would have lead to
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undue exclusion of real COPD patients. In real life clinical practice, a combina-
tion of COPD and asthma is common and hence we feel these patients should
not be excluded from COPD studies.Third, the balance between the benefits of
(high-dose) FP and the side effects is point of discussion. The patients in this
study received 1000 µg FP per day, which is the most common dose as mainte-
nance therapy in all previous COPD studies. As the effect of lower doses of FP
in COPD patients have not been studied, tapering doses of ICS in accordance to
new asthma studies might be an opportunity to find the optimum (25).
Fourth, since we studied only moderate to severe COPD outpatients in regu-
lar follow-up, it is hard to extrapolate these results to more severe patients and
to patients managed in general practice settings.
Bacterial colonisation and infection in relation to exacerbations and ICS
A remarkable finding of this study was that bacterial colonisation in moderate to
severe COPD patients with stable disease was not an independent risk factor for
the development of acute exacerbations both in patients who discontinued or
continued FP (Chapter 12). Furthermore, similar to the Sethi study (26), we found
in our study that most bacteria at exacerbations were different or new compared
to those seen in stable state. Finally, we developed a new simple prediction rule
for bacterial involvement in exacerbations in COPD to be used for a more
restrictive policy towards antibiotic use in exacerbations (Chapter 13). These
results should be considered in the light of some methodological aspects.
First, many issues related to the aetiology of exacerbations remain unclear or
controversial including the exact role of the interaction between the airways and
bacteria as an inflammatory stimulus, and the relationship with ICS (27-31) .We
assumed no direct relationship between lung function decline and exacerbations
caused by potential pathogenic microorganism (PPM) in moderate to severe
COPD patients.Therefore, we considered FEV1 to be an independent variable in
the etiologic model, and FEV1 was thus analysed as a potential confounder or
effect modifier. It might be argued, however, that FEV1 is an intermediate vari-
able, i.e. colonisation leads to a lower FEV1 and this subsequently induces exac-
erbations. But even assuming the latter mechanism, the conclusion would hold
that bacterial colonisation is not an independent risk factor for the development
of acute exacerbations in this kind of COPD patients.
Second, since bacterial colonisation may induce or enhance bronchial inflam-
mation, and ICS affect airway inflammation in COPD, we expected a beneficial
effect of ICS on exacerbations in colonised patients. Our study gives reason to
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believe that ICS merely influence the non-bacterial part of the airway inflam-
mation (32).
Third, we defined bacterial involvement in an exacerbation according to cri-
teria used in pneumonia (107 colony forming units per ml) (33). This lead to a
bacterial infection rate of about 20%. In other COPD studies, different criteria
are used (ranging from 105 to 107 colony forming units per ml); hence other
prevalence rates are reported (up to 50% bacterial exacerbations) (34-38).These
differences in methodology make comparison in literature difficult.
Finally, looking for predictors of bacterial exacerbations, we found that the
presence or absence of a combination of three rapid available criteria (Gram
stain, decline in lung function and exacerbation history) can be used as a deci-
sion aid in determining bacterial or non-bacterial origin of an exacerbation in
COPD, respectively. It should be emphasised that such a classification is only pos-
sible for about one third of the population while for the remaining patients no
prediction is possible based on these three criteria. As a consequence, for these
exacerbations, the indication for antibiotic treatment remains unclear.
Recommendations
Nowadays, many newly diagnosed COPD patients receive initial ICS treatment,
and since many of them will show an initial improvement in FEV1, they will be
prescribed ICS for life.The findings of our study justify considering discontinu-
ation of ICS, for patients with a FEV1>50% predicted. Such a policy might pre-
vent overtreatment and unnecessary costs. However, close follow-up of patients
to resume ICS in case of recurrent exacerbations is necessary.
In clinical practice, N=1 studies might help the treating physician on deciding
future use of ICS in the individual COPD patient in this subgroup. Future stud-
ies are needed to explore the effects of discontinuation of ICS in patients with a
FEV1<50%. Additional research is needed to investigate whether the results of
this study are also applicable to patients from general practice or to more severe
COPD patients.
Finally, future studies are necessary to determine the role of antibiotic therapy
in exacerbations in COPD in which the prediction rule presented in this thesis
is not applicable.
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Final conclusions and recommendations
In summary, our main conclusions and recommendations are:
• Implementation of self-management strategies including self-treatment of
exacerbations in COPD in regular clinical practice should only be consid-
ered after future studies have demonstrated the (cost) effectiveness of new,
modified intervention programmes.
• In smoking cessation studies in general, but especially when COPD patients
are involved, biochemical assessment of abstinence rates is essential to pre-
vent overestimation of quit rates.
• Pharmacological optimisation of pulmonary status is not necessary for sta-
ble moderate to severe COPD patients in clinical practice or prior to inclu-
sion in clinical trials.
• Discontinuation of ICS induces a more rapid onset and recurrence risk of
exacerbations especially in patients with a FEV1 ≤ 50%; However, in patients
with a FEV1> 50%, discontinuation of ICS might be an important new
option to prevent overtreatment and unnecessary costs.
• Bacterial colonisation in moderate to severe COPD patients with stable dis-
ease is not an independent risk factor for the development of acute exacer-
bations both in patients who discontinue or continue FP.
• Future studies are necessary to determine the role of antibiotic therapy for
exacerbations of COPD in which the prediction rule (Gram stain, decline
in lung function and exacerbation history) is not applicable.
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Chronic obstructive pulmonary disease (COPD) constitutes a major public health
burden worldwide. The Global Burden of Disease Study predicts that by 2020
COPD will be the fifth most prevalent disease worldwide and the third most com-
mon cause of death.Therapy for COPD is often primarily aimed at improving air-
flow obstruction by bronchodilator and anti-inflammatory therapy, despite the
apparent lack of effect of pharmacological interventions on the progressive decline
in lung function, which is characteristic of the disease. COPD is a reversible respi-
ratory impairment that has its primary effects in the lungs. It is increasingly seen
as a systemic inflammatory disease with systemic defects such as skeletal muscle
impairment and involuntary weight loss as prominent features. Many COPD
patients still experience substantial functional impairment, and there is a growing
need for new forms of therapy, not only to control and alleviate the symptoms and
complications of respiratory dysfunction, but also to teach patients the necessary
skills for adapting to their physiological impairment in daily life. In other chronic
diseases (i.e. rheumatic arthritis, diabetes mellitus, and asthma) interventions based
on the concept of self-management have been shown to improve disease outcomes.
In COPD, the effect of self-management is not clear.
Therefore, the main objective of this thesis was to study whether a compre-
hensive self-management programme including self-treatment of exacerbations
and a fitness programme is a clinically effective and economically efficient treat-
ment option for moderate to severe COPD patients.
Whilst designing the COPE self-management study, we took the opportunity also
to assess additional important research questions:
• Does optimisation of pulmonary status by appropriate up-to-date drug treat-
ment, inhalation instructions and smoking cessation result in beneficial
effects for COPD patients? 
• What is the effect of discontinuation of inhaled corticosteroids on exacer-
bations and Health-Related Quality of Life (HRQoL) in patients with
COPD? 
• What is the role of bacterial colonisation in relation to Inhaled
Corticosteroid (ICS) treatment and subsequent risk of exacerbations? 
• Which clinical factors can predict who needs treatment for antibiotics in
exacerbations of COPD? 
The COPE study was designed as a combination of two sub studies: 1) the dis-
continuation of ICS study and 2) the self-management study. Of 509 eligible
patients, 269 were enrolled in the COPE study. During a four months optimisa-
tion phase, 263 patients received the inhaled corticosteroid fluticasone propionate
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(FP). Of these, 244 patients were subsequently randomised to either continue FP
or to receive placebo for 6 months (discontinuation of ICS study): 123 continued
FP and 121 placebo during a period of 6 months. Follow-up visits were sched-
uled 3 and 6 months post randomisation. Patients were actively followed for the
development of exacerbations. All patients who finished the discontinuation of
ICS study (n=242) plus 6 patients who where excluded from this substudy
because of intolerance to FP, entered the self-management study. So, 248 COPD
patients were randomly allocated to either the self-management (n=127) or con-
trol (n=121) group. The self-management group received a comprehensive self-
management programme in addition to regular care from the chest physician.
Patients attended the hospital every six months during the one-year follow-up.
In chapter 2, we described the different elements of optimal management of
COPD.The goals of effective COPD management are to prevent disease progres-
sion, relieve symptoms, improve exercise tolerance and health status, prevent and
treat complications and exacerbations, and reduce mortality. The COPD manage-
ment strategy is based on an individualised assessment of disease severity and
response to various therapies. In order to achieve this, an individualised treatment
plan is designed which incorporates elements of smoking cessation, optimisation of
pulmonary status by pharmacotherapy and exercise embedded in a new lifestyle.
Chapter 3 describes the results of a systematic review on the effectiveness of self-
management programmes in COPD patients. This review systematically evaluated
eight studies of self-management education for patients with COPD compared to
usual care.We concluded that the data extracted by this review provide an insuffi-
cient basis for new recommendations regarding the effectiveness of self-manage-
ment education for COPD patients, because of the broad spectrum of outcome
parameters and other important limitations in the current published literature.
In chapter 4, we described the results of the COPE self-management study
with respect to HRQoL, symptoms and walking distance. The self-management
intervention consisted of a skill-oriented patient education programme including
self-treatment of exacerbations and a near-home fitness programme in addition
to usual care. No differences in HRQoL within study groups or between the self-
management and control groups were observed over one year. Similarly, we
found no differences in symptom scores and six minute walking distance within
and between groups.
Chapter 5 describes the results of a qualitative evaluation of the COPE self-
management programme.This evaluation was performed in order to understand
the discrepancy between the negative results of the self-management study on
HRQoL, compared to anecdotal reports of satisfaction by patients to the study
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team. In this qualitative study, a purposive sample of 20 participants of the COPE
self-management programme was interviewed at home using in-depth, semi-
structured, interviews. The fitness programme was most positively evaluated by
patients due to the perceived increase of exercise capacity and the social interac-
tion in group training. Major effects gained by the self-management education
course reported by these patients were the skills to evenly distribute their ener-
gy and to listen to their body signals. Most patients viewed self-treatment of
exacerbations favourably.The possibility to start treatment early, not having to call
a doctor and autonomy were raised as important advantages. Furthermore, sever-
al patients reported increased self-confidence and coping behaviour as important
effects of the COPE programme. Finally, many patients reported feeling safe, due
to the frequent follow-up visits and 24-hour access to the hospital, and this aspect
was deemed to be very important. In this study, the qualitative interviews sug-
gest that the St. George’s Respiratory Questionnaire (SGRQ) and possibly other
existing HRQoL instruments might fail to capture the full experience of COPD
patients in self-management studies.
In chapter 6, we presented the impact of the COPE self-management study on
exacerbations and health care contacts. During the one-year follow-up, 537 exac-
erbations were reported: 360 in the self-management group and 177 in the con-
trol group. Seventy-seven percent (n=98) of the self-management patients had at
least one exacerbation compared to 58% (n=70) of the control patients. The
majority (69%) of all exacerbations in the self-management group were self-
treated by the patient, resulting in a 42% reduction in doctor consultations per
patient per year compared to patients in the control group. Symptoms during
exacerbations were slightly less severe in the self-management group.
In chapter 7, we investigated whether the COPE self-management programme
is an efficient treatment option for COPD patients. This economic evaluation
showed that the incremental cost difference amounted to € 838 per patient per
year in favour of usual care.When only direct medical costs were included, the
incremental annual costs of self-management relative to usual care was € 179 per
person per year. As our self-management programme was twice as expensive as
usual care and had no measurable beneficial effects on quality adjusted life years
or HRQoL, we concluded that self-management is not an efficient treatment
option in this group of patients at the present time.
In chapter 8, we reported the effects of a minimal contact smoking cessation
programme for COPD patients, using a pre-test post-test design. At the start of
the COPE study, one third of the 269 participants were active smokers (based on
self-report). Almost 70 percent (n=64) of these patients were willing to partici-
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pate in the smoking cessation programme. After 9 months follow-up, 23 (36.5%,
95% CI 24.6-48.8) patients reported abstinence. However, the cotinine validated
abstinence rate was much lower: 12.7 % (95% CI 4.5-20.9) (n = 8), implying that
the actual abstinence rate is severely overestimated by self-report in this study.We
concluded that considering the urgent need for quitting in COPD-patients, a
more intensive programme is required for this highly addicted population, and
biochemical validation of abstinence rates is essential for future studies.
In chapter 9, we assessed the overall effect of an optimisation period of 4
months. During this period, we tried to optimise pulmonary status of the patients
by teaching them correct inhalation technique, appropriate up-to-date drug treat-
ment and a smoking cessation programme if applicable. Overall, this optimisation
period did not result in favourable effects on FEV1 and HRQoL.The results of this
optimisation period indicate regression to the mean using FEV1 as the outcome
measure. The most likely explanations for the lack of an optimisation effect here
may be that our patients had already reached their optimum pulmonary status, or
that the smoking cessation programme had a disappointingly low success rate.
In chapter 10, we presented the results of the discontinuation of ICS study.The
motive for this part of the study was the hypothesis that ICS may have a short-
term effect on pulmonary function, with long-term therapy providing no addi-
tional gain. The hazard ratio of a first exacerbation in the placebo group com-
pared to the FP-group was 1.5 (95% CI 1.1-2.1). In the placebo group 26
patients (21.5%) experienced rapid recurrent exacerbations and were subse-
quently unblinded and prescribed FP compared to 6 patients (4.9 %) in the FP-
group (Relative Risk = 4.4; 95% CI 1.9-10.3). A trend towards decreasing
HRQoL was observed for the placebo group.We concluded that discontinuation
of FP in patients with moderate to severe COPD induced a more rapid onset and
higher recurrence-risk of exacerbations. However, as 40% of the patients have no
untoward effect from the withdrawal of ICS there is an urgent need to identify
subgroups of COPD patients who do not need prolonged ICS therapy.
In chapter 11, we assessed the cost-effectiveness of the discontinuation of ICS
trial. In the primary cost-effectiveness analysis, the 6-month incremental cost-
effectiveness of the FP strategy compared to placebo was € 110 per exacerbation
prevented and € 1.286 per hospitalisation prevented. The long-term Markov
modeling approach showed that the discontinuation of FP strategy is dominant
with a negligible gain in quality adjusted life days, but with a large associated cost
saving of € 5012 per patient. Although the FP strategy seems reasonably cost
effective over a short follow up period of six months, in the long run it is the
more costly approach with debatable long-term benefits.
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In chapter 12, we assessed the effect of bacterial colonisation during stable dis-
ease on time to first exacerbation in patients who either discontinued or contin-
ued FP. At randomisation in the discontinuation of ICS study, we collected spu-
tum samples of 209 patients, of which 36% were colonised with potentially path-
ogenic microorganisms.We did not find effect modification by FP status (FP or
placebo), but effect modification by FEV1 was present.The adjusted hazard ratio
of a first exacerbation in colonised compared to non-colonised patients was 1.29
(95% CI 0.76-2.20) and 1.01 (95% CI 0.56; 1.81) in patients with a FEV1 ≥ 50%,
and FEV1<50%, respectively.We concluded that bacterial colonisation in moder-
ate to severe COPD patients is not an independent risk factor for the develop-
ment of acute exacerbations. There is no interaction between colonisation and
discontinuation of ICS on time to first exacerbation.
In chapter 13, we tried to identify clinical variables, which can predict a bac-
terial exacerbation requiring antibiotic treatment. Clinical data and sputum sam-
ples of 116 COPD patients were used for this analysis. According to our criteria
for a bacterial infection, 22 (19%) patients had a bacterial exacerbation and 94
(81%) did not. A multivariate logistic regression analysis revealed that the com-
bination of Gram’s stain, decrease of FEV1 and number of exacerbations in the
preceding year predict best bacterial involvement in an exacerbation. The posi-
tive predictive value of these variables together is 67% 95% CI (36-97) and the
negative predictive value 100%.We concluded that these easily accessible clinical
variables might help physicians decide whether or not to prescribe antibiotics for
the management of acute COPD exacerbations.
In chapter 14, the major results of the studies in this thesis are discussed and
put into perspective. We considered several methodological issues such as the
severity of disease in our study population, the outcome measures used, the inten-
sity of the self-management programme, the definition of an exacerbation and
the external validity of the results. In addition, we made several suggestions for
clinical and public health practice as well as for future research. In summary, our
main conclusions and recommendations are:
• Implementation of self-management strategies including self-treatment of
exacerbations in COPD in regular clinical practice, should only be consid-
ered after future studies have demonstrated the (cost) effectiveness of new,
modified intervention programmes.
• In smoking cessation studies in general, but especially when COPD patients
are involved, biochemical assessment of abstinence rates is essential to pre-
vent overestimation of quit rates.
CHAPTER 15
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• Pharmacological optimisation of pulmonary status is not necessary for sta-
ble moderate to severe COPD patients in clinical practice or prior to inclu-
sion in clinical trials.
• Discontinuation of ICS induces a more rapid onset and recurrence risk of
exacerbations especially in patients with a FEV1 ≤ 50%; However, in patients
with a FEV1> 50%, discontinuation of ICS might be an important new
option to prevent overtreatment and unnecessary costs.
• In patients with stable moderate to severe COPD, bacterial colonisation is
not an independent risk factor for the development of acute exacerbations
for patients who discontinue or continue FP.
• Future studies are necessary to determine the role of antibiotic therapy for
exacerbations of COPD in which the prediction rule (Gram stain, decline
in lung function and exacerbation history) is not applicable.
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Wat is COPD?
Chronic Obstructive Pulmonary Disease (COPD) is een verzamelnaam voor
chronische bronchitis en longemfyseem. De voornaamste klachten van de COPD
patiënt zijn kortademigheid, hoesten, het opgeven van slijm en een verminderde
inspanningstolerantie.Als deze klachten sterk verergeren is er sprake van een exa-
cerbatie. Het is belangrijk exacerbaties te voorkomen of zo snel mogelijk te
behandelen, omdat ze een grote invloed op de kwaliteit-van-leven van de patiënt
hebben. Een kenmerk van COPD is dat de uitademing belemmerd is (obstructie)
en dat er na uitademen teveel lucht achterblijft in de longen, ook wel hyperin-
flatie genoemd. Naast een verminderde longfunctie treden ook systemische effec-
ten op door de afgifte van ontstekingsfactoren vanuit de longen in de bloedbaan
Een voorbeeld van een systemisch effect is afname van de functie van arm- en
beenspieren, maar ook van de ademhalingspieren. Ook kan er sprake zijn van
ongewenst gewichtsverlies, zowel vanwege het feit dat de COPD patiënt meer
energie nodig heeft als vanwege verminderde eetlust.Voor het behoud van een
goede algehele lichamelijke conditie is een goede spierfunctie essentieel.
Inactiviteit en gewichtsverlies daarentegen leiden tot verlies van spierfunctie en
spiermassa bij COPD patiënten. Door toenemende kortademigheid en vermin-
derde lichamelijke activiteit neemt de algehele conditie af en de kortademigheid
nog verder toe. Vele COPD patiënten komen zo in een neerwaartse spiraal
terecht, die op zijn beurt kan leiden tot psychische klachten, verminderd zelf-
vertrouwen en depressie (zie Figuur 1).
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Figuur 1 Neerwaartse Spiraal van Toenemende
Kortademigheid en Verminderde Inspanningstolerantie
* Dyspnoe is kortademigheid
** fobie is angst 
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Epidemiologie van COPD
De belangrijkste oorzaak van COPD is veel en langdurig roken. Geschat wordt
dat bij ongeveer 95% van de COPD patiënten, roken de oorzaak is van hun ziek-
te.Van de rokers krijgt ongeveer 15% COPD, vaak pas na het 40ste levensjaar.
Hierdoor heeft COPD wereldwijd een enorme impact: men rekent COPD tot de
vijfde meest voorkomende ziekte en de vierde doodsoorzaak. Uit huisartsenregi-
straties blijkt dat in Nederland ongeveer 2,4% van de mannen en 1,4 % van de
vrouwen COPD heeft. Omdat de bevolking ouder wordt en er meer vrouwen
zijn gaan roken zal het aantal COPD patiënten en de sterfte als gevolg van
COPD toenemen. Behandeling van COPD kost gemiddeld meer dan € 1000 per
patiënt per jaar.
Behandeling van COPD
Hoofdstuk 2 beschrijft de reguliere behandeling van COPD. De enige behandeling
van COPD waarvan de effectiviteit vaststaat is stoppen met roken. Stoppen met
roken kan er voor zorgen dat de longfunctie minder snel afneemt.Voor het ove-
rige is de behandeling van COPD gericht op symptoombestrijding, het vermin-
deren van exacerbaties en het verbeteren van de kwaliteit-van-leven. Moderne
behandeling bestaat uit een combinatie van stoppen met roken, medicatie, maar
ook aandacht voor voeding en beweging: kortom een verandering van stijl van
leven. Dergelijke combinaties worden aangeboden in een longrevalidatiepro-
gramma en blijken daadwerkelijk te leiden tot een betere lichamelijke conditie
en kwaliteit-van-leven van COPD patiënten. Longrevalidatie is echter kostbaar
en slechts geschikt voor een kleine groep COPD patiënten. Bovendien verdwijnt
het effect van revalidatie spoedig na beëindigen.
Zelfmanagementprogramma’s zouden een alternatief kunnen vormen, omdat
ze aanzienlijk goedkoper zijn en een grotere groep COPD patiënten zouden
kunnen bereiken. In een zelfmanagementprogramma leert de patiënt met zijn
ziekte en alles wat daarbij hoort om te gaan en zichzelf te behandelen met medi-
cijnen.
Bij astma en andere chronische ziekten blijken zelfmanagementprogramma’s
zeer effectief ten aanzien van het verhogen van kwaliteit-van-leven en het ver-
minderen van de kosten van de gezondheidszorg. Hoofdstuk 3 geeft een overzicht
van alle studies voorafgaand aan het COPE onderzoek die het effect van een
zelfmanagementprogramma ten opzichte van reguliere zorg hebben onderzocht.
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Het bleek dat de studies te verschillend waren in opzet en gebruikte meetinstru-
menten om een algehele aanbeveling te doen omtrent het effect van zelfma-
nagement bij COPD. Dit vormde de aanleiding voor het COPE onderzoek.
COPE staat voor COPD Onderzoek afdeling Pulmonologie Enschede. Het ver-
wijst tevens naar het begrip ‘coping’, kunnen omgaan met ziekte. De hoofdvraag-
stelling van het COPE onderzoek was dan ook of een zelfmanagementprogramma
effectief zou zijn voor matig ernstige COPD patiënten.Het COPE onderzoek bood
daarnaast ook de mogelijkheid om andere belangrijke vraagstukken te bestuderen,
nl:
• Wat is het effect van het stoppen met inhalatiecorticosteroïden op exacer-
baties en kwaliteit-van-leven? 
• Wat betekent het op de korte en lange termijn voor de kosten als met de
behandeling van inhalatiecorticosteroïden wordt gestopt?
• Heeft het optimaliseren van onderhoudsmedicatie, het aanbieden van inha-
latie instructies en een stoppen met roken programma een positief effect op
COPD patiënten? 
• Wat is de rol van aanwezigheid van bacteriën in luchtwegen van stabiele
COPD patiënten (kolonisatie) op het risico van exacerbaties en wat is de
invloed van inhalatiecorticosteroïden op deze relatie? 
• Welke klinische factoren kunnen voorspellen welke COPD patiënten met
een exacerbatie behandeld moeten worden met antibiotica? 
Aanpak
Aan de COPE studie deden 269 matig tot ernstige COPD patiënten mee met een
gemiddelde leeftijd van 64 jaar. De COPE studie bestond uit twee fasen (zie
figuur 2). In de eerste fase van het onderzoek werden gedurende vier maanden
alle patiënten behandeld met inhalatiecorticosteroïden (ICS) en kregen de rokers
een stoppen-met-roken programma aan huis aangeboden.Vervolgens werd gedu-
rende 6 maanden het effect van stoppen met ICS bestudeerd in een gerandomi-
seerd, dubbelblind experiment.
Na deze eerste fase werd de gehele patiëntenpopulatie opnieuw random ver-
deeld in een interventie en een controlegroep. De controlegroep kreeg alleen
reguliere zorg van de eigen longarts. De interventiegroep kreeg naast reguliere
zorg tevens een zelfmanagementprogramma aangeboden.
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Resultaten 
Hoofdstuk 4 beschrijft de COPE zelfmanagementstudie en de resultaten van deze
studie op kwaliteit-van-leven, COPD symptomen en de afstand die de patiënt in
6 minuten kan afleggen. Het COPE zelfmanagementprogramma bestond uit een
cursus en een groepsfitnessprogramma. Een belangrijk onderdeel van de cursus
was dat de deelnemers leerden hoe en wanneer ze zelf exacerbaties met predni-
solon en antibiotica konden behandelen. Met de St. Georges Respiratory
Questionnaire (een ziektespecifieke kwaliteit-van-leven vragenlijst) hebben we
niet kunnen aantonen dat het programma een effect had op de kwaliteit-van-
leven. Evenmin waren er verschillen aantoonbaar op symptomen en loopafstand
in 6 minuten.
Aangezien de resultaten van de St. Georges Respiratory Questionnaire in con-
trast stonden met de subjectieve bevindingen van patiënten, fysiotherapeuten en
artsen hebben we ook een kwalitatief onderzoek uitgevoerd (hoofdstuk 5). Dit
kwalitatieve onderzoek bestond uit diepte-interviews bij een steekproef van 20
patiënten uit de zelfmanagementgroep. Tijdens deze interviews werd gevraagd
naar de veranderingen in het leven van de patiënt als gevolg van deelname aan
COPE zelfmanagementprogramma. De patiënten vonden het fitnessprogramma
het belangrijkste onderdeel van het zelfmanagementprogramma met name door
het verbeterde uithoudingsvermogen en het sociale aspect van de groepstraining.
De meeste patiënten waren positief over de mogelijkheid om zelf exacerbaties te
kunnen behandelen met prednisolon en eventueel antibiotica. Daarnaast rappor-
teerden verschillende patiënten toegenomen zelfvertrouwen en het beter kunnen
omgaan met COPD (coping) als positieve effecten van het zelfmanagementpro-
gramma.Tenminste drie aspecten van welbevinden die door de patiënten als zeer
belangrijk werden gezien (zelfvertrouwen; sociale contacten en gevoelens van
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Figuur 2 Opzet van de COPE studie 
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veiligheid), waren niet adequaat weerspiegeld in de St. Georges Respiratory
Questionnaire.
In hoofdstuk 6 beschrijven we het effect van het zelfmanagementprogramma op
exacerbaties en gezondheidszorgcontacten. De mogelijkheid van zelfbehandeling
leidde tot een verdubbeling van het totaal aantal gerapporteerde exacerbaties in
de zelfmanagementgroep ten opzichte van de controlegroep. De exacerbaties in
de zelfmanagementgroep werden in 70% van de gevallen thuis zelf door de
patiënt behandeld. Dit resulteerde in een absolute afname van het aantal consul-
ten met de longarts van 42% per patiënt per jaar. De symptomen behorende bij
de exacerbaties waren minder ernstig in de zelfmanagementgroep vergeleken met
de controlegroep.
De economische analyse van het zelfmanagementprogramma (hoofdstuk7) toonde
aan dat de kosten voor een patiënt die deelneemt aan een zelfmanagementgroep
ruim € 800 per jaar hoger zijn dan reguliere zorg. Gezien het feit dat het zelf-
managementprogramma twee keer zo duur was als reguliere zorg en geen meet-
baar voordeel had op kwaliteit-van-leven (Quality Adjusted Life Years), hebben
we vastgesteld dat zelfmanagement vooralsnog geen efficiënte behandeling is
voor COPD patiënten.
In hoofdstuk 8 staan de resultaten beschreven van het stoppen-met-roken pro-
gramma, een gemodificeerde versie van de “Minimale Interventie Strategie”
(MIS). De MIS werd uitgevoerd door speciaal opgeleide apothekersassistenten of
een longverpleegkundige die bij de patiënt thuis kwamen. Ongeveer éénderde
van de COPE patiënten rookte nog bij aanvang van de studie (op basis van zelf-
rapportage).Vierenzestig patiënten namen deel aan het stoppen-met-roken pro-
gramma en na 9 maanden rapporteerde 36% van de patiënten dat ze gestopt
waren. Uit controle van het cotininegehalte van het speeksel bleek echter dat
slechts 13% van hen daadwerkelijk gestopt was met roken. Kennelijk is een inten-
siever programma nodig om COPD patiënten van het roken af te krijgen en is
biochemische validatie essentieel bij het beoordelen van stoppercentages.
Door middel van inhalatie-instructies, adequate COPD medicatie en het boven
beschreven stoppen-met-roken programma is in de eerste vier maanden van het
onderzoek (run-in periode) getracht de longfunctie te optimaliseren. Hoofdstuk 9
laat zien dat deze optimalisatie niet geleid heeft tot een verbetering van de
luchtwegobstructie (FEV1) en kwaliteit-van-leven. Dit kan verklaard worden
doordat de patiënten al redelijk goed waren ingesteld en doordat slechts weinig
rokers daadwerkelijk zijn gestopt.
Hoofdstuk 10 beschrijft de resultaten van de studie naar het stoppen met inha-
latiecorticosteroïden (ICS), bedoeld om na te gaan of het korte termijn effect van
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ICS op de longfunctie beklijft. Vanwege het optreden van bijwerkingen is het
immers belangrijk na te gaan welke patiëntencategorie geen baat heeft bij lange
termijn gebruik van deze medicatie. De studie was als volgt opgezet: de eerste 4
maanden kregen alle patiënten ICS (fluticasone propionate).Vervolgens werd op
basis van loting bij de helft van de patiënten het medicijn gestaakt - ze kregen
een placebo - terwijl de andere helft doorging met het gebruik van ICS.
Gedurende 6 maanden follow-up werden de patiënten nauwkeurig gecontroleerd
met name op het krijgen van exacerbaties. Hoewel in de totale patiëntengroep
het stoppen met ICS leidde tot meer exacerbaties, bleek dit effect met name op
te treden bij patiënten met een relatief slechte longfunctie (FEV1≤50%).
Bovendien had 40% van alle patiënten op placebo geen enkele exacerbatie gedu-
rende 6 maanden follow-up.
Hoofdstuk 11 beschrijft de kosteneffectiviteit van het stoppen met ICS op de
korte en de lange termijn, waarbij alleen de directe medische kosten meegeno-
men zijn (perspectief van de zorgverzekeraar). Uit deze analyse kwam naar voren
dat doorgaan met ICS op de korte termijn weliswaar kosteneffectief was (€ 110
per voorkomen exacerbatie en € 1286 per voorkomen ziekenhuisopname), maar
op lange termijn analyse is het stoppen met ICS (met terugzetten op ICS wan-
neer de patiënt ontspoort) kosteneffectiever. De stoppen met ICS strategie levert
weinig winst op ten aanzien van kwaliteit-van-leven, maar kan wel leiden tot
aanzienlijke besparingen. Dit betekent voor de praktijk dat ICS gestopt kunnen
worden bij COPD patiënten met een relatief goede longfunctie (FEV1> 50%)
mits zij nauwkeurig gecontroleerd worden en snel teruggezet worden op ICS
indien herhaalde exacerbaties optreden.
In hoofdstuk 12 is het effect bestudeerd van bacteriën in de luchtwegen op het
ontstaan van exacerbaties, alsmede de rol van ICS daarbij. Hiertoe werd sputum
verzameld in de stabiele fase van 209 patiënten. Eénderde van de patiënten bleek
gekoloniseerd te zijn met bacteriën in de luchtwegen, maar dit bleek niet gere-
lateerd met de kans op een eerste exacerbatie. Bovendien was er geen interactie
met het stoppen van ICS.
In hoofdstuk 13 is vervolgens nagegaan of aan de hand van beschikbare klini-
sche gegevens van 116 patiënten voorspeld kan worden of een patiënt een exa-
cerbatie heeft die veroorzaakt is door bacteriën en dus behandeling met antibi-
otica behoeft. Ongeveer éénvijfde van de patiënten had een bacteriële exacerba-
tie. Voorspellers van een bacteriële exacerbatie waren een combinatie van een
positief Gram-preparaat, fors verlies van longfunctie ten opzichte van de stabiele
fase en meer dan 2 exacerbaties in het jaar voorafgaand aan de studie. De posi-
tief voorspellende waarde van deze combinatie was 67% en de negatief voor-
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spellende waarde 100%. Dit betekent dat deze snel beschikbare klinische facto-
ren de longarts kunnen helpen bij de besluitvorming over het geven van antibi-
otica in geval van een exacerbatie.
In hoofdstuk 14 worden de resultaten van dit proefschrift en de implicaties voor
toekomstig onderzoek geëvalueerd en bediscussieerd. De belangrijkste conclusies
en aanbevelingen van dit proefschrift zijn:
• Thans beschikbare zelfmanagementprogramma’s voor COPD patiënten heb-
ben hun waarde nog niet bewezen. Ook voor verbeterde programma’s dient
de kosten effectiviteit aangetoond te worden alvorens ze in aanmerking
komen voor gebruik in de praktijk.
• Stoppen met inhalatiecorticosteroïden bij patiënten met een relatief slechte
longfunctie (FEV1≤ 50%) leidt tot een sneller en vaker optreden van exa-
cerbaties; stoppen met inhalatiecorticosteroïden bij patiënten met een rela-
tief goede longfunctie (FEV1>50%) is echter een goede behandelstrategie
mits de patiënten in die fase strict gecontroleerd worden.
• Het is essentieel dat bij het beoordelen van stoppen met roken programma’s
voor COPD patiënten gebruik wordt gemaakt van biochemische validatie
van de stoppercentages om overschatting van de effectiviteit van het pro-
gramma te voorkomen.
• Het is niet noodzakelijk de longfunctie van stabiele COPD patiënten te
optimaliseren voorafgaand aan een klinische trial.
• Bacteriële kolonisatie bij matig ernstige COPD patiënten is geen onafhan-
kelijke risicofactor voor het ontwikkelen van exacerbaties.
• Afwezigheid van de drie voorspellers voor een bacteriële exacerbatie
(Gram-preparaat, longfunctieverlies en exacerbatiegeschiedenis) is reden om
geen antiobiotica te geven; toekomstige studies zijn nodig om de rol van
antibiotica bij de behandeling van exacerbaties te bepalen bij patiënten die
niet aan deze criteria voldoen.
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Dankwoord
Na meer dan vier jaar plezierige samenwerking met velen is deze COPE klus nu
geklaard.We zijn trots op het bereikte resultaat en kijken met enige weemoed terug
op het promotietraject. Het waren boeiende jaren waarin we als onderzoekersduo
met de vele solidaire mensen om ons heen de gebruikelijke ups en downs hebben
gedeeld. Graag willen we iedereen bedanken die op enige wijze een bijdrage heeft
geleverd aan het onderzoek. Een aantal mensen willen we hier met name noemen:
Allereerst natuurlijk alle COPD patiënten, om wie het uiteindelijk gaat, voor drie
jaar lang deelname aan het COPE onderzoek.Wij zijn er trots op dat bijna niemand
heeft afgehaakt! Uw betrokkenheid maakt dat we bij presentaties van het onderzoek
elders steeds weer moesten uitleggen dat in Twente “ja, ik doe mee”, ook echt “ja”
betekent.
In het bijzonder willen wij onze promotoren en copromotor bedanken: Gerhard
Zielhuis, Cees van Herwaarden en Job van der Palen. Beste Gerhard, je kritische
oordeel en je scherpe en stimulerende geest hield ons op een inspirerende manier
bij de les.Fijn dat je altijd tijd voor ons hebt gemaakt.We hebben veel van je geleerd:
van protocol tot publicatie! Beste Kees, jouw enthousiasme en grote ervaring in
pulmonologisch onderzoek was voor ons een enorme stimulans.Tijdens onze twee
maandelijkse bijeenkomsten borrelde je altijd van goede ideeën. Beste Job, tsja als
we jou niet hadden gehad… Je was onze helpdesk in optima forma. Je hebt voor alles
een praktische,inventieve en snelle oplossing:van computerprobleem tot ingewikkelde
methodologische vraagstukken. Jij stond aan de basis van dit onderzoek. Je bent een
bijzonder mens en wij zijn trots dat je onze CO(PE)-promotor bent!
Ook zonder de datamanagers Betty Rinsma en Petra Meerlo hadden we dit onderzoek
niet “overleefd”. Lieve Betty, jij runde de grillige patiëntenstromen van het COPE
onderzoek alsof het niets was.Voordat wij er lucht van kregen had je vaak al een
creatieve oplossing bedacht voor allerlei problemen.We waarderen je betrokkenheid
en nuchtere blik enorm! Lieve Petra, we vinden het fantastisch dat je altijd voor ons
klaar stond en zeer betrokken was bij het onderzoek! Je hebt een grote bijdrage
geleverd aan de kwaliteit van de database door je zeer nauwkeurige werkwijze.
Het COPE onderzoek was niet mogelijk geweest zonder de inzet en vakbekwaamheid
van onze longfunctieafdeling.Silvia Achterberg,Rolien Bekkema,Willemien Boersma,
Simone Bos, Mirjam Floor, Monique Groot, Petra Hemeltjen, Gerry Kruger, Hans
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Nieland,Martijn Nuis,Sylvia Punte,Angelique Puntman,Karin Smits,Marcel Vlutters,
Irma Wissink, Marquerite Zengerink, Cor Wegerif en Marcel Penterman: heel erg
bedankt voor jullie bijdrage en gezelligheid! Irma, bedankt voor je fantastische
bijdrage! We hebben nooit een foutje kunnen ontdekken in jouw registraties. Sylvia,
elke vrije minuut stond je klusjes voor ons te doen. Echt super! 
Heleen Mulder,Mayke Bergman en Karin Leferink voor het slagvaardig en enthousiast
organiseren en uitvoeren van de zelfmanagementcursus. Lieve Heleen, jij ging voor
deze klus. De cursusmap is een prachtig resultaat! We hebben veel van je geleerd.
De maatschap longziekten gaf ons de ruimte om dit onderzoek te doen en bovendien
waren ze altijd weer bereid om de COPE activiteiten te ondersteunen. Bert Dinkla,
Michiel Eysvogel, Nicolle Hekelaar, Jaap Klein, Arend van Knapen, Louis van der
Maas,Albert Polman en Hugo Schouwink: jullie waren COöPEratief bij uitstek! Ook
de assistenten longziekten en het secretariaat willen we noemen voor hun steun aan
het onderzoek.Niet te vergeten Jacky Boksem die voor Paul altijd alles weer in stilte
oploste! De longfysiologen Elly Oostveen en Frans de Jongh hebben steeds op een
hele positieve manier bijgedragen aan de kwaliteit van het onderzoek.
Ron Hendrix was onze microbiologische onderzoekspartner. Beste Ron, naarmate
het microsCOPE onderzoek vorderde, groeiden we steeds meer naar elkaar toe.
Bedankt voor je enorme inzet en loyaliteit! Tijdens de avondsessies aan jouw
keukentafel kregen de microbiologische artikelen steeds meer structuur en diepgang,
en leerden we je echt kennen.Zeker ook jouw team van laboranten danken we voor
hun inzet en betrokkenheid.
Steven Uil legde tijdens zijn stage epidemiologie de basis voor het onderzoeksprotocol.
Beste Steven, we hebben enorme bewondering voor je en vinden het nog steeds
jammer dat je niet in het MST kon blijven! 
Erwin Seydel en Marcel Pieterse hebben ons de basiskennis bijgebracht van de
psychosociale wetenschap. Beste Erwin, jouw heldere “colleges” hebben ons enorm
vooruit geholpen.We waarderen je oprechte belangstelling zeer. Beste Marcel, jouw
bijdrage, onder andere aan de opzet van het stoppen met roken programma en het
kwalitatieve onderzoek (KwaliCOPE), was fantastisch! Het is een plezier om met je
samen te werken. Karen Koning, bedankt voor de bijdrage aan KwaliCOPE.
Maaike van der Aa heeft het kwalitatieve onderzoek gedragen. Lieve Maaike, echt
DANKWOORD
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fantastisch hoe je deze gigantische klus hebt geklaard! We hebben genoten van je
soms wat wonderlijke interviewervaringen.
Wij bedanken alle fysiotherapeuten voor hun enthousiaste bijdrage aan CORE-fit:
Jolien Jentink, Luut Tip, Marjon Kramer, Marloes Stapelbroek, Renske Hommes,
Nicole Wielens,Martin Tenniglo, Raymond Westhoff,Hayke Kotte, Erik Vunderink,
Ben Boerrigter, Marieke Hoogkamer, Paul Weltevreden,Annemarie Kreuwel, Gary
Noordman,Marjon Diepemaat,Peter Coppens,Frank Koehorst,Gerard Mulder,Hans
van Wijck, Hans Wermers, Jeroen Vinke, Marianne Meerman, Margo Versteeg,Toon
Klomp en Wim te Wierik.
Voor het voedingsonderdeel werden we ondersteund door de diëtisten van ons
ziekenhuis, ’t Roessingh en de thuiszorg Enschede-Haaksbergen:Angela Otten,Dea
Schröder en Jeanette Overbeek.
Alle apothekers en hun assistenten voor hun medewerking aan het stoppen-met-
roken programma en het leveren van de medicatiegegevens.
Jan Goolkate en Tonny Knuyf voor het opzetten en uitvoeren van de cotinine
bepalingen in speeksel.
Het COPE onderzoek zou niet mogelijk geweest zijn zonder bijdragen van het
Nederlands Astma Fonds,GlaxoSmithkline,Boehringer Ingelheim,Novartis,Nutricia
en Amicon Zorgverzekeraar. Heel erg bedankt! Metname danken we de volgende
personen voor hun inzet en ondersteuning:Angeline Bommer,Martijn Akveld,Yvonne
Bookelmann, Marieke Vos, Peter Jagt, Bert Partmet,Wim van den Brink en Wim
Hop van GlaxoSmithkline,Guus Asijee van Boehringer Ingelheim en Chantel Kleier
en Patrick Bontekoe van Nutricia.
Wim Subelack heeft als infi-deskundige ons budget met veel betrokkenheid beheerd.
De medewerkers van de receptie en parkeerbeheer voor hun medewerking.
Debby Bogaert en Peter Hermans van de Erasmus Universiteit Rotterdam voor hun
kritische bijdrage aan het microbiologische onderdeel van het COPE onderzoek.
Martha Haveman en Justine van der Noordaa voor het ontwerp van de kaft.
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De gigantische klus van het invoeren van de data hebben we alleen kunnen klaren
dankzij: Bernadette Landewee, Ilse Kruiders,Astrid Boudrie, Linda Oude Maatman
en Sjouke Rinsma.Lieve Astrid, ik vond het erg bijzonder om drie COPE jaren samen
met jou aan de Haverstraatpassage gewoond te hebben!
Bas Monninkhof, Lieve Bas, dank voor het oplossen van alle computerproblemen en
het altijd weer klaar staan voor je soms wat chaotische zus.
Zeven enthousiaste stagiaires die hebben meegewerkt aan het COPE onderzoek:Ellen
Szwajcer,Anneke Jaspers,Saskia Kloet,Christine van Dijk,Karian van Gulick,Louise
Mast en Marjolein Keizer. Ellen, als een wervelwind heb je het implementatie-
onderzoek afgerond met een prachtig resultaat! Marjolein, tijdens onze laatste
hectische fase heb je fantastisch werk geleverd.We zijn blij dat je na je stage nog bij
ons blijft werken!
Medeonderzoekers Martine Veehof,Yvette Bulthuis en Lieke Christenhusz dank voor
jullie interesse en steun! Door jullie aanwezigheid leek het COPE-kantoor soms wel
een gezellig, maar toch uiterst productief,“kippenhok”.
Het COPE onderzoek heeft een vervolg met als onderzoeker Tanja Effing. Lieve
Tanja, we hopen dat je net zo’n goede COPE tijd tegemoet gaat als wij: succes!
De leden van de leescommissie,Prof.dr.RPNR Dekhuijzen,Prof.dr.CP van Schayck
en dr. PFM Krabbe, voor het kritisch beoordelen van ons proefschrift.
Onze paranimfen, Betty Rinsma, Linda Oude Maatman en Steef en Pieter van der
Valk, we zijn erg blij dat jullie ons willen bijstaan op deze spannende dag en alles
wat er bij komt kijken.
Moeder van Ginneken heeft mij als longarts pas echt geleerd wat een leven met
COPD betekent.
We zijn ontzettend blij met de vele vrienden en familie om ons heen, die oprecht
meeleefden gedurende het gehele promotietraject.
Patricia,Okke,Steef,Lorijn,Femke,mammie van der Valk,mam en pap Monninkhof,
we zijn dolgelukkig met jullie!
DANKWOORD
238
bw-monninkhof&valk  02-12-2003  09:00  Pagina 238
Curriculum Vitae / Evelyn Monninkhof
Evelyn Marielle Monninkhof werd op 16 maart 1976 geboren te Oldenzaal. In
1994 behaalde ze haar VWO diploma aan ’t Thijcollege te Oldenzaal. Zij ging
vervolgens Gezondheidswetenschappen studeren aan de Katholieke Universiteit
Nijmegen. Gedurende de studie koos zij de afstudeerrichting Epidemiologie.
Haar eerste stage vond plaats in het Sunny Brook Health Science Centre in
Toronto, Canada (begeleidster Dr.S. Jagal). De tweede stage vond plaats bij het
Julius Centrum van het Universitair Medisch Centrum Utrecht (begeleidster Dr.
P. Peeters). Na het behalen van haar doctoraal in 1998, volgde zij een aantal
modules van de studie “Beleid en Management van de Gezondheidszorg” aan de
Erasmus Universiteit te Rotterdam. Daarnaast werkte zij part-time aan het
Instituut Maatschappelijke Gezondheidszorg (iMGZ) van het Universitair
Medisch Centrum Rotterdam aan een familiair borstkankerproject. In mei 1999
begon ze als promovendus samen met longarts Paul van der Valk op het COPE
project. Dit proefschrift beschrijft de resultaten van de COPE studie. Van sep-
tember 2002 tot september 2003 heeft ze, naast de COPE studie, part-time
gewerkt als epidemioloog voor Medisch Spectrum Twente. De belangrijkste taken
van deze functie bestonden uit het begeleiden van artsen en assistenten bij het
doen van wetenschappelijk onderzoek, het verzorgen van epidemiologie en sta-
tistiek onderwijs en participatie in de Medisch Ethische Toetsingscommissie. Sinds
oktober 2003 is Evelyn werkzaam als post-doc bij het Julius Centrum van het
Universitair Medisch Centrum Utrecht. Zij onderzoekt het preventieve effect van
lichaamsbeweging op het ontstaan van borstkanker.
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Curriculum Vitae / Paul van der Valk
Paul van der Valk werd geboren op 22 september 1951 te Bergen op Zoom. Hij
bezocht daar het Moller Lyceum waar hij het diploma Gymnasium β behaalde in
1969.Vanaf 1969 studeerde hij Geneeskunde aan de Rijks Universiteit te Leiden.
In 1972 was hij gedurende 6 maanden werkzaam als kandidaatsassistent op de afde-
ling Pathologie van het Anthony van Leeuwenhoeck Ziekenhuis (Dr J Delemarre).
In 1976 werd het artsexamen gehaald, alsmede het Amerikaans artsexamen, het
ECFMG (Educational Council for Foreign Medical Graduates).Vanaf 1976 was hij
als assistent geneeskundige werkzaam op de afdeling Chirurgie van het Prinses
Irene Ziekenhuis te Almelo (Dr O Kluft). In 1978 werkte hij als assistent genees-
kunde op de afdeling Interne Geneeskunde van het Ziekenhuis Antoniushove te
Leiderdorp (Dr J van der Veer). Vervolgens werd aan het Tropeninstituut te
Amsterdam de Tropencusus gevolgd. Na het behalen van het Tropencertificaat in
1979 volgde uitzending via Memisa naar Kaduna, Nigeria, alwaar gedurende 3
maanden in het Saint Gerards Hospital werd gewerkt, waarna de verdere werk-
zaamheden als tropenarts in het Saint Louis Hospital te Zonkwa, Nigeria, werden
voortgezet tot 1982 (matron Sr Nuala Mc Cluskey). Na terugkeer in Nederland
werd in 1982 gestart met de vooropleiding interne geneeskunde in het Jozef
Ziekenhuis te Deventer (opleider Dr J Panders).Vanaf 1985 werd de opleiding tot
longarts voortgezet op de afdeling Longziekten van het Antonius Ziekenhuis te
Nieuwegein (opleider Dr R Vanderschueren). In september 1987 volgde zijn aan-
stelling als longarts in het toenmalige Ziekenhuis Ziekenzorg te Enschede. Sinds
1990 is hij een van de zeven longartsen in het aldaar door fusie tot stand gekomen
Medisch Spectrum Twente. Hij is plaatsvervangend opleider longziekten en TBC-
coördinator. De maatschap stelde hem per 1999 in staat om een deel van zijn werk-
zaamheden te wijden aan het in dit proefschrift beschreven onderzoek samen met
Evelyn Monninkhof, epidemiologe. Hij is gehuwd met Patricia van Ginneken, zij
hebben 3 kinderen, Steef, Lorijn en Femke.
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